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Abstract 
 
Introduction 
Chronic Fatigue Syndrome (CFS) is an incapacitating condition characterised by 
extreme fatigue. In the absence of an objective diagnostic test CFS remains a clinical 
diagnosis based on a broad spectrum of symptoms, including autonomic dysfunction 
and cognitive impairment. This has given rise to significant challenges, not least the 
development of multiple sets of diagnostic criteria that may represent different 
disease phenotypes. This thesis examines autonomic and cognitive features between 
subgroups that meet different diagnostic criteria to better understand this possibility. 
It also examines the overlap between symptoms of CFS and depression, a potential 
confounder. 
 
Methods 
A subset of data from a larger Medical Research Council funded observational study 
Understanding the pathogenesis of autonomic dysfunction in CFS and its relationship 
with cognitive impairment was examined. Patients were screened using the SCID-I 
assessment tool to exclude major depression prior to the main study. Depressive 
symptoms were compared to CFS Fukuda criteria. The DePaul Symptom Questionnaire 
(DSQ) was used to differentiate between diagnostic criteria. COMPASS and COGFAIL 
questionnaires were administered for self-reported autonomic and cognitive features 
respectively. The Task Force® Monitor was used for autonomic assessment and a 
battery of neuropsychological tests administered for objective cognitive assessment.  
 
Results 
Subjective autonomic and cognitive symptoms were significantly greater in CFS 
subjects compared to controls. There were no statistically significant differences in 
objective autonomic measures between CFS and controls. There were clinically 
significant differences between DSQ subgroups on objective autonomic testing. 
Psychomotor speed was significantly slower in CFS compared to controls. Visuospatial 
memory, verbal memory and psychomotor speed were significantly different between 
DSQ subgroups. 
 
Conclusion 
The findings indicate phenotypic differences between DSQ subsets and suggest that 
elucidating the symptoms seen in CFS, or its disease spectrum, will support research 
into its underlying pathophysiology and enable more tailored treatment. The absence 
of significant differences in objective autonomic function between CFS and controls in 
this cohort contrasts to findings of some other studies and may reflect study exclusion 
for depression. Together with the overlap between CFS and depressive symptoms, this 
reinforces the need to better understand the underpinning causality to allow 
appropriate identification and management. 
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Chapter 1. Introduction 
 Aims and objectives 1.1.
The biological underpinning of Chronic Fatigue Syndrome (CFS) is unknown but 
dysregulation of the autonomic nervous system (ANS) is a strong candidate. This thesis 
examines the prevalence of autonomic dysfunction (AD) in CFS compared to controls 
and considers the origin and impact of this dysautonomia. It also considers its presence 
in the context of current diagnostic criteria and case definitions, which lack consistency 
and consensus. 
 
It is widely acknowledged that there are limitations to current diagnostic criteria used 
for CFS and that there is disparity between them (1-4). Little is understood about the 
clinical implications of this or whether different criteria identify different phenotypes 
of CFS, although it has been suggested that criteria may select individuals with 
different levels of functional impairment (5, 6).  
 
This thesis will examine both self-reported and objective autonomic and cognitive 
features between cohorts that meet different diagnostic criteria as per the DePaul 
Symptom Questionnaire (DSQ). 
 
The aims and hypotheses of this thesis are given below: 
1.1.1. Primary aims 
 To identify differences in AD by subgroup of CFS patients, determined by 
diagnostic criteria; 
 To identify differences in cognitive impairment by subgroup of CFS patients, 
determined by diagnostic criteria; 
 To explore the prevalence and nature of depressive symptoms in this well-
defined cohort of CFS patients. 
1.1.2. Secondary aim 
 To determine whether CFS patients can participate in a study that involves 
considerable personal burden. 
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1.1.3. Hypotheses 
 AD does not differ by diagnostic criteria met; 
 Cognitive impairment does not differ by diagnostic criteria met; 
 Depressive symptoms are common in CFS patients; 
 CFS patients are able to participate in and complete a complex and physically-
demanding study. 
 History 1.2.
CFS is a poorly-understood condition of unknown aetiology. It is characterised by a 
broad spectrum of symptoms, including myalgia, sore throat and cognitive 
impairment, and underpinned by an incapacitating fatigue that is exacerbated by 
exertion (7, 8). The name Chronic Fatigue Syndrome is now the most widely-used term 
for this condition, which has had a number of different labels since its recognition (8-
10). 
 
Its origins appear to be long-standing. As early as the 1800s, physicians began 
describing a condition called Neurasthenia to define a combination of symptoms of 
fatigue and neuralgia (9, 11). At this time, symptoms were thought to be behaviour-
related and psychosomatic in origin. This perception of CFS as a psychological rather 
than physical condition is one which continues to divide clinicians and patients today 
and has fuelled debate and research into its aetiology throughout its history (12-15). 
 
In the 1900s clusters of patients with similar symptoms steered clinicians and 
researchers to identify and shape the recognition and diagnosis of this condition. 
Three notable outbreaks have had a defining role in this. In 1930s Los Angeles an 
outbreak of symptoms, including muscle weakness and cramps largely in hospital 
clinical staff, led Alexander Gilliam to describe a polio-like illness, which he coined an 
atypical poliomyelitis (11, 16). A similar phenotype presented in an outbreak in Iceland 
in the 1940s, which was initially thought to be a new form of polio, however patients 
were not affected by paralysis but had significant cognitive impairment post-illness 
(16). 
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A later outbreak at the Royal Free Hospital in London in 1955, managed by Dr Melvin 
Ramsey, saw the start of better-documented research into the illness and revealed 
dominant symptoms of headache, sore throat, fatigue and low-grade fever (16). As a 
result, the condition was thought to be infectious with a neuroimmune origin and 
caused by inflammation of the brain and spinal cord. It was subsequently called benign 
Myalgic-Encephalomyelitis, or ME, which is a term that prevailed into the 21st century 
and is still commonly used today (8, 11). This paved the way in the 1960s for the World 
Health Organisation (WHO) classification of ME as a condition of the central nervous 
system (17).  
 
The 1980s and 1990s saw a re-emergence of a trend towards viewing CFS as a 
behavioural condition and it was dubbed “yuppie flu” by many under the belief that it 
affected malingering professionals struggling to manage demanding jobs. This drove a 
stigmatisation that has since been difficult to remove and one which many sufferers 
still feel today (18). 
 
Towards the end of the twentieth century there was a growing school of thought that 
CFS was secondary to a viral infection, such as Epstein-Barr Virus (EBV),  and this gave 
rise to the term Post-Viral Fatigue Syndrome (8, 19). Diagnosis of ME or Post-Viral 
Fatigue Syndrome was complicated by the fact that the WHO classified Post-Viral 
Fatigue Syndrome as a separate condition. Since the 1980s there has been recognition, 
led by the Centre for Disease Control (CDC) and their 1988 research into a case 
definition, that one collective term was needed and consensus has determined that 
Chronic Fatigue Syndrome is the most representative (8, 16). 
 
Since this time, the aetiology of CFS has continued to be researched and debated. The 
original 1988 CDC diagnostic criteria have been superseded by other consensus 
criteria, which aim to incorporate the condition’s complex symptomatology (20-22). In 
the absence of a diagnostic test for the disease, there is continued debate about the 
suitability of existing criteria for its diagnosis and in 2015 the United States Institute of 
Medicine proposed that the condition be given a new name: Systemic Exertion 
Intolerance Disease (SEID) (23, 24). 
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There is acknowledgment that this new proposal offers more targeted diagnostic 
criteria to replace the existing lengthy criteria but there is continued concern that this 
proposed name and definition are, like their predecessors, still more descriptive than 
diagnostic and unlikely to appease the stigma associated with a condition that is often 
labelled as psychiatric (25). It has been suggested that priority should lie with 
classification of the number and severity of symptoms as a means of predicting 
prognosis rather than with the development of additional case definitions (1). 
 
Anecdotally, the condition and its sufferers have never been able to escape the idea 
initially planted in the 1800s of behaviour and psychology playing a major role in the 
aetiology of CFS and studies of the disease continue to focus on psychological 
aetiological factors. This creates tension within and between clinicians, researchers 
and patients. Improved understanding of the condition’s aetiology will enable us to 
better inform patients, their families and society and will ultimately lead to the 
development of targeted treatment strategies. 
 Symptoms and presentation 1.3.
CFS is by definition a constellation of symptoms that cluster together. Not all patients 
with CFS experience all symptoms and, where present, symptoms appear to vary in 
presentation and in severity. A lack of understanding of the condition’s 
pathophysiology may have resulted in multiple symptoms being required in its 
diagnosis. This has also given rise to the use of more than one set of criteria for clinical 
diagnosis, which not only has implications in clinical practice but also in terms of 
research. This is highlighted by the Institute of Medicine’s recent commissioning of a 
panel to examine these criteria resulting in the proposal in February 2015 of a further 
new set of criteria (23). 
 
The most common presenting symptoms (11, 26) are summarised below and in table 1 
together with their reported sensitivity – the predictive ability of the symptom to 
diagnose CFS – where available. A summary of the different diagnostic criteria is 
outlined in table 2. 
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1.3.1. Fatigue 
Fatigue is a pathological state defined as “extreme tiredness from mental or physical 
exertion or illness” (27) and is distinct from tiredness – the normal physiological “state 
of wishing for sleep or rest” (28), or malaise – “a general feeling of discomfort, illness, 
or unease whose exact cause is difficult to identify” (29, 30).  
 
As the primary symptom that leads to a diagnosis of CFS (26), understanding the 
nature of what patients express as fatigue is central to clinical evaluation. Patients 
present with new-onset debilitating fatigue that often results in inactivity for 
prolonged periods, despite high levels of pre-morbid energy and fitness (31). Fatigue in 
CFS is incapacitating, not related to exertion, is often worsened by activity (post-
exertional malaise) and is not alleviated by rest (8, 32). 
1.3.2. Sore throat 
Many patients describe having a viral-type infection prior to becoming unwell, often 
associated with a low-grade fever (26). One of the main features of this illness is a sore 
throat (8), which can be a presenting symptom, as well as a recurrent feature 
associated with relapse or chronic illness. 
1.3.3. Muscle and joint pain 
Persistent muscle ache is seen in 20-95% of patients and painful joints in the absence 
of swelling or inflammation are described in approximately half of patients (26). 
1.3.4. Cognitive problems 
Often described as a “brain fog” 85-95% of patients report problems with short-term 
memory and concentration (26, 33). 
1.3.5. Other symptoms  
These include dizziness, tachycardia, problems with bowel and bladder function, dry 
eyes and visual blurring (26, 32). Table 1 reports frequency of symptoms determined 
from a review of studies of CFS between 1991 and 2014. 
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Symptom Frequency (%) Sensitivity (%) 
Fatigue 100 95.7 
Low-grade fever 60-95  
Myalgia 20-95 75.1 
Sleep disorder 15-90 85.4 
Impaired cognition 50-85 72-82.9 
Headache 35-85  
Muscle weakness 40-70 74.2 
Visual blurring 50-60  
Nocturia 50-60  
Dizziness 30-50  
Tachycardia 40-50  
Dry eyes 30-40  
Dry mouth 30-40  
Diarrhoea 30-40  
Painful lymph nodes 30-40  
 
Table 1 Summary of symptoms in CFS and their frequency 
adapted from Komaroff et al and Watson et al (26, 34) 
 Diagnostic criteria 1.4.
There is no definitive objective diagnostic test for CFS (35). Diagnosis is based on 
clinical presentation and the diagnostic process has supported four distinct sets of 
diagnostic criteria, outlined in table 2. 
 
The development of a case definition and diagnostic criteria for CFS originated from 
the CDC in 1988 (8, 36). This case definition has been the foundation for subsequent 
criteria, which have attempted to encapsulate the broad symptomatology of CFS and 
improve the accuracy of diagnosis. These criteria are discussed below. 
 
The 1991 Oxford criteria were developed by a United Kingdom (UK) based consensus 
group to address a lack of agreement about a case definition for CFS and concerns 
about the reliability of the 1988 definition (3, 37). The Oxford criteria proposed a 
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definition that required at least six months of mental and physical fatigue that inhibits 
function at least 50% of the time. It also proposed a subtype of CFS called Post-
Infectious Fatigue Syndrome, associated with the presence of an infective agent (37). 
The Oxford criteria are recorded in table 2 and notably do not include problems with 
cognitive function. 
 
In 1994 the CDC CFS study group further revised this definition to provide an 
integrated approach to CFS diagnosis and developed the Fukuda criteria (22). These 
require patients to have persistent or relapsing debilitating fatigue for at least six 
months with significant impairment in functioning and at least four minor symptoms, 
which include cognitive dysfunction, sore throat and myalgia. Criticisms of the Fukuda 
criteria include the lack of a rating scale for symptom severity and the challenges 
presented in their application (38). 
 
The 2003 Canadian Consensus definition (39) was written to aid diagnosis on the basis 
of symptom clusters in an attempt to overcome the challenge of such a breadth of 
symptoms. As such, it includes more symptoms than the criteria above and does not 
describe fatigue as a defining feature of CFS, in recognition of the fact that this 
symptom is a feature of many diseases. Instead it describes post-exertional malaise as 
a central feature of the illness. It also requires at least one autonomic, neuroendocrine 
or immune symptom, as well as at least two other symptoms including arthralgia and 
poor sleep. The authors of the 2003 Canadian Consensus definition also criticised the 
Fukuda criteria for the overlap with depressive symptoms and differentiated between 
this by focussing on physical and cognitive functional impairment. 
 
These 2003 criteria were further developed into the 2011 International Consensus 
Criteria (40). The most significant change was the removal of a temporal requirement, 
in that the six-month period of symptoms prior to diagnosis is no longer required 
before a diagnosis of CFS can be made. Once again, it also criticised the use of the 
word fatigue in the condition’s name, arguing that focus on this as the primary 
symptom gives too great an emphasis on a symptom that is widespread through many 
chronic conditions (41).  
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Part of the challenge of having diverse sets of criteria is the possibility that they select 
a slightly different disease phenotype, which may not represent the same condition (5, 
6, 42) and which complicates research into underlying aetiology. The 2003 Canadian 
criteria appear to select more functionally impaired patients, with physical and 
cognitive symptoms, compared to the Fukuda criteria and there is inconsistency about 
whether different criteria include or exclude patients with co-morbid psychiatric 
disease (3, 38). 
 
Identifying diagnostic symptoms, rating their severity and standardising their 
measurement will improve the consistency of existing diagnostic criteria (3). Since the 
1988 CDC case definition, revisions of CFS diagnostic criteria have attempted to arrive 
at a more focussed definition to improve reliability and to minimise overlap with other 
diseases, such as depression, and the hunt for an appropriate and accurate set of 
criteria continues. 
 
The recently proposed case definition from the Institute of Medicine has been formed 
on the basis of a literature review and input from an expert committee. It places three 
common symptoms at the heart of the definition: impaired day-to-day function, post-
exertional malaise and unrefreshing sleep (23). Yet, in the context of existing 
systematic, consistent definitions, some experts feel that emphasis on the 
identification of a definitive set of diagnostic criteria should be relegated in favour of 
focussing on number and severity of symptoms to help target treatment and improve 
prognosis (1). 
 
Furthermore, the continued and varied development of polythetic diagnostic criteria 
for CFS, where some but not all symptoms must be present to reach a diagnosis, 
illustrates the challenge of knowing which symptoms are CFS-specific and may be a 
sign of the disorder’s heterogeneity or which arise as co-morbidities secondary to the 
underlying pathophysiology. While there is no doubt that a definitive diagnostic test is 
key to recognition of this stigmatised disease and its accurate diagnosis, understanding 
these symptoms is central to better elucidating whether tests will identify different 
subsets of patients on a disease spectrum with different treatment requirements. 
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Although no set of diagnostic criteria is without limitations (43), the Fukuda case 
definition has widespread support (44-46). The lack of understanding of the true 
aetiological underpinning of CFS implies that these apparently comprehensive criteria 
may still not be valid. Nevertheless, they are the most widely used both in the United 
States (US) and in the UK, where they underpin the recommendations of the National 
Institute for Health and Care Excellence (NICE) (1, 3, 35). In the absence of an objective 
diagnostic test, the Fukuda criteria continue to present the most comprehensive and 
consistent set of criteria to date. 
1.4.1. DePaul Symptom Questionnaire 
The DSQ was devised by Leonard Jason et al to better assess the “core” symptoms of 
CFS and provide a consistent method of evaluating them (47-49). It is a self-reported 
measure of CFS symptoms, demographics and medical, occupational, and social 
history.  
 
From these measures it is possible to give a “diagnosis” of CFS based on the Fukuda 
criteria (22), the 2003 Carruthers (Canadian) criteria (39) or the 2011 Carruthers 
(Canadian) consensus criteria (40). The 2003 Canadian criteria are further subdivided 
into clinical and research. The clinical criteria are the original 2003 Canadian criteria. 
The research criteria have been developed by a group led by Jason Leonard from the 
2003 Canadian case definition with elements of the Fukuda criteria to limit symptoms 
and allow for better categorisation of patients (47). These research criteria are defined 
in table 2 and the principle differences between them are outlined in chapter 4, table 
69. 
 
A diagnosis is given according to four categories. The Fukuda criteria; the Fukuda+2003 
Canadian Clinical criteria; the Fukuda+2003 Canadian Research criteria, or the 
Fukuda+2003+2011 Canadian criteria together. The Fukuda+2003 Canadian Clinical 
criteria build on the Fukuda alone criteria with the addition of neurological, 
neuroendocrine and autonomic symptoms. The Fukuda+2003 Canadian Research build 
on this by including these symptoms not as minor but major symptoms, core to a CFS 
diagnosis. Fukuda+2003+2011 make a further addition of more widespread, migratory 
pain and require wide-ranging and greater symptomatology (see table 2). 
10 
 
In broad terms, the difference in DSQ “diagnoses” represents increasing numbers of 
symptoms affecting more of the body’s systems. While this recognises the complex 
presenting symptoms, it may also complicate the picture with the inclusion of 
symptoms that are too broad and all-encompassing, and which may not all be core 
features of CFS. 
 
Studies show that different diagnostic criteria identify patients with different 
functional impairment (50-52). To date no studies have assessed the difference in 
autonomic or cognitive phenotype using in-depth, objective dynamic tests according to 
DSQ criteria. This thesis addresses this knowledge gap, examining objective and 
subjective autonomic and cognitive performance by DSQ criteria to better determine 
whether they select different phenotypes.
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 Aetiology 1.5.
The biological underpinning of CFS is not known. Dysregulation of the ANS is a strong 
candidate, but infection, the immune system and genetics have also been implicated in 
its pathophysiology. These uncertain origins are highlighted by the fact that specialist 
CFS clinics in the UK can be based in different departments, including Immunology, 
Infectious Diseases and Psychiatry, and contributes to diagnostic uncertainty, difficulty 
in finding effective therapeutic interventions and patient frustration. 
 
The WHO classifies CFS as a neurological condition (17) and, although opinion about its 
aetiology is divided, this is recognised by current NICE guidance in the absence of a 
better understanding of its pathogenesis (35). The focus of this thesis is on the ANS 
and its regulation and dysregulation, which is presented from section 1.10. Evidence 
for the roles of different underlying pathologies is discussed below. 
1.5.1. Genetics and environment 
An interaction of genetic and environmental risk factors is likely to underlie the 
development of CFS. Anecdotal stories of CFS affecting members of the same family 
have been evidenced in studies (53), suggesting there may be a genetic predisposition 
to developing the disease. Studies have also shown a higher concordance rate (55%) 
between monozygotic twins compared to dizygotic twins (19%) (54) suggesting that 
genetic make-up may be an important factor in developing CFS and may underlie its 
pathology in some individuals. 
 
These studies are often small and few in number, however, and there is conflicting 
evidence for the role that genetic susceptibility versus environmental factors might 
play. Some studies have shown a strong genetic contribution to fatigue with negligible 
environmental influence (55, 56), while other research suggests that environment – 
with factors including infection and stress – plays a key role and that the interplay 
between both factors is central (57). The role of environmental factors is discussed 
below. 
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1.5.1.1. Infection 
Patients frequently report symptoms of infection, including flu-like symptoms and sore 
throat (26, 42), which often precede the development of CFS – giving the name post-
viral fatigue syndrome – and can reoccur or persist. In addition, several infectious 
organisms have been associated with CFS, including EBV, parvovirus, retrovirus, 
cytomegalovirus, coxsackie B virus and giardiasis (15, 58, 59). Research is inconsistent, 
however, and causality has not been demonstrated.  
 
Furthermore, trials of treatment with antivirals have been ineffective (60), which may 
imply that, rather than one infectious agent causing CFS, a group of infections may 
trigger an individual susceptibility determined by a genetic predisposition. 
1.5.1.2. Occupational stress 
The role of stress in disease causality is uncertain (61). Conducting well-executed, high-
validity studies is problematic because of significant ethical considerations. Despite 
this, there is some evidence of an association between psychological stress and certain 
conditions, including cardiovascular disease and depression, where long-term 
occupational stress and stressful life events appear to precede disease (61). 
1.5.1.3. Early stress 
Evidence for precipitating life events in the development of CFS is limited (62). A 
recent case control study has, however, shown that childhood trauma may be a 
predisposing factor for CFS and that greater levels of childhood trauma were 
associated with a higher risk of CFS (63). This may reflect a model of stress-
vulnerability, in which underlying vulnerability is triggered by external events.  
1.5.1.4. Current stress 
Pre-morbid lifestyle is thought to have a role to play by some researchers and was 
implicated in causality during the 1980s when “yuppie flu” was thought to be a disease 
of individuals with high levels of occupational stress and long, demanding work hours. 
More recent research has shown an association between this ergomania – an 
excessive desire to work or exercise (64) – and development of CFS (65); however, 
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study limitations, including the role of confounders and subjective reporting, make it 
difficult to interpret and justify a causal role. 
 
Despite gaps in research, there is a compelling argument that underlying stress, 
vulnerability and lifestyle may predispose to CFS, particularly when considered in the 
context of a possible underlying genetic predisposition, which affects only some family 
members. 
1.5.2. Biological systems 
These genetic and environmental factors may underlie the symptoms of CFS through 
an impact on the ANS and/or through the immune or endocrine systems. 
1.5.2.1. The immune system 
Some of the key symptoms of CFS, including sore throat, lymphadenopathy and 
arthralgia, can be linked to inflammatory processes. This has led researchers to believe 
that the immune system is implicated in the pathophysiology of CFS. A review of the 
physiology of the immune system is outwith the scope of this thesis but can be found 
in Jawetz, Melnick & Adelberg's Medical Microbiology (66). Relevant key findings 
related to CFS are discussed below. 
 
A large systematic review found inconsistent evidence for the role of the immune 
system in CFS (67). Studies focussed on the role of natural killer (NK) cells, pro-
inflammatory cytokines and T cells. The findings contribute to an overall picture that is 
inconclusive and mixed, as discussed below.  
1.5.2.1.1. Innate immunity 
Abnormalities of immune activation of the acute innate response have been 
demonstrated in CFS (68). Disrupted NK cell function (69, 70) has been shown, with 
reduced NK cell numbers and low cytotoxicity. Studies also suggest that a bigger 
response may be mounted by the complement system in CFS and may be implicated in 
changes in immune cells’ gene expression and enhanced oxidative stress (71), an 
imbalance which is associated with pathophysiology and ageing (72). 
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1.5.2.1.2. Cytokines 
Cytokines are proteins produced as a result of a mounted immunological response that 
act as ‘messengers’ in the immune system. Some – IL-1, IL-2, IL-4, IL-6, IL-12, tumour 
necrosis factor (TNF), interferon (IFN) g – are pro-inflammatory and others – IL-10, 
TGF-ß – are inhibitory (73). Measuring serum cytokines has challenges (74), 
nevertheless studies have successfully compared cytokine levels in CFS and control 
groups.  
 
A recent study looking at the relationship between leptin – which stimulates the 
release of some pro-inflammatory cytokines – and fatigue found that self-reported 
daily fluctuations in fatigue positively correlated with leptin level (75), which in turn 
correlated to a number of cytokines, including IL-6, IFN-α and IFN-ß. 
 
Nevertheless, evidence for the role of the immune system is conflicting. A number of 
studies, of varying quality, show no evidence of difference in cytokine levels between 
CFS and control subjects (67). Others have found opposing results with both increased 
and decreased levels of pro-inflammatory and inhibitory cytokines observed (71, 76).  
1.5.2.1.3. Adaptive immunity 
There is evidence indicating abnormal adaptive immunity in CFS. Some studies 
demonstrate no difference in T cell quality and function between CFS and control 
groups while others showed reduced T cell and CD4 cell number in CFS (58, 59). Other 
research has shown prolonged T cell survival (76) illustrating the challenges of 
interpreting study findings, which may be influenced by confounding factors including 
the presence of co-morbidities, such as depression.  
 
Furthermore, there is also evidence of abnormal autoimmune reactions and some 
studies have shown elevated antibodies and B cells, as well as immunoglobulin-G 
deficiencies (42, 69).  
 
Nevertheless, studies are often based on small sample sizes and causality, or the role 
of co-morbidities, cannot be determined. Together, these findings paint a picture of 
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the complexity of the immune system and the challenges faced in identifying 
consistent markers of the disease. 
1.5.2.2. The nervous system 
CFS is currently classified by the WHO as a chronic neurological condition (17). 
Symptoms including dizziness, palpitations, bowel and bladder disturbances and 
problems with temperature regulation, which are commonly seen in CFS patients (26), 
are regulated by the ANS (77) and strongly suggest that nervous system dysfunction 
might be implicated its pathophysiology. It has long been postulated that symptoms 
including orthostatic intolerance (OI) and postural hypotension, seen in both multiple 
sclerosis (MS) and CFS (78), imply a shared causal pathway with an underlying 
neuroimmune mechanism.  
 
Disruption of the ANS is, however, observed in a number of chronic conditions (79), 
including depression (80), and studies have not yet demonstrated whether these 
symptoms underpin the pathogenesis of CFS or whether they result from a secondary 
mechanism. 
 
One of the strongest evidence bases that CFS may be an abnormality of the nervous 
system comes from the overlap that has been demonstrated between CFS and 
Postural Tachycardia Syndrome (PoTS) – a dysautonomia (81). The symptoms of PoTS 
include OI and abnormal heart rate response and may encompass a group of 
dysautonomias (82) including CFS and is suggestive of a parallel underlying causal 
pathway. 
 
The role of the ANS in CFS is discussed in more detail from section 1.10. 
1.5.2.3. Endocrine dysregulation 
The hypothalamic-pituitary-adrenal (HPA) axis is under homeostatic control and 
regulates many of the body’s systems, including the cardiovascular, immune and 
central nervous systems (83). One of the hormones synthesised and secreted as a 
consequence of HPA axis function is cortisol, a glucocorticoid released in response to 
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stress. The HPA axis is sensitive to multiple influences, including diurnal rhythm and 
stress (84, 85). A summary of its regulation is depicted in figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Schematic of the HPA axis showing regulation and negative feedback 
Adapted from Pocock and Richards, Human Physiology and Kohm and Sanders (86, 87) 
 
Dysregulation of the HPA axis has been associated with CFS (15, 88). Down-regulation 
has been shown in CFS (89) by reduced cortisol levels (56, 90) and decreased diurnal 
variability of HPA axis hormones (91-93). A dose-response relationship has also been 
observed with increased HPA axis dysfunction associated with longer illness duration 
(94). Furthermore, low-dose hydrocortisone has been shown to be effective at 
reducing fatigue levels in the shorter term, strengthening support for an association 
between HPA axis dysregulation and CFS (95). 
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The ANS, HPA axis and the immune system are interconnected systems (96-99), as 
depicted in figure 1.  
 
The immune system releases cytokines, including IL-1, IL-6, IL-10 and TNF-α, that can 
stimulate the HPA axis and the ANS (99). In itself it is regulated through hormonal and 
neural responses. HPA axis activation stimulates the release of glucocorticoids that 
inhibit the immune system. The ANS releases noradrenalin, which has a regulatory role 
on the release of pro-inflammatory cytokines (87). As such, changes in one system 
(hormonal/neural/immune) will affect the others and CFS may be the phenotypic 
expression of dysregulation of any aspect of these interconnected systems. 
 
Existing research suggests that the complex interplay between the ANS and its immune 
and endocrine regulation may be implicated in the pathogenesis of CFS. Understanding 
the underlying pathophysiology will enable diagnosis to be made on 
pathophysiological grounds and may reveal that what we now think of as CFS is in fact 
a number of different disorders. 
 
Further research is needed to explore this possibility and to better elucidate whether 
CFS, as currently diagnosed, represents one condition or a spectrum of disorders with 
a similar symptom base. 
 Prevalence 1.6.
Estimates of CFS prevalence vary (100, 101).  One of the principle challenges in 
obtaining accurate data stems from the lack of a pathophysiological diagnostic test. As 
a result, clinician-led diagnostic criteria are used. The variability in these criteria, as 
discussed, as well as inconsistency in use across clinics and the broad case definition 
for CFS give rise to a likelihood of both under- and over-diagnosis (102) and specifically 
the misdiagnosis of psychiatric conditions, such as depression (101).  
 
Given the lack of epidemiological data, NICE bases prevalence estimates on 
extrapolations from other countries and gives the current UK prevalence of CFS as a 
minimum of 0.2-0.4% (103); however, recent studies suggest that such prevalence 
estimates may only account for 10% of those affected by the condition (104). 
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 Cost and impact 1.7.
The true economic burden of CFS is difficult to measure. Lack of adequate data 
regarding healthcare, welfare and productivity costs is exacerbated by probable 
underestimation of true disease prevalence. A US study estimated that household 
productivity in people with CFS reduced by one third and that labour productivity was 
over 50% lower, resulting in a total annual cost of $9.1 billion (105). A more recent 
paper from the UK looking solely at loss of productivity estimated the annual cost to 
the UK economy to be £75.5-£128.9 million (106). The cost of informal care is also 
thought to be substantial (107) and contribute to a high overall financial cost. 
 Prognosis  1.8.
The natural history of CFS is variable and full recovery is rare (108). Studies point 
towards four patterns of recovery: 0-20% report full recovery; 8-63% report some 
improvement in symptoms; 5-20% have worsening of symptoms and 24-57% report no 
change (108). 
  
Improved outcome appears to be associated with lower fatigue severity at baseline, 
shorter illness duration and absence of co-morbid psychiatric disorders (8, 109). 
Protective factors appear to be a younger age at diagnosis and absence of co-morbid 
depression or anxiety (110). 
 Management 1.9.
Current NICE guidance centres on improving function and quality of life and focusses 
on improved sleep hygiene, adopting rest periods and maintaining a healthy diet (35). 
Pharmacological intervention is recommended only for symptom control, for example 
pain management or symptoms of hypotension. 
 
More specialist care includes cognitive behavioural therapy and graded exercise 
therapy, which is aimed at a gradual increase in activity duration and intensity, as well 
as improving emotional and cognitive capacity and resilience (35). 
 
 
23 
 
 The autonomic nervous system 1.10.
The ANS is a complex neural network largely under involuntary control (77). It controls 
contraction and relaxation of organs, blood vessel dilation and constriction and the 
force and rate of heart contraction. There are two complementary divisions: the 
parasympathetic and the sympathetic systems. The sympathetic nervous system drives 
a flight-or-fight response in part by increasing heart rate and blood pressure. The 
parasympathetic system has competing effects and works to save energy and reduce 
heart rate and blood pressure. 
1.10.1. The sympathetic nervous system 
The sympathetic division of the ANS acts largely to prepare the body for action. Its 
origins are in the sympathetic preganglionic neurons, which originate in the thoracic 
and lumbar spines (T1-L2/L3) (77). The axons of these neurons travel to the 
sympathetic ganglia, most of which are located at the vertebrae, which then synapse 
forming the postganglionic sympathetic fibres. These postganglionic sympathetic fibres 
innervate multiple organs, including the heart, lungs, digestive tract, blood vessels and 
sweat glands (86). 
1.10.2. The parasympathetic nervous system 
The parasympathetic division is involved in more restorative functions than its 
sympathetic counterpart, for example digestion and slowing of heart rate. It origins are 
in the sacral spine (S3-S4) and brainstem (77). The parasympathetic ganglia are often 
close to or on the target organ and, like their sympathetic equivalents, innervate the 
heart, lungs, digestive tract and visceral organs (86). 
 
Many organs are innervated by both arms of the ANS, often antagonistically, as 
outlined in table 3. 
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Affected organ Sympathetic action Parasympathetic action 
Heart Increased heart rate 
and force of contraction 
Decreased heart rate 
Blood vessels Vasoconstriction 
(vasodilation in skeletal 
muscle) 
Vasodilation in some 
exocrine glands 
Lungs Bronchial dilatation Bronchial constriction 
Eye Pupillary dilatation Pupillary constriction 
Adrenal medullae Secretion of epinephrine 
and norepinephrine 
No innervation 
Gastrointestinal tract Decreased motility and 
secretion 
Sphincter constriction 
Increased motility and 
secretion 
Sphincter relaxation 
Urinary bladder Inhibition of micturition Initiation of micturition 
Sweat glands Sweat secretion No innervation 
Metabolism Increase No effect 
 
Table 3 Principle antagonistic actions of the ANS 
Adapted from Pocock and Richards (86) 
 
The focus of this thesis is on the cardiac and blood pressure effects of the ANS. These 
are discussed below. 
1.10.3. Regulation: Baroreceptor reflex 
The degree of pressure in circulation is monitored in the short-term by baroreceptors, 
located primarily in the carotid sinuses – informing the carotid sinus nerves – and 
aortic arch, which relay information to the vagus nerve by sensing the amount of 
stretch in the vessel wall. Arterial blood pressure is tightly regulated in the longer-term 
by the kidneys and more acutely by hormonal and neural control (86).  
 
The baroreceptor reflex responds to subtle, prolonged changes in blood pressure over 
15 minutes at which time the threshold for feedback increases, for example when 
exercising, to allow for a maintained heart rate and ensure adequate cardiac output. 
 
It also plays an important role on standing to avoid postural hypotension. Starling’s 
Law describes the phenomenon of a drop in venous return to the heart on standing, 
resulting in a drop in cardiac output and blood pressure. The baroreceptor reflex acts 
to increase heart rate via sympathetic drive, thereby increasing total peripheral 
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resistance and increasing blood pressure. Although this response is acute, delays in 
blood pressure restoration can lead to postural hypotension or dizziness. 
1.10.3.1. At rest 
At rest the heart is dominated by parasympathetic control via the vagus nerve (86). 
This exerts an inhibitory function, slowing an otherwise unfettered heart rate of 
approximately 100 bpm to a resting heart rate of 60-80 bpm. 
1.10.3.2. On standing 
After standing there is a significant fall in venous return to the heart, which results in a 
fall in blood pressure. This is also known as postural hypotension. In response, 
increased sympathetic discharge results in an increase in heart rate and total 
peripheral resistance, which acts to restore blood pressure (86). 
1.10.3.3. The Valsalva manoeuvre 
The Valsalva manoeuvre is the act of expiration against a closed glottis. This gives rise 
to an increase in intrathoracic pressure and an initial rise in blood pressure followed by 
a brief fall in heart rate. As venous return is restricted by continued raised 
intrathoracic pressure, cardiac output and mean arterial pressure fall resulting in an 
increase in heart rate to maintain blood pressure. The end of the manoeuvre signals a 
transient fall in blood pressure before increased venous return results in increased 
cardiac output and a rise in blood pressure (86). 
 
There are four phases to the Valsalva manoeuvre. Their physiological changes and 
effect on blood pressure and heart rate are outlined in table 4. 
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Phase Response Systolic blood 
pressure 
Heart rate 
I 
Onset of strain: increased 
intrathoracic pressure 
 
Baroreceptor 
activation 
 
Increase 
 
Stable 
II 
Persistent strain: 
increased intrathoracic 
pressure 
 
Low venous return 
and stroke volume 
 
Decrease 
 
Increase 
III 
Release of breath-holding 
and glottic pressure: drop 
in intrathoracic pressure 
 
Release 
 
Decrease 
 
Stable 
IV 
Recovery: sudden 
increase in cardiac output 
 
Baroreceptor 
activation 
 
Increase 
 
Decrease 
 
Table 4 Phases of the Valsalva manoeuvre 
Adapted from Yale and Zygmunt (111, 112) 
1.10.4. Measuring autonomic nervous system function 
ANS function (or dysfunction) can be assessed subjectively using self-reported 
questionnaires and objectively through the measurement of defined physiological 
parameters. 
1.10.4.1. Subjective assessment 
Validated self-reported questionnaires provide a measure of subjective symptoms of 
AD across affected organ systems. 
 
The Orthostatic Grading Scale (OGS) is a validated tool (113) consisting of five items 
that assess the frequency and severity of orthostatic symptoms and the conditions 
under which they occur. Participants grade each item on a scale of 0–4, where 0 is the 
lowest and 4 the highest. These scores are then added to give a total score. Higher 
27 
 
scores indicate greater severity of OI. A limitation of this questionnaire is the narrow 
focus of symptoms covered, however it is an effective, easy-to-administer tool. 
 
The Composite Autonomic Symptom Score (COMPASS) encompasses a broader set of 
symptoms of AD and is validated for use as a quantitative measure of autonomic 
symptoms (114). It consists of 73 questions grouped into eight domains corresponding 
to different aspects of the ANS. These domains – OI, vasomotor, secretomotor, 
gastrointestinal, bladder, pupillary responses, sleep disorder, and syncope – are 
weighted according to their clinical relevance and the individual scores are totalled. 
The highest possible sore is 179 and the higher the score the greater the symptom 
load. 
 
The COMPASS 31 is an abbreviated version of the full COMPASS questionnaire. It has 
been shown to associate strongly with the full questionnaire (115, 116) and is suitable 
for use in a clinical environment. It consists of 31 questions across six domains. These 
domains are OI, vasomotor, secretomotor, gastrointestinal, bladder and pupillomotor. 
The highest possible score is 100 and is a marker of greatest symptom load. 
1.10.4.2. Objective assessment 
Responses of individual organs to the ANS can be measured. These include cardiac 
activity, respiration, pupillary responses, thermodynamics and the HPA axis (117). In 
relevance to this thesis, assessment of cardiovascular function is discussed below. 
 
Clinical assessment of cardiac autonomic function can be conducted as a one-off 
measure or as a continuous beat-to-beat outcome. Limitations of these methods 
include the possible confounding effects of co-morbidities, such as anaemia or thyroid 
dysfunction, or medications. 
1.10.4.2.1. One-off measures 
Autonomic effects on the heart can be measured with a 12-lead electrocardiogram 
(ECG), which provides a transient measure of cardiac electrical activity. Usually 
performed supine when vagal tone is greatest (118), the ECG depicts waves of 
depolarisation and repolarisation and allows assessment of heart rate and 
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conductivity, as well as other pathology (86). Assessment of heart rate provides an 
indication of sympathetic and parasympathetic response, as depicted in table 4. 
 
A limitation of this approach is that it measures heart rate at one time point, which 
may be affected by confounding factors including medication, co-morbidities and 
temperature. Furthermore, it is not a good distinguisher of sympathetic and 
parasympathetic activation (119). 
1.10.4.2.2. Continuous monitoring 
Continuous assessment over longer periods of time allows parameters such as heart 
rate, blood pressure variability and baroreceptor sensitivity to be measured. This can 
be achieved with an ambulatory ECG over a specified time period, for example 24 
hours, or by using more specialist equipment, such as a Task Force® Monitor. 
Additional electrodes that allow measurement of impedance cardiography can also be 
applied to investigate parameters such as stroke volume (120). 
 
Invasive measurement is also feasible and considered the Gold Standard, but rarely 
practical in circumstances other than in the context of therapeutic interventions in a 
clinical setting (121). 
 
As with other methods, limitations of continuous measurement include the lack of 
controlled conditions, whereby medications, ambient temperature and co-morbidities 
can all affect the ANS. 
1.10.4.2.3. Stimuli 
Both one-off and continuous assessment can be performed in response to different 
stimuli. The cold pressor involves submerging a hand in cold water for one minute and 
provides a measure of sympathetic activity. Active stand and head-up tilt (HUT) give a 
measure of parasympathetic response and sympathetic activation. The Valsalva 
manoeuvre can be performed to measure both sympathetic and parasympathetic 
activity. 
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 The prevalence of autonomic dysfunction in CFS 1.11.
A picture is emerging of an association between AD and CFS on subjective and 
objective testing. Nevertheless, studies are not without their limitations and direction 
of causality cannot be proven. The evidence for AD in CFS is reviewed below.  
 
A cross-sectional study of self-reported autonomic symptoms using COMPASS showed 
that almost 90% of CFS patients experience symptoms related to AD (122). These 
symptoms range from mild to severe and include palpitations, OI, urinary frequency 
and problems with temperature regulation (26). These subjective dysautonomic 
symptoms have been shown to be a better predictor of functional ability, or disability, 
than fatigue severity (122, 123). This strongly suggests that controlling autonomic 
symptoms could improve function in CFS and that effectiveness trials of medications 
that treat autonomic symptoms should be investigated. 
 
Over the last two decades consecutive studies have found an association between 
objective signs of AD and CFS. Some of the challenges that arise from interpreting this 
research, however, include the observational nature of many of the studies, meaning 
that direction of causality cannot be established – that is to say that AD might result 
from a more sedentary lifestyle secondary to the distinguishing features of the disease, 
rather than being a primary feature in itself. Furthermore, studies often work with 
small sample sizes of “well” patients with milder disease who are able to attend for 
investigations, which suggests a significant potential for volunteer bias and implies that 
those with more severe disease are not assessed. This has important implications for a 
condition which may be a spectrum of disorders and may be limiting the phenotype 
that is investigated. 
 
Despite the emerging picture of the role of the ANS, findings from existing research are 
not always reproducible and frequently describe small changes in autonomic function 
across a broad range of measures, which weakens the argument for its role. 
Nevertheless, evidence continues to suggest that ANS function differs in CFS compared 
to controls indicating that it may be a core feature of the disease and has utility as a 
potential clinical diagnostic biomarker. 
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 Literature review: Autonomic dysfunction in CFS 1.12.
A literature review was conducted to better understand existing evidence for the role 
of the ANS in CFS. A search was conducted via Ovid MEDLINE ® and Embase from 2000 
to present day. English language articles were sought. The search terms chronic fatigue 
syndrome and autonomic were used, which produced 250 articles after deduplication. 
Abstracts were reviewed and non-relevant studies excluded. Further articles 
referenced by these articles were reviewed. Opinion was also sought from experts in 
the field regarding more recent and current research and these articles were 
identified. The procedure of the literature search is outlined in figure 2. In total 26 
studies were reviewed (table 5). 
 
 
Figure 2 Procedure of literature search AD and CFS 
 
Literature search 
(n= 486) 
References and cited 
articles (n= 22) 
Search terms: chronic fatigue syndrome; autonomic 
Excluded (n= 409) 
Duplicate (n=109) 
Outside time limit (n=62) 
Not Englsh language (n=33) 
Not humans (32) 
Not relevant (n=173) 
 
Abstracts viewed 
(n= 77) 
Excluded as not 
relevant (n= 34) 
Studies included  
(n= 26) 
Systematic review (n=2) 
Review (n=1) 
Randomised control trial (n=1) 
Cohort (n=1) 
Prospective controled (n=1) 
Case control (n=9) 
Cross sectional (n=11) 
Full text viewed  
(n= 43) 
 
Excluded as not 
relevant (n= 17)  
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Two recent systematic reviews support the finding of AD in CFS. In a recent review 
looking at 27 case-control studies van Cauwenbergh et al conclude that autonomic 
response to HUT appears to be an important diagnostic feature of CFS (124). A further 
systematic review by Meeus et al examines heart rate variability (HRV) in CFS and 
fibromyalgia (125) and concludes that CFS patients show increased sympathetic 
activity at night. Significantly, however, the quality of evidence reviewed in both 
articles is variable and focusses on case-control studies. This raises two principle 
issues: firstly of undetermined causality and secondly of the possibility of confounders, 
for which adjustment is not consistently made. 
 
Concerns about the validity of Meeus et al’s review have been voiced by Tak et al (126) 
and centre on the complexity of measuring HRV and uncertainty about its validity as an 
outcome, as well as possible publication bias in existing studies which, when adjusted 
for, results in no demonstrable association between parasympathetic activity and 
conditions including CFS. In their response to Meeus et al, Tak et al discuss their own 
systematic review of the methodological quality of HRV studies in somatic disorders, in 
which they conclude that the quality of existing evidence is inadequate to determine 
the role of AD in somatic disorders such as CFS. 
 
These reviews and their opposing conclusions highlight the challenges of both 
conducting research into a condition that is little understood and of interpreting 
findings. This is discussed further below. 
1.12.1. Diagnostic criteria 
One of the fundamental difficulties in identifying patients with CFS lies in the use of 
different diagnostic criteria, as discussed previously in section 1.4. Research has shown 
that the degree of subjective impairment differs between criteria (5). By implication 
this suggests that different pathologies may underpin the phenotypes; however, 
without an accurate and consistent identification of disease phenotypes research into 
underlying aetiology becomes complicated. 
 
The studies reviewed considered patients who fulfilled established criteria for CFS (20, 
22, 37, 39, 40). While these criteria are widely used in clinical practice and have similar 
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core features, each defines CFS in a slightly different manner (see table 2 section 1.4). 
The majority of studies used the Fukuda criteria (122, 127-133) and CDC definition 
(133-146), however a small number used the 1988 criteria, upon which the 1994 CDC 
definition was based (147, 148) and one used the Oxford criteria (149).  
 
As discussed, there is disparity between criteria. The most noteworthy discrepancies 
include the limited symptom base in the Oxford criteria (37), as well as the absence of 
autonomic symptoms in the Fukuda criteria (22) and the CDC case definition (20). It is, 
therefore, plausible that different phenotypes across a spectrum of chronic fatigue 
syndromes are being investigated. If these phenotypes have different presenting 
features or underlying signs of dysautonomia, this will cloud research findings and 
make them difficult to interpret. Furthermore, it is accepted that fatigue can have 
different origins, as discussed by Newton et al (150), reinforcing the need for a 
consistent set of diagnostic criteria. 
1.12.2. Average heart rate 
Heart rate has been shown to be increased in CFS groups both at rest: at baseline (134, 
148) and when asleep (134); and in response to stress: on standing (142, 148), after 
tilting (135) and after the cold pressor test (135).  
 
The corrected QT interval (QTc) represents the time for ventricular depolarisation and 
repolarisation. It is influenced by autonomic – particularly vagal – tone. Naschitz et al 
(138) found that the average supine QTc in CFS was significantly shorter than the 
control group, indicating abnormality at rest. Scott et al (131) studied 220 patients 
with fatigue, 177 of whom fulfilled Fukuda criteria for CFS. They also observed that the 
QTc was significantly shorter in the CFS group compared to non-fatigued controls, 
indicating rapid repolarisation that has been associated with sudden cardiac death 
(151). 
 
Changes in heart rate have been found in response to stress. The findings of van 
Cauwenbergh et al’s systematic review suggest that heart rate in response to the 
physiological stress of a HUT represents an important marker of AD in CFS, despite an 
overall moderate quality of case-control studies included (124). 
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Furthermore, mental arithmetic testing has been associated with an increased heart 
rate, suggestive of a decreased cardiac sympathetic response to mental stress (149). 
The same study by Soetekouw et al investigated response to a number of other 
physiological stimuli, including standing or Valsalva, and found no significant 
differences in heart rate between CFS patients and controls. This illustrates the lack of 
consistent findings across studies, perhaps as a consequence of small sample sizes, and 
implicates the possible role of confounders, such as deconditioning. 
1.12.3. Heart rate variability 
Individual studies have observed fluctuations in HRV between CFS and control groups. 
Like many studies of AD in CFS, however, findings are not always consistent and show 
variation in outcome measures.  
 
This is illustrated by the findings of the following studies. Frith et al (152) found greater 
HRV in CFS – specifically representing low frequency (LF) variability – reflecting 
sympathetic function suggestive of an association between CFS and increased 
sympathetic activity. In response to the physiological stress of HUT, aperiodic spectral 
components of HRV have also been shown to be significantly lower in CFS compared to 
controls (144) and may relate to loss of HRV modulation. 
 
Meeus et al’s recent systematic review looking at HRV found moderate evidence to 
support decreased HRV in sleep in CFS subjects. From their review they concluded that 
parasympathetic activity, as seen by reduced high frequency (HF) bands and low 
frequency/high frequency (LF/HF) ratio, and sympathetic activity on upright tilt were 
similar in CFS patients compared to controls (125). Limitations of this review have been 
discussed and include concerns over the methods used to measure HRV and lack of 
consistency in the outcomes assessed, such that an earlier meta-analysis concluded 
that the quality of existing evidence is insufficient to demonstrate that AD is associated 
with CFS (153). 
 
Therefore, while there is evidence that supports abnormal HRV in CFS, lack of 
consistency and reproducibility suggest that potential confounders, such as medication 
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or co-morbid conditions, may have an important role to play and once again highlights 
the need for gold standard, reproducible research methods. 
1.12.4. Blood pressure 
Abnormal blood pressure has been associated with CFS. Newton et al (129) observed 
that, compared to a sedentary control group, a CFS group had statistically significantly 
(p=<0.0001) lower systolic blood pressure and lower mean arterial blood pressure 
(p=0.0002) assessed by 24-hour ambulatory blood pressure measurement. 
 
This study also assessed a fatigue comparison group looking at patients with primary 
biliary cirrhosis (PBC). The CFS group had a lower systolic blood pressure compared to 
this fatigue comparison group; however, both ‘fatigue’ groups had comparable 
diastolic blood pressure. As with many studies of CFS, causality cannot be inferred 
from this cross-sectional study and it is important to note that the CFS group was 
younger at baseline, which may be a cause of the lower systolic blood pressure seen. 
 
Nevertheless, this study did show an inverse relationship between subjective fatigue 
and diurnal variation of blood pressure in both CFS and PBC groups suggesting that a 
dysautonomia-associated fatigue may underpin CFS and PBC. This possibility is 
supported by a further study by the same team looking at a subjective measure of 
autonomic symptoms using the COMPASS questionnaire, which found that it has a 
positive predictive value for CFS of 0.96 95%CI 0.86–0.99) (122). 
1.12.5. Orthostatic hypotension 
Orthostatic intolerance is a common feature of many chronic diseases (154) with 
distinct aetiologies and may relate to secondary symptoms of these conditions rather 
than arise from a primary dysautonomia.  
 
Jones et al (136) looked at the potential association between orthostatic instability and 
CFS. Their findings showed no orthostatic instability on stand-up test in either group 
and found that 30% of CFS patients had orthostatic instability on HUT compared to 
48% of controls. They questioned the validity of primary dysautonomia in the 
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pathophysiology of CFS, as they found similar patterns of instability in both the CFS 
and control groups. 
 
This is supported by Naschitz et al‘s study conducting HUT in CFS subjects. The 
investigation had to be halted prematurely in 22.5% of CFS patients and 23.3% of non-
CFS fatigued patients, as a result of orthostatic symptoms (146). Non-fatigued controls 
all tolerated the procedure, which does suggest a fatigue-associated dysautonomia (as 
Newton et al suggest (122)), however the similar termination rate in both fatigue 
groups raises the question of whether this dysautonomia is secondary to fatigue, or 
whether a similar underlying aetiopathogenesis is present. 
 
Hollingsworth et al (128) examined the relationship between skeletal and cardiac 
function and symptoms on standing. They found a high prevalence of orthostatic 
problems in the CFS group, including increased cardiac contractility in response to the 
stress of standing. The CFS group also appeared to require greater cardiac activity on 
standing, reflected by a higher left ventricular work index (LVWI). Although a small 
study, its results have some clinical significance when considered in the context of 
evidence of an increased risk of cardiac mortality in fatigued PBC patients (155), which 
may imply an underlying causative mechanism. 
1.12.6. Blood pressure variation 
A number of studies have observed abnormalities in blood pressure variation in CFS 
patients in response to physiologic stress. Frith et al (152) found reduced systolic blood 
pressure variability on standing and greater LF HRV (a sympathetic marker) in CFS 
subjects compared to controls. 
 
These findings are supported by Wyller et al (143) who examined blood pressure 
variability and closed-loop baroreflex function both at rest and during mild orthostatic 
stress. They found lower variability of HF systolic blood pressure and greater 
sympathetic baroreflex heart rate control during orthostatic stress in the CFS group. 
 
Measures at rest do not appear to be significant (149), however greater diurnal 
variation in blood pressure has been observed (129) in CFS patients compared to 
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controls. Although Soetekouw’s observation of greater responses in systolic and 
diastolic blood pressure during Valsalva in the CFS group was not statistically 
significant and therefore not considered to indicate a meaningful difference in 
cardiovascular autonomic function in CFS (149), evidence does appear to suggest that 
blood pressure variation is response to orthostatic stress may have potential for use as 
a biomarker of CFS. 
1.12.7. Postural Tachycardia Syndrome 
The hypothesis that PoTS patients may represent a clinically important subgroup of 
CFS is gaining momentum (156, 157). 
 
PoTS is a disorder of OI characterised by an increase in heart rate on standing of at 
least 30 beats per minute (bpm) higher than the baseline value without concurrent 
orthostatic hypotension (OH), defined as a drop in systolic blood pressure of >25 
mmHg or a drop in diastolic blood pressure of >10 mmHg (158). It is associated with 
symptoms of OI, such as dizziness, tingling, light-headedness or presyncope. 
 
There is a growing body of evidence suggesting an association between postural 
tachycardia and CFS. Hollingsworth et al (128) observed that nearly one third of 64 
participants in a CFS/ME cohort had diagnosable PoTS on haemodynamic testing 
compared to four in the control group. Although the prevalence of PoTs in the whole 
population is not known, it has been estimated to be 0.2-1% (159, 160). 
 
A recent cross-sectional study from Australia of 306 CFS patients found co-morbid 
PoTS in 11% of the cohort (158) and suggests that associated haemodynamic between-
group differences, including heart rate and blood pressure on standing, may be seen in 
a subset of CFS patients pointing towards the possibility of a disease spectrum. 
 
This association is further seen when assessing fatigued PoTS patients according to CFS 
criteria. Okamoto et al (140) examined 47 patients with established PoTS. They found 
that 93% of this group had symptoms of severe fatigue and 30 fulfilled CDC criteria for 
CFS. They also observed greater orthostatic tachycardia in the CFS-PoTS group 
compared to the non-CFS-PoTS group and more variability in LF blood pressure, 
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suggesting greater sympathetic activity and the possibility of a similar underlying 
causal pathway. 
 
Furthermore, a recent cross-sectional study examined subjective autonomic symptom 
burden, as assessed by the orthostatic grading scale. Findings of a significantly higher 
symptom burden in patients with PoTS alone and PoTS with co-morbid CFS compared 
to CFS alone suggest that these two conditions may share a similar aetiopathogenesis 
(132). 
1.12.8. Sources of variation and potential confounders 
The hierarchical level of evidence of these studies is predominantly low (125). Studies 
of AD and fatigue are largely observational (case control) and it is, therefore, not 
possible to determine the causal direction for abnormalities observed. In addition, 
many studies are limited by small cohort sizes, perhaps resulting from illness severity 
prohibiting participation, which weakens the statistical likelihood of findings being 
significant.  
 
While most studies attempt to reduce confounding variables with specified exclusion 
criteria, including medications and co-morbid conditions, as well as matching baseline 
characteristic between cohorts, these are not uniformly adopted across all studies. The 
effect of this may be such that associated variables, rather than CFS, contribute to the 
observed dysautonomia. 
1.12.9. Autonomic assessment 
Most of the studies reviewed used continuous beat-to-beat monitoring; others 
assessed autonomic function as a series of one-off measurements. There is recognised 
difficulty in assessing and evaluating autonomic function (112, 161). Technology now 
allows assessment of continuous measurement of autonomic parameters over the 
short to medium term. This advancement is important for appropriate clinical 
assessment and future studies, and may represent a more comprehensive way of 
measuring autonomic function. The development of longer-term continuous 
measurement tools will further enhance future research and may be developed as a 
gold standard assessment tool. 
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1.12.10. Medication 
Medications, such as antidepressants and analgesics, can affect the ANS. Some of the 
studies excluded medications for this reason, however it is not clear whether this was 
the case in all studies. Standardised exclusion of medication would strengthen results 
and reduce potential confounders. 
1.12.11. Depression 
Three studies excluded participants with a diagnosed psychiatric disorder. Of these, 
two found minimal change in autonomic function between the CFS and control groups. 
This raises a question of whether the demonstrated AD in CFS studies is accounted for 
by inclusion of patients with depression. 
1.12.12. Co-morbidities 
Conditions that affect cardiovascular or ANS function, such as existing cardiovascular 
disease, diabetes mellitus or anaemia, are potential confounders and are not 
consistently excluded. 
1.12.13. Cardiovascular deconditioning  
There are arguments that cardiovascular deconditioning related to less vigorous 
activity may be the cause of the ANS problems, including PoTS (162), in CFS (142, 148, 
163). As with other studies investigating the underlying pathology of CFS, the direction 
of causality has not been proven and this remains, therefore, a controversial and 
much-debated subject. 
 
Other studies (130) have examined BMI-matched CFS and control groups with similar 
patterns of sedentary behaviour and observed different autonomic findings in the CFS 
group, reinforcing the argument that it is an underlying pathology in this group that 
leads to a reduction in physical activity. Furthermore, a recent case control study 
identified a subgroup of fatigued CFS patients with no AD symptoms, suggesting that 
deconditioning cannot explain the principle symptoms of CFS (122) and supporting the 
finding in another study that physical deconditioning is not a perpetuating feature of 
CFS (164). 
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It may be that the autonomic profile represents an indicator of disease severity with 
sympathetic overactivity as an initial abnormality with subsequent associated 
parasympathetic withdrawal. There is evidence in favour of both decreased 
parasympathetic activity and increased sympathetic activity. Findings by Frith et al 
(152) and De Becker et al (135) are indicative of sympathetic overactivity. Similarly, 
Okamoto et al (140) found greater low-frequency blood pressure variability - a marker 
of sympathetic activation - in the CFS-PoTS group. Conversely, Naschitz et al (138) 
comment that if the shortened QTc intervals they observed were due to 
parasympathetic withdrawal they would have expected to see a shorter QTc on tilt 
testing compared to baseline. 
 
While there are pointers that sympathetic activity may be increased and be the 
consistent feature of AD in CFS patients, future electrophysiological studies could 
delineate the relative contribution of parasympathetic and sympathetic change in CFS. 
 
These are important considerations. Nevertheless, in the context of clinically-
significant symptoms seen on subjective questionnaires such as COMPASS or during 
objective testing, there is a plausible basis for the hypothesis that dysautonomia is a 
central feature of CFS. 
1.12.14. Treatment implications 
Defining the specific autonomic abnormalities in CFS has implications not only for 
diagnosis but also for treatment. Sutcliffe et al examined the effectiveness of home 
orthostatic training in CFS and found that there was an improvement in blood pressure 
maintenance on standing in the group receiving training, which was maintained at six 
months (165). There was also a trend towards fatigue improvement at six months. This 
indicates that a larger-scale trial would be beneficial. 
 
There is mixed evidence about pharmaceutical interventions. Fludrocortisone acetate 
has been shown to have some benefit in global wellness in CFS (141) but the study 
team concluded that there was insufficient difference compared to controls to 
determine that fludrocortisone acetate is an appropriate treatment option.  
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Newton et al’s (129) study looking at blood pressure circadian rhythm in CFS patients 
suggests an area for future research is the effectiveness of agents to increase blood 
pressure, such as midodrine.  
 
Midodrine has not yet been subject to a randomised controlled trial but has been 
shown to be beneficial in case series. Naschitz et al (137) conducted a pilot study with 
midodrine in CFS patients with observed dysautonomia on HUT test. Six out of ten of 
the group had subjective and objective symptom improvement during ten months of 
treatment, which would indicate a place for further research into its efficacy and use in 
managing the symptoms of AD in CFS. 
1.12.15. Conclusion 
The findings of this literature review support the case for abnormalities in the 
autonomic nervous system in CFS. Subjective autonomic symptoms are well 
documented and appear to correlate to fatigue severity. There is an emerging picture 
across studies of subtle changes in objective autonomic function in CFS that include a 
raised heart rate – at rest and in response to stress – and lowered blood pressure, with 
possible sympathetic overactivity and corresponding decreased parasympathetic 
modulation. These changes may arise secondary to infection and a predisposing 
genetic susceptibility (166). 
 
Nevertheless, this picture is blurred as a result of the use of different diagnostic 
criteria, which may be selecting CFS participants with different symptom burdens. 
Furthermore, inconsistent exclusion for comorbid disease – in particular depression 
where AD has also been demonstrated – means it is difficult to attribute abnormalities 
to one or other condition. The use of consistent criteria in future research would 
facilitate delineation of these autonomic symptoms. 
1.12.16. Future research 
Studies to date demonstrate AD in CFS. Future research is needed to explore AD with 
standardised measures and with more uniform diagnostic and exclusion criteria, 
including examining sedentary controls, in order to avoid the confounder of 
deconditioning, and ensuring consistency with psychiatric exclusion criteria.  
41 
 
Defining the specific abnormalities of autonomic function that occur in CFS, 
particularly whether they are central or peripheral, will lead to objective diagnostic 
criteria and identify potential treatment targets for this chronic debilitating condition. 
 
Key to this is the exploration of potential functional and phenotypic differences by 
diagnostic criteria, which will enable better characterisation of a condition which may 
present across a spectrum of disease. 
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 Depression: A potential confounder 1.13.
There is a complex relationship between chronic diseases, particularly those that are 
difficult to manage and treat, and depression. This is further complicated in CFS by the 
absence of a biological marker and by the significant shared symptomatology. As such, 
it is an often-ignored confounder in studies. This section considers the implications of 
these common symptoms. 
1.13.1. Shared symptoms 
There is significant overlap between the symptoms of depression and the symptoms of 
CFS (table 8). Diagnostic criteria for CFS are detailed in table 2, section 1.4. Diagnostic 
criteria for depression are shown in tables 6 and 7. The WHO International 
Classification of Diseases version 10 (ICD-10) is the standard diagnostic tool for disease 
in clinical practice in the UK (167). The Diagnostic and Statistical Manual of Mental 
Disorders version IV (DSM-IV) is the standard classification of mental disorders in 
research (worldwide and in clinical practice in the US (168)): it forms the basis of the 
diagnostic tool used in this study. 
ICD-10  
F32 Depressive episode 
 
 
 
 
 
 
 
 
 
 
 
 
 
Core symptoms: 
 Depressed mood 
 Loss of interest and enjoyment 
 Increased fatigability 
Other symptoms: 
 Reduced concentration and attention 
 Reduced self-esteem and confidence 
 Guilt and unworthiness 
 Pessimistic views of the future 
 Ideas of self-harm/suicide 
 Disturbed sleep 
 Diminished appetite 
 Mild 
 
 
Moderate 
 
 
Severe 
 
≥ two weeks of ≥ two core symptoms 
≥ two other symptoms 
 
≥ two weeks of ≥ two core symptoms 
≥ three and preferably four other symptoms 
 
All three core symptoms 
≥ four other symptoms of severe intensity 
Table 6 ICD-10 diagnostic criteria for depressive episode 
Taken from (169) 
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DSM-IV 
Major Depressive Disorder 
requires ≥ two episodes 
≥ two weeks of  
 Depressed mood, and/or  
 Loss of interest or pleasure in life activities 
≥ five of the following (causing clinically significant 
impairment in social, work, or other important areas of 
functioning almost every day): 
 Depressed mood most of the day 
 Diminished interest or pleasure in all or most 
activities 
 Significant unintentional weight loss or gain 
 Insomnia or sleeping too much 
 Agitation or psychomotor retardation noticed by 
others 
 Fatigue or loss of energy 
 Feelings of worthlessness or excessive guilt 
 Diminished ability to think or concentrate, or 
indecisiveness 
 Recurrent thoughts of death 
Table 7 DSM-IV diagnostic criteria for depression 
Taken from (168)  
 
Proper exploration of the origin and nature of depressive symptoms is essential. Low 
mood is distinguishable from depressed mood and does not meet the diagnostic 
criteria. Furthermore, depressive symptoms may be better accounted for by the 
presence of a physical disorder, classified as F54 Psychological and behavioural factors 
associated with disorders or diseases classified elsewhere. 
 
Within the WHO’s ICD-10 criteria there is acknowledgement that differentiation 
between mild, moderate, and severe depressive episodes relies on a “complicated 
clinical judgement” of the number, nature, and severity of symptoms (169). Reaching a 
diagnosis of depression is a subjective judgement that is prone to inter and intra-
individual variation. 
 
Severity of depression is determined by the presence of increasing numbers of 
symptoms and increasing severity of functional impairment. This loss of function and 
its variable nature overlaps with features of CFS and complicates distinction between 
the two conditions. 
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Comparison of CFS and depression diagnostic criteria reveals the shared 
symptomatology. A recent study investigating this overlap found that 38% of those 
with Major Depressive Disorder (MDD) met the CDC criteria for CFS (38).  
 
Symptoms Forms part 
of ICD-10 
criteria for 
depression 
Forms part 
of Fukuda 
criteria of 
CFS 
Prevalence (%) 
 
Depressive 
disorder 
CFS Healthy 
controls 
Depressed 
mood 
  95 65 1 
Loss of interest 
or pleasure 
     
Fatigue or low 
energy 
  19 100 4 
Disturbed sleep   95 98 9 
Poor memory 
or 
concentration 
  79 83 1 
Low self-
confidence 
     
Change in 
appetite 
     
Suicidal 
ideation 
     
Agitation or 
slowing of 
movement 
     
Guilt      
Sore throat   11 64 8 
Tender lymph 
nodes 
  11 65 4 
Myalgia   68 89 31 
Arthralgia   50 73 17 
Headache   22 59 7 
Table 8 ICD-10 Symptoms shared between depression and CFS and their prevalence 
Taken from Komaroff (26, 46) 
 
This shared symptomatology may characterise an underlying common causal pathway 
(170) whose phenotype represents a spectrum of disease. This spectrum may include 
patients who are currently classified as having either CFS or depression, some with 
more fatigue-type symptoms and some with more depressive-type symptoms (171). 
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Evidence examining the potential for a shared aetiopathogenesis is discussed in 
section 1.13.2. Alternatively, CFS and depression may indeed be distinct disorders, 
which will one day be biologically separable. 
 
It may be that clinicians intuitively apply more sophisticated assessment to 
differentiate CFS from MDD than that available in ICD or DSM. Anecdotally, patients 
with CFS report frustration and inability to perform tasks as limiting factors rather than 
a lack of motivation, this suggests a definite lack of physical capacity to participate in 
activities rather than a lack of impetus or motivation.  
 
Moreover, low mood experienced by CFS subjects is described as secondary to 
frustration about physical symptoms and a sense of profound helplessness, which may 
be distinguishable from the low mood seen in depression that is often accompanied by 
pessimistic feelings about the future with or without suicidal ideation (172). 
Furthermore there is evidence that low self-esteem is not a feature of CFS, whereas it 
is common in depression (172, 173), and indicates that a detailed exploration of each 
symptom is central to reaching the correct diagnosis.  
 
Studies show that the criteria for depression that are met by CFS patients relate to 
changes and disturbances in mood, weight, appetite and sleep, as well as somatic 
symptoms. If this mood change reflects and arises from a change in physical 
functioning there is an argument that the underlying origin is different from that in 
depression. 
 
Criteria that are currently recognised as the Gold Standard diagnostic tool for these 
conditions may, in fact, be confounding a distinction between depression and CFS. If 
they are two distinct disorders, diagnosed clinically on the basis of many shared 
symptoms, patients with one condition may meet the criteria for the other. This has 
important implications, firstly in terms of clinical management and the wider 
perception of CFS, and secondly in terms of research into its pathogenesis.  
 
Studies have attempted to differentiate between these overlapping symptoms and 
elucidate whether discrimination between their presence in these two conditions is 
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possible. A randomised controlled trial of the efficacy of fluoxetine on symptoms in 
CFS patients found no beneficial effect on any CFS characteristics (174). Although it is 
difficult to draw conclusions about the underlying pathophysiology from this (not all 
MDD patients respond to antidepressants (175)) it may be an indication that CFS is 
distinct from major depression (where Fluoxetine can improve symptoms (176)). 
 
Deeper understanding of the nature of symptoms and associated features, for example 
mood and esteem, will help differentiate between the two. In the context of the 
challenge of differentiating between these two conditions, proposals that specific 
symptoms are suited to enable distinction offer promise. A better understanding of 
these symptoms – post-exertional malaise, unrefreshing sleep, and impaired memory 
or concentration (177) – as well as a deeper exploration of individual patients’ clinical 
presentation will allow more accurate diagnosis. 
1.13.2. Biological mechanisms 
Some researchers hypothesise that the same biological mechanisms underpin these 
common characteristics, forming part of a disease spectrum. Similar underlying 
inflammation and cell-mediated immune activation has been seen in both CFS and 
depression, suggesting a common underlying causal pathway may be responsible for 
the overlapping phenotype (178).  
1.13.2.1. Autonomic dysfunction 
Depression has been associated with markers of AD, including elevated levels of 
catecholamines (80) and abnormalities of heart rate, such as lower HRV. A number of 
studies have shown elevated resting heart rate in patients with depression, as well as 
higher responses to physical stressors, such as standing (179), and suggest that 
parasympathetic activity may be diminished with an associated increase in 
sympathetic activity (180). This differs from some studies exploring CFS, which have 
found decreased LF and very LF in CFS subjects (134), suggesting an impaired 
sympathetic drive. 
 
Altered HRV with lower HF components and higher LF have also been associated with 
depression, again suggesting an enhanced sympathetic drive, with a positive dose-
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response shown by greater severity of AD correlating to greater depression severity 
(181). Other studies have found no significant association between depression and LF 
or HF after adjustment for confounders (182).  
 
Although AD may be important, lack of consistent research makes it difficult to 
determine the direction of causality or to fully support the hypothesis that AD is a 
common mechanism for CFS and depression. Furthermore, AD is found in a number of 
other conditions and may therefore not be disease specific or may arise from common 
symptoms such as fatigue. 
1.13.2.2. Immune system 
While some research has shown higher inflammatory markers in CFS compared to 
depression (183), other studies suggest that the presence of somatic symptoms may 
be the determining factor in immune dysfunction in both conditions. Patients with 
depression who also exhibit somatic symptoms have been shown to have significantly 
increased IL1 and TNF-α compared to those without somatic symptoms (178), which 
mirrors the findings of some studies that have found these to be elevated in CFS (76). 
This points towards the possibility of a spectrum of related disorders.  
 
The role that co-morbid depression has in this is unclear. The neurotransmitter 
neuropeptide Y, a stress mediator produced by neurons of the sympathetic nervous 
system, has been shown to be elevated in CFS and also correlates with both stress and 
depression (184), complicating interpretation of the underlying reasons for this 
elevation.  
1.13.2.3. Hypothalamic-pituitary-adrenal axis 
Both depression and CFS are linked to disruption of the HPA axis. Findings suggest 
opposing directions of dysfunction with down-regulation of the HPA axis seen in CFS 
and up-regulation in depression (185-187). Research findings are not consistent, 
however, and it is likely that findings are confounded by the presence of both CFS and 
depression in some subjects. 
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1.13.3. Cognitive impairment 
Cognitive impairment has been shown in CFS and MDD. Similar motor impairment on 
cognitive testing has been seen in both conditions with MDD subjects demonstrating 
impaired performance compared to CFS (188).  
 
Cognitive impairments in MDD subjects have been shown to be strongly associated 
with depression severity and subjective fatigue; in patients with CFS, one study has 
shown  a weaker correlation between cognition and depression (and no correlation 
with fatigue) (189). This study found that CFS subjects were less depressed than MDD 
subjects and raises the question of whether the observed cognitive impairment was 
secondary to CFS or arose from co-morbid depressive symptoms. 
1.13.4. Current challenges 
There are important questions to be considered. Depression and CFS may lie on the 
same disease spectrum, sharing symptoms but manifesting with different phenotypes 
(170, 171). Another important consideration is whether depression predisposes to or 
causes CFS. Early adversity may also be important, as a trigger for subsequent major 
depressive disorder which may, as a series of stages or as a result of complex interplay, 
cause CFS. 
 
If depression and CFS are different disease processes, co-morbid depression may 
impact the effect of CFS and resilience to symptoms. Furthermore, it may alter the 
recollection or impact of adversity. Future research should, therefore, control for co-
morbid depression to enable better understand of the relationship between the 
conditions. 
 
The available evidence relating to commonalities in the symptom profiles and 
biological associations of these two disorders mean that it is not possible to confirm or 
exclude the supposition that they are distinct and separable disorders, neither that 
they have a unitary shared pathogenesis nor that the disorders represent the 
phenotypic expression of complex interplay between the body’s regulatory 
homeostatic systems. In research and in clinical practice differentiation between the 
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two disorders and the determination of comorbidity is imprecise and subject to 
judgement without clear anchor points.  
1.13.5. Future direction 
A better understanding of the qualitative nature of the distinguishing symptoms that 
can be taken into field trials for revised diagnostic criteria, utilisation of more 
sophisticated clinical precision in pathophysiological studies, a better understanding of 
the impact of potentially shared aetiological factors, such as early adversity, and the 
use of a systems-based approach to examine the relationships between symptoms and 
biological concomitants will allow the field to progress and will support stratified or 
shared treatment decisions. 
 Impact of autonomic dysfunction in CFS: Cognitive function 1.14.
Autonomic dysfunction in CFS affects many of the body’s systems. This thesis focusses 
on its potential role in cognitive impairment.  
 
Cognitive impairment is a recognised symptom of CFS and is one of the diagnostic 
criteria for Fukuda (22). Up to 95% of people with CFS have reported problems with 
cognitive function at some point during the course of their illness (26, 33). Studies 
examining cognitive problems in CFS are limited and interpretation complicated by the 
use of different test batteries and by a lack of consistency, both in terms of results and 
control conditions. Despite this, findings suggest that abnormalities of information 
processing speed, impaired working memory and information learning are features of 
cognitive impairment in CFS and appear to occur independently of fatigue and co-
morbid depression (190). 
 
The possible underlying aetiology of cognitive impairment encompasses degenerative, 
vascular, metabolic, psychiatric and iatrogenic causes (191). Some of these are 
implicated in the presence of autonomic dysfunction, which has been associated with 
cognitive impairment and is discussed in section 1.14.2. 
 
The heterogeneous clinical presentation and aetiology of cognitive impairment is 
illustrated though its association with many chronic diseases, including 
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neuroendocrine disorders and organic brain disease. Sleep disorders have been shown 
to be associated with an increased risk of developing OH and cognitive impairment 
(192). Similarly, type 2 Diabetes Mellitus has been shown to negatively impact 
cognitive function, which may represent a link between metabolic syndrome and 
vascular dementia (193). Elevated cortisol has also been associated with cognitive 
impairment – and with dementia (194, 195) – suggesting that HPA axis dysregulation 
may be a risk factor for poor cognitive function. 
 
Both hypertension and hypotension have been associated with impaired cognitive 
function (196-200). This has been evidenced particularly among elderly populations 
but research has also shown an association between hypotension and impaired 
cognitive function, specifically visuospatial function, in younger individuals (201), 
possibly secondary to cerebral hypoperfusion. 
1.14.1. Cognitive function 
Table 9 outlines cognitive function and its corresponding neuroanatomical control.  
 
In broad terms, the frontal regions of the brain – the limbic system, thalamus, 
hypothalamus, basal ganglia, and cerebral cortex – are used for planning and thinking 
and the posterior – medulla, cerebellum, and pons – for vision, memory, movement 
and sleep. Exact functioning is not fully understood and results from a complex 
interplay of processes and regions (202). 
 
 
 
 
 
 
 
 
 
 
56 
 
Function Control 
Memory Verbal Prefrontal cortex; left temporal lobe; 
hippocampus; limbic system 
  Visuospatial Prefrontal cortex; hippocampus; occipital lobe; 
posterior parietal lobe 
Executive  
Composed of several higher 
cognitive skills, including 
working memory, reasoning, 
problem solving, execution 
 
Pre-frontal cortex 
Psychomotor speed 
Relationship between 
cognition and physical 
movement 
 
Frontoparietal lobe 
Attention Parietal lobe 
 
Table 9 Cognitive function and corresponding brain centre 
Taken from (202-209) 
1.14.2. Autonomic dysfunction and cognitive function in non-CFS 
Studies of the pathophysiology of organic psychiatric disorders, including dementia, 
have demonstrated a ‘U’ or ‘J’-shaped association with abnormalities in blood pressure 
– that is they are more prevalent at both extremes and the upper end of blood 
pressure. A systematic review examining the relationship between blood pressure and 
Alzheimer’s disease found an inverse association between hypertension later in life 
and Alzheimer’s. Studies included are, however, limited by selection bias, lack of 
participant homogeneity and an inability to determine causality (210). 
 
Hypotension has been found to be protective of memory, as tested using the Mini 
Mental Status Examination in an elderly population over 80 years of age (211). 
Conversely, OH appears to be negatively associated with memory and overall global 
functioning in both younger and older populations (196, 212, 213) and has been 
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associated with poorer cognitive performance, both in terms of a drop in blood 
pressure on standing and longer time to recovery to baseline blood pressure (214).  
 
This may reflect the ‘U’-shaped association and point towards the existence of a 
protective threshold, below which risk of developing cognitive problems increases. 
Furthermore, blood pressure variability has also been linked to cognitive impairment 
with increased variability being associated with greater dysfunction in elderly patients 
(215, 216). 
 
Evidence currently provides a mixed picture for the role that AD has to play in 
cognitive impairment and studies tend to focus on effects in older patients. This means 
that comparison with CFS patients, where the patient demographic is younger (mean 
age of onset age 30 years (217)) is difficult. This mixed picture is mirrored in research 
into cognitive impairment in CFS, as described in the following review.  
 Literature review: Cognitive function in CFS 1.15.
A literature review was conducted to examine existing research assessing subjective 
and objective cognitive problems in CFS and to explore the pathophysiological 
processes that might be underpinning these problems. 
 
The search was conducted via Ovid MEDLINE ® and Embase from 2000 to present day. 
English language articles were sought. The search terms chronic fatigue syndrome and 
cognitive dysfunction were used, which produced 44 articles after deduplication. 
Abstracts were reviewed and non-relevant studies excluded. Further articles 
referenced by these articles were reviewed. Opinion was also sought from experts in 
the field regarding more recent and current research and these articles were 
identified. The procedure of the literature search is outlined in figure 3. In total 10 
studies were reviewed (table 11). 
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Figure 3 Procedure of literature search cognitive function and CFS 
1.15.1. Challenges of testing cognitive function in CFS 
The limitations of investigating cognitive dysfunction in CFS are well recognised (218). 
As with studies examining the role of the ANS in CFS, research investigating cognitive 
function is limited by lack of heterogeneous cohorts and comparison groups and small 
sample sizes leading to insufficient statistical power. 
 
One of the primary challenges lies with a lack of consistent test battery for 
neuropsychological testing. Table 10 shows some of the tests used in research, as well 
as the domain assessed, and gives a picture of the breadth of tools available. While 
they examine the same overarching area of functioning, many of the deficits observed 
Literature search 
(n=98) 
References and cited 
articles (n=44) 
Search terms: chronic fatigue syndrome; cognitive dysfunction 
Excluded (n=98) 
Duplicate (n=19) 
Outside time limit (n=23) 
Not Englsh language (n=6) 
Not humans (4) 
Not relevant (n=46) 
 
Abstracts viewed 
(n=44) 
Excluded as not 
relevant (n=23) 
Studies included  
(n=10) 
Systematic review (n=1) 
Review (n=2) 
Case control (n=3) 
Cross sectional (n=4) 
Full text viewed  
(n=21) 
 
Excluded as not 
relevant (n=11)  
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in studies are subtle and as such they are sensitive to the use of varying tests, which 
can result in variation in findings (219). 
 
Another significant challenge of assessing cognitive function stems from the fact that 
individual participants have a unique ability, with strengths and weaknesses in 
different cognitive domains. This makes assessment at group level difficult, as variation 
between individual participants may be significant. In addition, there is an absence of 
literature examining individual ability pre- and post-morbidity and therefore assessing 
the direct impact that CFS might have on individual cognitive function presents huge 
challenges. 
1.15.1.1. Subjective measures of cognitive function 
Subjective measures of cognitive function are an important tool in determining self-
perception of cognitive problems. Tools used include the Cognitive Failures 
Questionnaire (COGFAIL) (220), Everyday Attention Questionnaire (221), and 
questionnaires of memory and attention symptom severity. Some studies have also 
used the Mental Fatigue Scale and rating of energy (222, 223). 
 
Metacognition – self-perception and understanding about one’s own thought 
processes (224) –  is an important concept to consider when evaluating self-reported 
assessment. Self-recognition of individual strengths and weaknesses in learning and 
information processing has been shown to be positively associated with symptom 
severity (225-228). Furthermore, subjective rating of cognitive function is not a simple 
proxy measure for objective assessment. There is evidence that the two measures do 
not correlate (229). Metacognition helps to explain this. 
 
CFS patients report greater subjective cognitive impairment (230), particularly in terms 
of problems with memory and attention (231), which impacts functional ability (123). 
Studies show conflicting evidence about whether these self-reported measures 
correlate to objective measures or to performance. Perceived fatigue has been shown 
both to have no impact on objective performance (230), as well as correlate to 
significant impairment of spatial working memory and sustained attention (232). The 
studies reviewed examined small cohorts and each used different test batteries. While 
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these limitations may explain the different findings, they also highlight the challenges 
of investigating cognitive function in CFS. 
 
A recent study by Cockshell and Mathias supports the finding of a mismatch between 
subjective and objective assessment. They examined the relationship between 
subjective perception of cognitive problems and objective assessment (231). The 
findings show that CFS patients rated themselves more highly in terms of cognitive 
deficit compared to controls, but objectively both cohorts had similar results. 
 
The reasons for this disparity might be explained by metacognitive function and relate 
to a perception of pre-morbid cognitive function, which is rarely measured, or to a 
persistence to push towards “expected” levels when CFS subjects undergo objective 
testing. 
1.15.1.2. Objective measures of cognitive function 
The challenges of objective measurement are discussed in section 1.15.1. In this 
context, a pooled analysis of research may provide an overall picture of cognitive 
dysfunction in CFS. A recent meta-analysis of 50 studies over a 20-year period suggests 
patients with CFS have cognitive deficits in attention, memory and reaction time but 
no significant deficit in fine motor speed, vocabulary, reasoning and global functioning 
(219). 
 
Claypoole et al examined a number of domains in 22 pairs of monozygotic twins and 
found statistically significant differences in motor functioning, speed of information 
processing, verbal memory functioning and executive functioning but similar 
intellectual and visual memory functioning. These results are suggestive of poorer 
neuropsychological performance in CFS (233). 
 
Domain-specific deficits are discussed below. 
1.15.1.2.1. Psychomotor speed 
Delineating between psychomotor speed (coordinating thinking and doing) and 
processing speed (the ability to understand and retrieve information) can be 
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challenging (234). Collated evidence suggests that motor speed is not impaired in CFS 
subjects (219, 232) pointing towards a greater role of impaired processing speed 
rather than motor function. 
 
There is consistency in evidence of impaired cognitive and processing speed among 
CFS subjects compared to controls (190, 230, 232, 235-237). This finding is supported 
by evidence that orthostatic stress impairs neurocognitive abilities of working memory, 
accuracy and information processing in CFS/PoTS patients (238). 
 
Beaumont et al’s case-control study of the relationship between HRV and cognitive 
function found a mismatch between low perceived fatigue and effort in CFS subjects 
and actual performance (230). Although testing relatively small numbers of 
participants and a limited range of cognitive functions, they found that while ability 
was comparable between groups, CFS participants were statistically significantly 
slower at completing the tasks. They also observed a higher baseline heart rate and a 
sustained increase with long recovery period in this group compared to controls, 
suggesting that cognitive and autonomic function may be related. 
1.15.1.2.2. Attention 
Attention has been shown to be similar across CFS and control groups (231, 232, 236). 
This picture is complicated by the fact that some tests encompass both attention and 
working memory and assessment with specific tests (for example STROOP) has shown 
attention deficits while others (for example Digit Span) have not.  
 
Some researchers suggest that this discrepancy may be explained by deficits in verbal 
rather than working memory (231), on the basis that attention and working memory 
(the ability to store and manipulate information) may interact closely with one another 
(239) and that immediate attention span may be considered a form of working 
memory (207). This differs from verbal memory – the ability to store and retrieve 
verbal information. 
1.15.1.2.3. Memory 
Memory (verbal and visuospatial) has been seen to be impaired in CFS patients 
suffering with self-reported mental fatigue, in particular working memory, which has 
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been shown to positively correlate with fatigue and immediate and delayed recall 
(219, 232). Increasing fatigue levels have also been shown to be associated with 
decreasing attention (240), highlighting the potential interplay between the two 
domains and the challenges of identifying specific deficits on testing. 
 
Studies have demonstrated impaired visual and verbal episodic memory compared to 
controls (189, 235). Nevertheless, others have shown no deficit in memory functions 
between CFS and control groups (231), illustrating the disparity in results and 
challenges of testing and interpreting findings as discussed above. 
1.15.2. Role of psychiatric co-morbidities 
Depression and psychiatric co-morbidities have been associated with poor cognitive 
performance (241, 242), once again raising the question of a relationship between 
depression and CFS. This is further complicated by the possibility that depression may 
present as a result of existing cognitive impairment (243). 
 
Nevertheless, studies investigating this relationship point towards distinct features and 
no association between depression and CFS (190). Claypoole et al’s study of 
monozygotic twins suggests that cognitive performance in CFS subjects was 
independent of MDD, implying a separate causal pathway (233). 
 
This is supported by Cockshell and Mathias’ study of cognitive impairment in CFS and 
its relationship with function and psychological status. On testing for information 
processing speed, attention, memory, motor functioning and verbal and visuospatial 
performance they found information processing speed alone was different in the CFS 
group compared to controls. On further examining its association with CFS symptoms, 
psychological co-morbidities and functional ability they found no correlation and 
suggest that the cognitive impairment seen in CFS is not secondary to other variables, 
including depression and anxiety (236). 
1.15.3. Impact 
The impact of cognitive impairment can be significant with a strong association 
between functional disability and poor cognitive ability (244, 245). Many patients 
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remain functionally impaired over time with consequent unemployment (246) and 
long-term detriment to confidence and quality of life. 
1.15.4. Underpinning 
Many hypotheses regarding the possible biological underpinning of cognitive 
dysfunction in CFS centre on a neuroimmune origin. Similarities in symptomatology 
between CFS and MS have added weight to this argument. Impaired (low) levels of NK 
cells have been demonstrated in both conditions (78) and have been associated with 
poorer performance on objective measures of cognitive functioning in CFS (247).  
 
Furthermore, the nature of the impairment in MS – of domain-specific deficits rather 
than global cognitive decline, subtle in nature and characterized by great inter-patient 
variability – appears to be mirrored by the type of impairment seen in CFS (248). The 
cause of this impairment in MS is thought to be related to its autoimmune or 
inflammatory origins (249), an aetiology that may explain the same symptoms in CFS. 
 
Studies also suggest that cognitive impairment may result from AD, which results in 
impaired cerebral blood flow and low-level hypoxia leading to reduced cognitive ability 
over time. Cognitive impairment has been associated with reduced cardiac vagal tone 
and reduced vagal activity (230). Increasing orthostatic stress with a cognitive 
challenge has also been shown to impair neurocognitive abilities of working memory, 
accuracy and information processing in CFS/PoTS (238, 250). 
 
Co-morbid depression – or perhaps the common pathogenesis underlying both it and 
CFS – has been proposed as the cause of cognitive impairment (251), however greater 
deficits have been found in CFS patients without depression (189, 219, 252) and other 
studies show no association between psychological status and cognitive function (236). 
 
An important consideration is the fact that it may be the fatigue itself that is central to 
understanding cognitive impairment. Fatigue, a feature of many diseases (41, 253), is 
associated with significant objective impairment of cognitive functioning and motor 
performance (254). 
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Lack of understanding of the pathogenesis of CFS and the ubiquitous nature of 
cognitive deficits across a broad range of diseases makes it is difficult to postulate the 
mechanism that underlies cognitive impairment in CFS. Nevertheless, evidence does 
suggest that there may be a neuroimmune role. 
1.15.5. Longitudinal impact 
Few studies have assessed cognitive performance over time. A recent cross-sectional 
study suggests that cognitive impairment does not deteriorate with disease duration 
(237); however, this study is significantly limited by a lack of longitudinal data and the 
use of different participants over time and is therefore difficult to interpret. 
 
There is also little evidence to support the presence of mental fatigability with 
performance over time (219, 255). Studies assessing this impact are limited as they do 
not examine performance over consecutive days or weeks but instead focus on 
performance over the course of one-off “sessions”. Future research to understand the 
impact of repeated testing over consecutive days would better discern whether 
fatigability is a feature of cognitive impairment seen in CFS. 
1.15.6. Limitations 
There are limitations to the tests used to assess cognitive function, not least the fact 
that different tests are used in different research studies. While each battery of tests 
broadly assesses similar gross areas of functioning, the use of different tests and 
methods of application does present problems in drawing comparisons between 
studies. Sensitivity and specificity of tests used differs, which leads to varying results 
across studies (256). Despite the fact that there are merits and problems with each, 
there is scope for multiple studies using the same tests to strengthen comparison 
between groups. 
 
There are limitations with individual tests and with their interpretation. In the digit 
span test forward and backward measures reflect different areas of functioning – 
immediate recall and working memory respectively – and these scores should be 
assessed separately. Some studies have, however, assessed the aggregate score of 
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forward and backward measures, which therefore poses a problem in terms of what 
this actually measures. 
 
Mode of delivery of the tests can impact results, for example the time of day that the 
tests are completed, their duration and the way in which they are administered - by 
computer or manually. Comparison between CFS and control cohorts also creates 
challenges with different age groups and different education levels.  
 
These challenges are exacerbated by the fact that any research project investigating 
CFS faces the difficulty of maintaining heterogeneity in and between cohorts, not only 
in terms of cohort demographics but also in terms of the diagnostic criteria used, as 
described in Chapter 1.  
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es co
m
p
rised
 o
f th
ree co
lo
u
rs 
P
art 2: p
articip
an
t n
am
es th
e co
lo
u
r o
f th
e in
k fro
m
 a list o
f X
X
X
X
s p
rin
ted
 in
 o
n
e o
f th
ree 
d
iffe
ren
t co
lo
u
red
 in
ks 
P
art 3: p
articip
an
t n
am
es th
e co
lo
u
r o
f th
e in
k fro
m
 a list o
f th
ree co
lo
u
rs p
rin
ted
 in
 
d
iffere
n
t co
lo
u
red
 in
ks e.g. th
e w
o
rd
 R
ED
 p
rin
ted
 in
 B
LU
E in
k an
sw
e
r B
LU
E
 
Tim
ed
 an
d
 in
co
rre
ct resp
o
n
ses reco
rd
ed
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 A
re
a 
o
f 
fu
n
ct
io
n
in
g 
 
Te
st
 
D
es
cr
ip
ti
o
n
 
V
er
b
al
 M
em
o
ry
 
A
u
d
it
o
ry
-V
er
b
al
 L
ea
rn
in
g 
Te
st
 
(A
V
LT
) 
A
sk
ed
 t
o
 r
em
em
b
er
 a
n
d
 r
ec
al
l a
 1
5 
w
o
rd
 li
st
 (
A
) 
re
ad
 o
u
t 
fi
ve
 c
o
n
se
cu
ti
ve
 t
im
es
; f
o
llo
w
e
d
 
b
y 
o
n
e 
si
n
gl
e 
in
te
rf
er
e
n
ce
 li
st
 (
B
);
 a
sk
ed
 t
o
 r
ec
al
l l
is
t 
A
 p
o
st
 in
te
rf
er
en
ce
 –
 o
n
e 
im
m
ed
ia
te
, 
o
n
e 
d
el
ay
ed
 
H
o
p
ki
n
s 
V
er
b
al
 L
ea
rn
in
g 
Te
st
-
R
ev
is
ed
 (
H
V
LT
-R
) 
A
sk
ed
 t
o
 le
ar
n
 a
n
d
 r
ec
al
l 1
2 
n
o
u
n
s:
 a
ss
es
se
s 
ve
rb
al
 s
h
o
rt
-t
er
m
 le
ar
n
in
g 
C
al
if
o
rn
ia
 V
er
b
al
 L
ea
rn
in
g 
Te
st
 
(C
V
LT
) 
A
sk
ed
 t
o
 r
ec
al
l i
te
m
s 
in
 a
n
y 
o
rd
er
; n
o
t 
to
ld
 a
b
o
u
t 
ca
te
go
ri
es
, b
u
t 
ex
p
ec
te
d
 t
o
 r
ec
o
gn
is
e 
th
is
 
an
d
 u
se
 it
 t
o
 a
id
 r
ec
al
l: 
as
se
ss
es
 s
em
an
ti
c 
as
so
ci
at
io
n
s 
e.
g.
 a
n
im
al
s,
 v
eg
et
ab
le
s 
V
is
u
al
 M
em
o
ry
 
R
EY
 
A
sk
ed
 t
o
 r
ep
ro
d
u
ce
 a
 c
o
m
p
lic
at
ed
 d
ra
w
in
g,
 f
ir
st
 b
y 
co
p
yi
n
g 
th
en
 f
ro
m
 m
em
o
ry
 
B
en
to
n
 V
is
u
al
 R
et
en
ti
o
n
 
R
ec
al
l o
f 
th
re
e 
fi
gu
re
s 
C
o
n
ti
n
u
o
u
s 
V
is
u
al
 M
em
o
ry
 
Ta
sk
 t
o
 d
is
cr
im
in
at
e 
n
ew
 f
ro
m
 r
ep
ea
te
d
 s
ti
m
u
li 
W
ec
h
sl
er
 W
M
S-
III
 F
ac
es
 
Fa
ci
al
 r
ec
o
gn
it
io
n
 m
em
o
ry
 o
f 
n
ew
 a
n
d
 r
ep
ea
te
d
 f
ac
es
 
P
sy
ch
o
m
o
to
r 
C
o
o
rd
in
at
io
n
 
R
ea
ct
io
n
 T
im
e 
Te
st
 
Te
st
s 
o
f 
re
sp
o
n
se
 s
p
ee
d
 
 
C
al
if
o
rn
ia
  
C
o
m
p
u
te
ri
ze
d
 A
ss
es
sm
en
t 
P
ac
ka
ge
 
Se
ri
es
 o
f 
te
n
 r
ea
ct
io
n
 t
im
e 
m
ea
su
re
s 
to
 t
es
t 
re
ac
ti
o
n
 t
im
e 
an
d
 s
p
ee
d
 o
f 
in
fo
rm
at
io
n
 
p
ro
ce
ss
in
g 
P
ro
ce
ss
in
g 
Sp
ee
d
 
R
ea
ct
io
n
 T
im
e 
Te
st
 
A
s 
ab
o
ve
 
M
o
to
r 
Sp
ee
d
 
R
ea
ct
io
n
 T
im
e 
Te
st
 
A
s 
ab
o
ve
 
Ex
ec
u
ti
ve
 
Fu
n
ct
io
n
 
Tr
ai
l m
ak
in
g 
A
s 
ab
o
ve
 
St
ro
o
p
 
A
s 
ab
o
ve
 
W
is
co
n
si
n
 C
ar
d
 S
o
rt
in
g 
A
sk
ed
 t
o
 s
o
rt
 c
ar
d
s 
b
y 
ru
le
s 
w
it
h
 d
if
fe
re
n
t 
co
lo
u
r,
 n
u
m
b
er
 a
n
d
 f
o
rm
ed
 s
h
ap
es
 
 
A
tt
en
ti
o
n
al
 s
h
if
t:
 in
tr
a/
 e
xt
ra
 
d
im
en
si
o
n
al
 s
h
if
t 
(I
ED
) 
ta
sk
 
M
u
st
 c
o
rr
e
ct
ly
 id
en
ti
fy
 s
ti
m
u
li 
o
f 
w
h
it
e 
lin
es
 o
ve
rl
yi
n
g 
co
lo
u
r-
fi
lle
d
 s
h
ap
es
 
 
St
o
ck
in
gs
 o
f 
C
am
b
ri
d
ge
 
Sh
o
w
n
 t
w
o
 d
is
p
la
ys
 c
o
n
ta
in
in
g 
th
re
e 
co
lo
u
re
d
 b
al
ls
 a
n
d
 m
u
st
 r
ec
re
at
e 
a 
sp
ec
if
ie
d
 p
at
te
rn
 
Ti
m
e 
ta
ke
n
 t
o
 c
o
m
p
le
te
 a
n
d
 a
cc
u
ra
cy
 r
ec
o
rd
ed
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 A
rea o
f fu
n
ctio
n
in
g 
 
Test 
D
escrip
tio
n
 
W
o
rkin
g M
em
o
ry 
D
igit Sp
an
 b
ackw
ard
 
W
o
rkin
g m
em
o
ry 
A
lp
h
a Sp
an
 
A
lp
h
ab
etically o
rd
ers in
creasin
gly lo
n
g list o
f u
n
related
 w
o
rd
s: w
o
rkin
g m
em
o
ry 
D
igit Seq
u
en
cin
g 
Listen
s to
 strin
gs o
f ran
d
o
m
 n
u
m
b
ers an
d
 im
m
e
d
iately recalls in
 ascen
d
in
g o
rd
er 
P
aced
 A
u
d
ito
ry Serial A
d
d
itio
n
 
Test-R
evised
 
A
d
d
s p
airs o
f ran
d
o
m
 d
igits; ad
d
s each
 d
igit to
 p
reced
in
g d
igit 
C
o
n
sid
ered
 b
y p
articip
an
ts d
o
 b
e very stressfu
l –
 o
ften
 fee
l th
ey are d
o
in
g b
ad
ly w
h
en
 
d
o
in
g w
e
ll 
N
-B
ack Task 
R
ep
o
rts w
h
en
 an
 item
 is th
e sam
e as an
 item
 see
n
 a sp
ecified
 n
u
m
b
er (n
) o
f step
s b
ack, fo
r 
exam
p
le in
 2
-b
ack th
e p
articip
an
t says yes after th
e 3 in
 th
is se
q
u
en
ce 1
-4-5
-3-8-3
 
 
Tab
le 10 Su
m
m
ary o
f co
gn
itive tests 
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 Ar
ti
cl
e 
St
u
d
y 
ty
p
e
 
A
im
 
D
ia
gn
o
st
ic
 
cr
it
e
ri
a 
an
d
 
M
e
th
o
d
s 
C
o
gn
it
iv
e
 
p
e
rf
o
rm
an
ce
 
m
e
as
u
re
s 
– 
o
b
je
ct
iv
e
 
C
o
gn
it
iv
e
 
p
e
rf
o
rm
an
ce
 
m
e
as
u
re
s 
- 
su
b
je
ct
iv
e
 
C
o
gn
it
iv
e
 
p
e
rf
o
rm
an
ce
 
w
it
h
 t
im
e 
Fi
n
d
in
gs
 -
 
O
b
je
ct
iv
e
 
Fi
n
d
in
gs
 -
 
Su
b
je
ct
iv
e
 
O
ve
ra
ll 
fi
n
d
in
g 
Li
m
it
at
io
n
s 
B
ea
u
m
o
n
t 
et
 a
l 
2
0
1
2 
R
ed
u
ce
d
 C
ar
d
ia
c 
V
ag
al
 
M
o
d
u
la
ti
o
n
 
Im
p
ac
ts
 o
n
 
C
o
gn
it
iv
e
 
P
er
fo
rm
an
ce
 in
 
C
h
ro
n
ic
 F
at
ig
u
e 
Sy
n
d
ro
m
e 
(2
30
) 
C
as
e-
co
n
tr
o
l 
 
Ex
am
in
e 
th
e 
re
la
ti
o
n
sh
ip
 
b
et
w
ee
n
 H
R
V
 
an
d
 c
o
gn
it
iv
e 
p
er
fo
rm
an
ce
 
Fu
ku
d
a 
Sy
d
n
ey
: 3
0
 C
FS
 
re
cr
u
it
ed
 f
ro
m
 
cl
in
ic
; 4
0
 
co
n
tr
o
ls
 
re
cr
u
it
ed
 b
y 
ad
ve
rt
 in
 lo
ca
l 
p
ap
er
 
N
o
 s
ti
m
u
la
n
ts
 
fo
r 
1
2
 h
o
u
rs
 
b
ef
o
re
 
H
R
: 3
-l
ea
d
 E
C
G
 
H
R
V
 c
al
cu
la
te
d
 
D
ig
it
 S
ym
b
o
l 
Te
st
; 
Sp
at
ia
l 
W
o
rk
in
g 
M
em
o
ry
 
Ta
sk
; 
St
ro
o
p
. 
Su
st
ai
n
ed
 
at
te
n
ti
o
n
, 
w
o
rk
in
g 
m
em
o
ry
, 
re
sp
o
n
se
 
fl
ex
ib
ili
ty
 
R
at
ed
 f
at
ig
u
e;
 
p
h
ys
ic
al
 a
n
d
 
m
en
ta
l 
SP
H
ER
E 
an
d
 
K
es
sl
er
 1
0
 
va
lid
at
ed
 f
o
r 
p
sy
ch
o
lo
gi
ca
l 
sy
m
p
to
m
s 
an
d
 
d
is
tr
es
s 
B
ri
ef
 d
is
ab
ili
ty
 
Q
 a
n
d
 
P
it
ts
b
u
rg
h
 
Sl
ee
p
 Q
u
al
it
y 
In
d
ex
 
M
cG
ill
 P
ai
n
 Q
 
 
B
as
el
in
e 
ch
ar
ac
te
ri
st
ic
s 
co
m
p
ar
ab
le
 
C
FS
 –
 n
o
 le
ss
 
ac
cu
ra
te
 b
u
t 
si
gn
if
ic
an
tl
y 
sl
o
w
er
 
H
ig
h
er
 b
as
el
in
e 
H
R
 in
 C
FS
 (
7
2
 v
. 
6
7
b
p
m
 p
= 
0
.0
2
) 
H
R
 in
cr
ea
se
 in
 
b
o
th
 g
ro
u
p
s 
o
n
 
st
ar
ti
n
g 
te
st
in
g 
b
u
t 
co
n
ti
n
u
ed
 in
 
C
FS
 a
n
d
 lo
n
ge
r 
to
 
re
co
ve
r;
 
st
ab
ili
se
d
 in
 
co
n
tr
o
ls
 
Lo
w
er
 H
R
V
 in
 C
FS
 
M
o
re
 p
er
ce
iv
ed
 
fa
ti
gu
e 
an
d
 
ef
fo
rt
 b
u
t 
n
o
 
im
p
ac
t 
o
n
 
p
er
fo
rm
an
ce
 
C
FS
: r
ed
u
ce
d
 
co
gn
it
iv
e 
sp
ee
d
; 
h
ig
h
er
 r
es
ti
n
g 
H
R
 
Sm
al
l n
u
m
b
er
s 
in
 c
o
h
o
rt
 
Sm
al
l n
u
m
b
er
 
o
f 
te
st
s 
Se
lf
-p
ac
ed
 
B
ec
ke
r 
et
 a
l 
1
9
9
1 
M
et
h
o
d
o
lo
gi
c 
C
o
n
si
d
er
at
io
n
s 
in
 
A
ss
es
sm
en
t 
o
f 
C
o
gn
it
iv
e 
Fu
n
ct
io
n
 
in
 C
h
ro
n
ic
 
Fa
ti
gu
e 
Sy
n
d
ro
m
e 
(2
18
) 
R
ev
ie
w
 
W
o
rk
sh
o
p
 t
o
 
co
n
si
d
er
 d
es
ig
n
 
o
f 
co
gn
it
iv
e 
te
st
in
g 
in
 C
FS
 
 
Te
st
s 
m
ay
 
h
av
e 
to
 b
e 
n
o
n
-s
p
ec
if
ic
 
as
 s
ym
p
to
m
s 
o
ft
en
 n
o
n
-
sp
ec
if
ic
 
D
if
fi
cu
lt
y 
co
m
p
ar
in
g 
in
d
iv
id
u
al
s,
 i.
e.
 
h
av
e 
d
if
fe
re
n
t 
st
re
n
gt
h
s 
an
d
 
p
re
-m
o
rb
id
 
fu
n
ct
io
n
 
 
 
 
In
cl
u
d
e 
ve
rb
al
 
an
d
 n
o
n
-v
er
b
al
 a
s 
w
el
l a
s 
re
ca
ll,
 
re
co
gn
it
io
n
 a
n
d
 
le
ar
n
in
g 
Sh
o
u
ld
 b
e 
ch
al
le
n
gi
n
g 
an
d
 
h
av
e 
ti
m
e 
p
re
ss
u
re
 a
n
d
 
co
n
si
d
er
 im
p
ac
t 
o
f 
co
-m
o
rb
id
it
ie
s 
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 A
rticle 
Stu
d
y 
typ
e
 
A
im
 
D
iagn
o
stic 
crite
ria an
d
 
M
e
th
o
d
s 
C
o
gn
itive
 
p
e
rfo
rm
an
ce
 
m
e
asu
re
s – 
o
b
je
ctive
 
C
o
gn
itive
 
p
e
rfo
rm
an
ce
 
m
e
asu
re
s - 
su
b
je
ctive
 
C
o
gn
itive
 
p
e
rfo
rm
an
ce
 
w
ith
 tim
e 
Fin
d
in
gs - 
O
b
je
ctive
 
Fin
d
in
gs - 
Su
b
je
ctive
 
O
ve
rall fin
d
in
g 
Lim
itatio
n
s 
C
ap
u
ro
n
 et a
l 
2
0
0
6 
C
o
gn
itive 
D
ysfu
n
ctio
n
 
R
elates to
 
Su
b
jective 
R
ep
o
rt o
f M
en
tal 
Fatigu
e in
 
P
atien
ts w
ith
 
C
h
ro
n
ic Fatigu
e 
Syn
d
ro
m
e (2
32
) 
C
ro
ss-
sectio
n
 
Exam
in
e 
su
b
jective 
m
en
tal fatigu
e 
an
d
 co
gn
itive 
fu
n
ctio
n
 
Fu
ku
d
a 
W
ich
ita 
4
3
 C
FS 
5
3
 n
o
n
-
fatigu
ed
 ad
u
lt 
co
n
tro
ls 
Exclu
d
ed
 p
sych
 
an
d
 co
-
m
o
rb
id
ity SC
ID
-
I M
D
D
 exclu
d
ed
 
SF-3
6
 fo
r 
fu
n
ctio
n
al 
im
p
airm
en
t 
C
A
N
TA
B
 
co
m
p
u
terise
d
 b
attery: 
P
sych
o
m
o
to
r 
R
TT; 
R
easo
n
in
g  
SO
C
; 
M
em
o
ry 
SW
M
, P
R
M
, 
SR
M
; 
A
tten
tio
n
 
IED
, R
V
IP
 
Fatigu
e: M
en
tal 
fatigu
e 
su
b
scale 
 
N
o
 d
ifferen
ce in
 
p
sych
o
m
o
to
r co
-
o
rd
in
atio
n
 o
r 
m
o
to
r sp
eed
, 
atten
tio
n
 o
r 
reaso
n
in
g skills. 
C
FS w
ith
 m
en
tal 
fatigu
e h
ad
 
im
p
aired
 m
em
o
ry 
 
M
en
tal fatigu
e 
co
rrelates to
 
im
p
aired
 sh
o
rt-
term
 m
em
o
ry 
Selectio
n
 b
ias 
C
layp
o
o
le et a
l 
2
0
0
1 
C
o
gn
itive 
C
o
m
p
ro
m
ise 
Fo
llo
w
in
g 
Exercise in
 
M
o
n
o
zygo
tic 
Tw
in
s 
D
isco
rd
an
t fo
r 
C
h
ro
n
ic Fatigu
e 
Syn
d
ro
m
e: Fact 
o
r A
rtifact? (23
5
) 
C
ro
ss-
sectio
n
 
Exam
in
e 
n
eu
ro
p
sych
o
lo
gical after ex 
resp
o
n
se in
 C
FS 
tw
in
s 
co
m
p
ared
 to
 
h
ealth
y co
-
tw
in
s 
Fu
ku
d
a 
2
2
 p
airs o
f 
m
o
n
o
zygo
tic 
tw
in
s 
In
telle
ctu
al 
fu
n
ctio
n
in
g 
W
A
IS; m
o
to
r 
fu
n
ctio
n
in
g 
R
TT; sp
eed
 o
f 
in
fo
rm
atio
n
 
p
ro
cessin
g 
STR
O
O
P
, 
P
A
SA
T; 
verb
al 
m
em
o
ry 
W
ech
sler 
W
M
S-R
; 
visu
al 
m
em
o
ry R
-
A
V
LT; 
execu
tive
 
Fu
n
ctio
n
in
g 
trail m
akin
g 
 
 
 
A
d
ju
sted
 fo
r age, 
sex, ed
u
catio
n
 
C
FS lo
w
er m
o
to
r 
fu
n
ctio
n
in
g, 
sp
eed
 o
f 
in
fo
rm
atio
n
 
p
ro
cessin
g, 
verb
al m
em
o
ry 
fu
n
ctio
n
in
g, an
d
 
execu
tive 
fu
n
ctio
n
in
g 
Sim
ilar 
in
telle
ctu
al  
an
d
 visu
al 
m
em
o
ry 
fu
n
ctio
n
in
g 
 
 
V
o
lu
n
teer an
d
 
rep
o
rtin
g b
ias 
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 Ar
ti
cl
e 
St
u
d
y 
ty
p
e
 
A
im
 
D
ia
gn
o
st
ic
 
cr
it
e
ri
a 
an
d
 
M
e
th
o
d
s 
C
o
gn
it
iv
e
 
p
e
rf
o
rm
an
ce
 
m
e
as
u
re
s 
– 
o
b
je
ct
iv
e
 
C
o
gn
it
iv
e
 
p
e
rf
o
rm
an
ce
 
m
e
as
u
re
s 
- 
su
b
je
ct
iv
e
 
C
o
gn
it
iv
e
 
p
e
rf
o
rm
an
ce
 
w
it
h
 t
im
e 
Fi
n
d
in
gs
 -
 
O
b
je
ct
iv
e
 
Fi
n
d
in
gs
 -
 
Su
b
je
ct
iv
e
 
O
ve
ra
ll 
fi
n
d
in
g 
Li
m
it
at
io
n
s 
C
o
ck
sh
el
l &
 
M
at
h
ia
s 
2
0
1
0
 
C
o
gn
it
iv
e 
fu
n
ct
io
n
in
g 
in
 
ch
ro
n
ic
 f
at
ig
u
e 
sy
n
d
ro
m
e:
 
a 
m
et
a-
an
al
ys
is
 
(2
1
9
) 
Sy
st
em
-
at
ic
 
re
vi
ew
 
Ex
am
in
e 
p
at
te
rn
 a
n
d
 
si
ze
 o
f 
co
gn
it
iv
e 
d
ef
ic
it
s 
in
 C
FS
 
5
0
 s
tu
d
ie
s 
fr
o
m
 
1
9
9
8
-2
00
8 
 
 
Im
p
ai
re
d
 
in
fo
rm
at
io
n
 
p
ro
ce
ss
in
g 
sp
ee
d
 a
n
d
 
w
o
rk
in
g 
m
em
o
ry
 o
ve
r 
ti
m
e
 
 
 
D
ef
ic
it
s 
in
 
at
te
n
ti
o
n
, 
m
em
o
ry
, r
ea
ct
io
n
 
ti
m
e
 
N
o
 d
ef
ic
it
s 
in
 f
in
e 
m
o
to
r 
sp
ee
d
, 
re
as
o
n
in
g,
 g
lo
b
al
 
fu
n
ct
io
n
in
g 
V
ar
ia
ti
o
n
 in
 
fi
n
d
in
gs
 d
u
e 
to
 m
et
h
o
d
s 
C
o
ck
sh
el
l &
 
M
at
h
ia
s 
2
0
1
3
 
C
o
gn
it
iv
e 
D
ef
ic
it
s 
in
 C
h
ro
n
ic
 
Fa
ti
gu
e 
Sy
n
d
ro
m
e 
an
d
 
Th
ei
r 
R
el
at
io
n
sh
ip
 t
o
 
P
sy
ch
o
lo
gi
ca
l 
St
at
u
s,
 
Sy
m
p
to
m
at
o
lo
gy
, a
n
d
 E
ve
ry
d
ay
 
Fu
n
ct
io
n
in
g 
(2
3
6
) 
C
ro
ss
-
se
ct
io
n
 
A
ss
es
s 
co
gn
it
iv
e 
fu
n
ct
io
n
 in
 C
FS
 
an
d
  
re
la
ti
o
n
sh
ip
 t
o
 
p
sy
ch
o
lo
gi
ca
l 
st
at
u
s,
 C
FS
 
sy
m
p
to
m
s 
an
d
 
fu
n
ct
io
n
in
g 
Fu
ku
d
a 
5
0
 C
FS
 
5
0
 c
o
n
tr
o
ls
 
Ex
cl
u
si
o
n
 f
o
r 
o
th
er
 d
is
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Chapter 2. Methodology 
I was appointed as Clinical Research Associate (CRA) with Medical Research Council 
(MRC) funds obtained by my supervisor Professor Julia Newton to conduct a study 
investigating the pathogenesis of AD in CFS. I was involved in its setup and delivery. 
The data that I present here are from the MRC study. 
 
Participants were recruited as part of the larger MRC-funded project Understanding 
the pathogenesis of autonomic dysfunction in chronic fatigue syndrome and its 
relationship with cognitive impairment. MRC grant number: MR/J002712/1; Trust R&D 
number: 6132. 
 
This thesis looks at a subset of data from the MRC project to examine the prevalence 
of AD and cognitive impairment in CFS and to better understand whether prevalence 
differs depending on which diagnostic criteria are used. It also examines the 
prevalence and nature of depressive symptoms in this cohort of CFS patients. 
 
This chapter will introduce the MRC study and will describe the aspects of the 
methodology of the MRC project that are relevant to this thesis. 
 Introduction to the MRC study 2.1.
The MRC project was designed to better understand the role that AD has to play in the 
pathophysiology of CFS and was a case-control study intended to address two areas:  
 
1. The pathogenesis of AD in CFS 
To determine whether AD in CFS is  
 a primary abnormality in brain autonomic centres; 
 due to abnormalities in the HPA axis; 
 a problem of downstream ANS control; 
 secondary to hypovolaemia which has resulted in compensatory autonomic 
abnormalities. 
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2. The relationship between AD and cognitive impairment in CFS 
To explore whether AD and cognitive impairment in CFS are caused by similar 
underlying central processes, causing damage to both autonomic and cognitive brain 
centres, or whether cognitive impairment is secondary to peripheral hypotension 
arising from AD and resulting in reduced cerebral perfusion and cerebral damage. 
 
In order to investigate the above, participants were required to undergo a series of 
investigations for the MRC project. These were as follows: 
 
 autonomic assessment with the Task Force® Monitor for continuous beat-to-
beat blood pressure and heart rate measurement comprising of a ten minute 
rest, two minute active stand and Valsalva manoeuvre; 
 cognitive assessment using a battery of established neurocognitive tests lasting 
approximately 90 minutes; 
 HPA axis testing including blood tests for cytokines and a dexamethasone 
suppression test; 
 cardiac, liver and brain Magnetic Resonance Imaging (MRI); 
 plasma volume and red cell mass; 
 cardiac meta-iodobenzylguanidine (mIBG). 
 
The approximate timeline of these investigations is outlined in figure 4 below. The aim 
was to carry out all investigations within an eight-week period. The interval between 
each investigation was predominately determined by participant choice and in part by 
resource availability. 
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Figure 4 Schematic depicting timeline of investigations for the MRC project 
 
Recruitment commenced in October 2012 and ended in April 2014. Assessments were 
conducted at the Clinical Research Facility (CRF), Royal Victoria Infirmary, Newcastle 
upon Tyne; the Magnetic Resonance Centre at the Campus for Ageing and Vitality, 
Newcastle University, and the Nuclear Medicine Department at the Freeman Hospital, 
Newcastle upon Tyne. 
 
The MRC project was delivered by a team of clinicians and non-clinicians, whose 
involvement is depicted in figure 5 below. 
 
The project was designed by Professor Julia Newton, Professor Andrew Blamire, Dr 
Stuart Watson and Dr Peter Gallagher. The Research Associate was involved in the 
protocol development, analysis and interpretation of the MRI scans. The CRA had 
responsibility for the day-to-day management of the project, including recruitment, 
screening and autonomic and cognitive assessment. 
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Figure 5 Schematic depicting the MRC project team and their roles 
 Ethics 2.2.
The MRC study was conducted in accordance with the recommendations for physicians 
involved in research on human subjects adopted by the 18th World Medical Assembly, 
Helsinki 1964 and later revisions (257). 
 
Favourable ethical opinion was obtained from the NRES Committee North East - 
Newcastle & North Tyneside 2 prior to commencement of the study (see Appendix D).  
Local research and development approval was obtained from Newcastle upon Tyne 
Hospitals NHS Foundation Trust’s Research and Development office.   
 Confidentiality 2.3.
Personal data were regarded as strictly confidential.  All data leaving the site identified 
participants by a unique study identification number only.  The study complied with 
the Data Protection Act 1998 (258) and Caldicott principles (259).  The study records 
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and Investigator Site Files were kept on site in a locked filing cabinet with restricted 
access. 
 Participants 2.4.
Participants were patients with CFS and age-matched sedentary, community controls. 
 Recruitment 2.5.
Potential participants with CFS were initially identified through routine clinic 
outpatient appointments in the Newcastle upon Tyne specialist CFS clinics and regional 
specialist CFS services. All CFS subjects met the Fukuda criteria for CFS (see table 2 for 
diagnostic criteria).  
 
Eligible participants were invited to take part by the consultant and the study was 
explained to them.  A study participant information sheet (PIS) was provided at this 
time. 
 
Other CFS participants contacted the team after learning about the study via support 
groups and the Clinical Research Network (CRN) website. 
 
Controls were recruited by established methods including via University-held volunteer 
databases, local advertisements and by “word of mouth”, for example via friends, 
colleagues and family members of CFS participants. 
 
The contact details of the research team were made available to potential controls to 
allow them to contact the team. A controls version of the PIS was then provided. 
 
Following receipt of information about the study, participants were given a minimum 
of 24 hours to decide whether or not they would like to participate.  Those interested 
in taking part in the study returned a form expressing their interest and were 
subsequently contacted by telephone by a member of the study team to discuss the 
project and undergo an initial telephone screening. Telephone screening was 
conducted to avoid the need for potentially unwell CFS subjects to attend in person, 
resulting in unnecessary exertion, if there was a clear exclusion criterion. If no obvious 
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exclusion criteria were identified, potential participants invited to a more detailed 
screening visit. 
 
A screening log was kept to document details of subjects were invited to participate in 
the study.  For subjects who declined to participate or who were not eligible to take 
part reasons for non-participation were documented where available. 
 Consent procedures 2.6.
Informed consent was taken by the CRA, trained in Good Clinical Practice, as per the 
consent standard operating procedure (SOP) (Appendix B). Participants had an 
opportunity to ask any questions.  Those wishing to take part provided written 
informed consent by signing and dating the study consent form, which was witnessed 
and dated by a member of the research team with documented, delegated 
responsibility to do so.  Written informed consent was obtained prior to study specific 
investigations. 
 
The original signed consent form was retained in the investigator site file, with a copy 
in the clinical notes and a copy provided to the participant.  The participant specifically 
consented to their GP being informed of their participation in the study. 
 Withdrawal  2.7.
Participants had the right to withdraw from the study at any time for any reason, and 
without giving a reason.  The investigator was also able to withdraw participants from 
the study if this was felt to be in the in the participant’s best interests.  
 Inclusion criteria  2.8.
 Participant able to provide written informed consent for participation in the 
study prior to any study specific procedures; 
 Aged 18 years or older; 
 Not pregnant; 
 Available for the duration of the study; 
 Willing and able to comply with the procedures required as described in the 
information leaflet and as directed by the study doctor. 
79 
 
Controls were required to live a sedentary lifestyle. There is no agreed definition of 
sedentary in terms of activity, however it has been described as a group of behaviours 
that occur whilst sitting or lying down while awake typically requiring very low energy 
expenditure (260). The National Health Service (NHS) describes it as activities such as 
sitting or lying down for long periods (261). 
 
Control subjects were eligible for inclusion in the study if they participated in moderate 
exercise for fewer than 30 minutes three times a week.  
 Exclusion criteria  2.9.
 Previous participation in this study; 
 Co-morbid depression as assessed using the Structured Clinical Interview for 
DSM-IV Axis I Disorders (SCID-I) for research. 
Participants were excluded if, on assessment, they had any current or past 
diagnosis according to SCID-I with the following exceptions: 
o Simple bereavement 
o Pain Disorder 
o Anxiety Disorders 
o Substance Abuse if not in the last six months and for substance 
dependence if not in the last year; 
 Currently being treated for hypertension. 
 Medications 2.10.
Cardioactive medications were stopped 72 hours prior to autonomic and cognitive 
testing. These included, but were not limited to: 
 Amitriptyline; 
 Antidepressants; 
 Antihistamines; 
 LDN (low dose naltrexone); 
 Opioid analgesics; 
 Fludrocortisone for PoTS; 
 Bendroflumethiazide for idiopathic oedema; 
 Midodrine for management of PoTS was stopped 12 hours prior to testing. 
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 Data Handling & Record Keeping  2.11.
The original autonomic data were summarised in the case report form. Cognitive 
results were written into the cognitive assessment booklet with the exception of the 
Attentional Network Task, which was kept on the laptop used for cognitive testing. 
 
Results were databased using Excel. The database was set up by the CRA and the data 
were entered by the MRC project administrator. Ten percent of the data were checked 
by the CRA for accuracy. 
 
This thesis focusses on the following data from the MRC study: 
 
 phenotype data comprising clinical, symptom and demographic assessment; 
 autonomic assessment; 
 cognitive assessment; 
 depression symptoms. 
 
The methods of collection for these data are detailed below. 
 Characteristics of the study cohort 2.12.
To better define the phenotype of the study population a number of parameters were 
examined using validated tools, as discussed below. Questionnaires (detailed below 
and included in Appendix A) were given to participants after screening and inclusion, 
completed independently and returned at the time of the initial visit to the CRF. 
2.12.1. Demographics 
Details regarding medication use, past and current medical history, length of history, 
mobility, education and employment status were gathered by the CRA at the time of 
screening. 
2.12.2. Fatigue severity 
Fatigue status was determined using the generic fatigue measure the Fatigue Impact 
Scale (FIS). This tool helps to quantify individual perception of the impact that fatigue 
has on daily functioning (262). There are 40 items, each scored on a 5-point Likert scale 
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(no problem=0, small problem=1, moderate problem=2, big problem=3, extreme 
problem=4) with an option to indicate not applicable, thus providing a continuous 
scale of 0-160. It comprises three subscales looking at the impact that fatigue has on 
physical (10 items: motivation, effort, stamina and coordination), psychosocial (20 
items: isolation, emotions, coping and workload) and cognitive (10 items: 
concentration, memory, thinking and though organisation) functioning (263).  
2.12.3. Autonomic symptoms 
Subjects completed the validated autonomic symptom assessment tool Composite 
Autonomic Symptom Scale (COMPASS). The COMPASS forms a comprehensive and 
highly sensitive assessment of the prevalence, degree, and association between 
symptoms of AD (115). 
 
It consists of 73 questions grouped into eight domains corresponding to different 
aspects of the ANS. These domains are OI, vasomotor, secretomotor, gastrointestinal, 
bladder, pupil responses, sleep disorder, and syncope. The domains are weighted 
according to their clinical relevance and individual scores are then totalled, which 
provides an indicator of overall symptom burden. The highest possible score is 179 and 
the higher the score, the greater the symptom load. 
 
The COMPASS 31 is an abbreviated version with 31 questions addressing six domains. 
These domains are OI, vasomotor, secretomotor, gastrointestinal, bladder and 
pupillomotor. It provides a more refined measure of autonomic symptoms and can be 
calculated from the full COMPASS questionnaire. Both are included in this analysis.  
2.12.4. Cognitive function 
Cognitive symptoms were quantified by COGFAIL (220), which is a measure of self-
reported failures in perception,  memory and motor function. The questionnaire 
consists of 25 questions measuring the frequency of cognitive failures in the previous 
six months. The questions are answered on a 5-point Likert scale from (0=never, 
1=very rarely, 2=occasionally, 3=quite often, 4=very often) giving a possible total score 
of 100. The higher the score, the greater the cognitive impairment. 
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2.12.5. DePaul Symptom Questionnaire 
The DSQ (47) is a self-reported measure of CFS symptoms, demographics, and medical, 
occupational, and social history. From these measures, it is possible to give a 
“diagnosis” of CFS based on the Fukuda criteria (22), the 2003 Carruthers (Canadian) 
criteria (39) or the 2011 Carruthers (Canadian) consensus criteria (40) (see table 2 and 
section 1.4.1). 
 
The development of the DSQ was based upon the CFS Questionnaire (264), which has 
been shown to have good inter-rater and test-retest reliability and to differentiate 
between individuals with CFS, MDD, and healthy controls (265, 266). The DSQ has 
been demonstrated as a valid tool for assessing CFS symptoms and discriminating 
between diagnostic criteria (49). 
 
Participants rate each symptom’s frequency over the past six months on a 5-point 
Likert scale (0=none of the time, 1=a little of the time, 2=about half the time, 3=most 
of the time, and 4=all of the time), as well as each symptom’s severity over the past six 
months (0=symptom not present, 1=mild, 2=moderate, 3=severe, 4=very severe).  
2.12.6. International Physical Activity Questionnaire 
There is currently no standardised way to measure self-reported activity levels. The 
International Physical Activity Questionnaire (IPAQ) was established in 1998 to provide 
a measure of physical activity and has been shown to be reliable. 
 
The short version of the IPAQ questionnaire was used. It is an instrument used to 
assess activity levels in adults aged 15-69. This questionnaire asks about three types of 
activity: walking, moderate-intensity activities and vigorous-intensity activities, 
undertaken in four domains: leisure time physical activity, domestic and gardening 
(yard) activities, work-related physical activity and transport-related physical activity. It 
applies to the preceding seven days and as such is not necessarily a good indicator of 
longer-term lifestyle. 
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The duration in minutes and frequency in days of the three types of activity is 
calculated and scored. The score is a measure of energy required defined in metabolic 
equivalents (METs). METs are multiples of resting metabolic rate. 
Scores are then equated to levels of activity, described as low, moderate or high. This 
is depicted in table 12.  
 
Low • No activity is reported, or 
• Some activity is reported but not enough to meet moderate or high 
Moderate  
 
Any of the following three criteria  
• ≥ three days of vigorous activity of at least 20 minutes per day, or  
• ≥ five days of moderate-intensity activity and/or walking of at least 
30 minutes  
• ≥ five days of any combination of walking, moderate-intensity, or   
vigorous-intensity activities achieving a minimum of at least 600 
MET-minutes/week 
High  
 
Any one of the following two criteria per day, or 
• vigorous-intensity activity on at least three days and accumulating at 
least 1500 MET-minutes/week, or 
• ≥ seven days of any combination of walking, moderate- or vigorous-
intensity activities accumulating at least 3000 MET-minutes/week 
 
Table 12 IPAQ activity level 
2.12.7. Reproducibility and reliability of subjective questionnaires  
The questionnaires and assessment tools used in this study have been tested for 
consistency and reproducibility. The Cronbach alpha coefficient provides a measure of 
reliability and internal consistency (267). The coefficient is expressed as a number 
between 0 and 1, where a value above 0.70 indicates acceptable internal consistency. 
The Spearman’s correlation coefficient is used for non-parametric data and shows the 
strength of relationship between data. It derives a value between 0 and 1 where 0 
shows a very weak association and 1 a very strong one. 
 
The fatigue impact scale has been shown to be a valid and reliable measure of fatigue 
in a number of chronic conditions, including MS, with a very high Cronbach’s alpha 
coefficient of 0.88-0.98 (267, 268). Both the COMPASS and COMPASS-31 have been 
shown to have a Cronbach's alpha of >0.7 indicating good internal validity (269, 270). 
The COGFAIL questionnaire has been shown to have excellent internal reliability with a 
Cronbach’s alpha of 0.92 (271). The IPAQ has been shown to be reliable and have good 
84 
 
test re-test reliability with a Spearman coefficient clustered around 0.8 indicating 
strong to very strong reproducibility (272). 
 Depression 2.13.
All potential participants were screened prior to inclusion in the study. Part of the 
screening process involved assessment for psychiatric co-morbidities using the SCID-I 
(273). 
2.13.1. Structured Clinical Interview for DSM-IV Axis I Disorders 
The SCID-I for research is a standardised tool used to screen for mood episodes and 
disorders, psychotic symptoms and disorders, anxiety and substance use disorders as 
per DSM-IV (274). This is a validated tool often used as the “gold standard” as a 
screening tool (275) and is considered to be a reliable reflection of DSM-IV diagnoses 
(276). Conducting the SCID-I in its entirety takes approximately 45-90 minutes. 
 
The following sections were not included during the screening interview: 
 A38 Dysthymic Disorder; 
 G1-5 Somatoform Disorders. 
 
This is due to shared features with CFS symptoms, with the potential to inaccurately 
exclude potential participants. 
 
A diagnosis of past or current depressive episode requires criteria to be met for five 
specified symptoms, which must include depressed mood or loss of interest, be 
present for a two-week period and be associated with functional impairment. The 
structure of the SCID-I determines that subjects who do not meet criteria for 
depressed mood or lack of interest are not asked about other depressive symptoms.   
 
A database of results from the SCID-I was kept and provided the starting point to 
better understand the overlap between symptoms of depression and CFS. All SCID-I 
assessments, with the exception of one, were completed by the CRA. 
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 Autonomic nervous system 2.14.
Participants underwent autonomic testing using the Task Force® Monitor. This was 
conducted at the CRF by the CRA. Prior to commencement of the study the Task Force® 
Monitor was calibrated by the Newcastle-upon-Tyne Hospital Medical Physics 
Department. 
2.14.1. Autonomic Testing 
A ten minute rest, two minute active stand and Valsalva manoeuvre were performed. 
The procedures for performing these tests are outlined below and their SOPs can be 
viewed in Appendix B. 
 
The Task Force® Monitor programme version 2.2 was used to record and analyse ECG 
and blood pressure (BP) recordings.  An individual report is provided for each 
participant, detailing mean heart rate (HR bpm), mean systolic BP (sBP, mmHg), mean 
diastolic BP (dBP, mmHg), mean low frequency normalised units (LFnu, %), mean very 
low frequency (VLF, ms2), mean LF (ms2), mean HF (ms2), mean power spectral density 
[PSD, ms2), LFnu:HFnu, LF:HF, baroreceptor slope mean (a measure of baroreceptor 
sensitivity, ms/mmHg) and baroreflex effectiveness index (BEI, %). These are explained 
in tables 13 and 14. 
2.14.2. Task Force® Monitor Set up 
The CRA, trained in the use of the Task Force® Monitor, performed all autonomic 
assessments.  A pack of eight electrodes (CNSystems Medizintechnik GmbH, accessory 
01616) were attached to each individual. These consisted of four ECG electrodes; one 
on the anterior surface of the left shoulder, one on the anterior surface of the right 
shoulder, one over the lower left thorax in the anterior axillary line and one over the 
lower right thorax in the anterior axillary line, providing a four channel ECG, and three 
impedance electrodes; one on the posterior neck, one superior to the ECG electrode 
over the lower left thorax crossing the anterior axillary line and the mid-clavicular line 
and one superior to the ECG electrode over the lower right thorax crossing the anterior 
axillary line and the mid-clavicular line. One electrode was attached to the left lateral 
ankle. A pictorial representation is shown in the autonomic assessment SOP in 
Appendix B. 
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2.14.3. Blood pressure 
For continuous beat-to-beat BP recording the appropriately-sized “Flying-V” finger cuff 
and oscillometric BP cuff were selected.  The finger cuff was then connected to the 
Task Force® Vascular Unloading Monitor and placed proximally over two fingers on the 
left hand. The Task Force® Vascular Unloading Monitor was attached to the forearm 
using a Velcro fixing cuff.  The appropriately-sized oscillometric BP cuff was placed on 
the opposite upper arm. 
2.14.4. ECG 
ECG recordings were based on the bipolar principles of Einthoven. Oscillometric and 
continuous beat-to-beat BP recording has an accuracy of ± 5 mmHg between 50 and 
250 mmHg (277). 
2.14.5. Impedance cardiography 
Impedance cardiography provides measures of AD by examining haemodynamic 
activity. It provides parameters of continuous beat-to-beat stroke volume and 
maximum ejection speed (278). These are outlined in table 13. 
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Parameter Measure Normal range 
Acceleration 
index (ACI) 
Measure of myocardial contractility: 
maximum acceleration of the impedance 
signal (2nd deviation) between opening of 
aortic valve and dZ/dtmax 
1-400 /100s2 
Baroreflex 
effectiveness 
index (BEI) 
A measure of baroreflex response to 
changes in blood pressure 
% 
Baroreflex 
sensitivity (BRS) 
Measure of baroreflex control on the heart ms/mmHg 
Cardiac index (CI) Cardiac output normalised for body surface 
area 
2.5 - 4.0 l/min/m2 
Cardiac output 
(CO) 
Volume of blood pumped from left ventricle 
over one minute 
4.0 - 8.0 l/min 
Ejection fraction Proportion of blood ejected during systole 55-70 % 
End diastolic 
index (EDI) 
Ratio of stroke index to ejection fraction 60-110 ml/mm2 at 
rest 
Index of 
contractility (IC) 
Maximum blood flow during left ventricular 
ejection 
1000/s 
Left ventricular 
ejection time 
(LVET) 
Time interval from opening to closing of the 
aortic valve 
0-1500 msec 
Left ventricular 
work index (LVWI) 
Work of left ventricle for each heartbeat 0-200 gm-m/m2 
Stroke index (SI) Stroke volume normalised for body surface 
area 
33 - 47 
ml/m2/beat 
Stroke volume 
(SV) 
Volume of blood ejected from left 
ventricular contraction 
60 - 100 ml/beat 
Thoracic fluid 
content (TFC) 
Total fluid content of the thorax 10-150 1/kOhm 
Total peripheral 
resistance (TPR) 
Total resistance of all peripheral vessels 800-1200 
dyn*sec/cm5 
Total peripheral 
resistance index 
(TPRI) 
Total peripheral resistance normalised for 
body surface area 
1970-2390 
dyn*sec/cm5 
 
Table 13 Parameters to examine autonomic dysfunction 
Taken from (86, 278-283) 
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2.14.6. Heart rate variability 
Heart rate variability – beat-to-beat variations in heart rate measured at the RRI – is a 
reliable, objective marker of autonomic activity and the balance between sympathetic 
and parasympathetic activation (279, 284). ECGs of healthy individuals at rest show 
regular variations in RRI described as respiratory sinus arrhythmia where the RRI is 
shortened during inspiration and prolonged during expiration (86).  
 
Studies have shown that spectral analysis of HRV can provide a quantitative measure 
of sympathovagal function in a number of conditions including OH (285), post 
myocardial infarction prognosis (286) and diabetic neuropathy (287). Figure 6 shows a 
spectral analysis of HRV.  
 
 
 
 
Figure 6 Spectral analysis of heart rate variability 
Taken from (288) 
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In figure 6, ten minute supine rest is taken between four and 14 minutes (z axis). 
Parasympathetic drive is seen as the large peaks (y axis) between 0.3 and 0.4 Hz (x 
axis).  At 15 minutes upright stand is performed.  The change in peaks from high to low 
frequency represents reduced parasympathetic drive and increased sympathetic 
stimulation. 
 
The Task Force® Monitor programme version 2.2 is an effective tool to assess HRV over 
periods of more than five minutes, producing a measure of how variance distributes as 
a function of frequency using the Fast Fourier Transformation (279). 
 
Power spectral density (PSD) is divided into HR fluctuations and subsequently into LF, 
VLF and HF. The Task Force® Monitor programme also provides normalised units of the 
LF and HF spectral components. These are outlined in figure 6 and table 14. The LF/HF 
ratio is used as a measure of sympathovagal balance where increases in LF/HF ratio are 
thought to reflect sympathetic dominance. Accuracy of calculating the LF/HF ratio in 
this way has, however, been criticised, as it relies on several assumptions about the 
changes in parasympathetic and sympathetic activity, which may not be present (289). 
It should therefore be interpreted in this context. 
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Parameter Measure 
High frequency (ms2) HF Reflection of parasympathetic modulation 
High frequency 
normalised units (%) 
HFnu HF/(LF+HF) 
Index of parasympathetic modulation 
 HFnu-dBP Parasympathetic modulation of dBP 
 HFnu-RRI Parasympathetic modulation of 
cardiovascular activity 
 HFnu-sBP Parasympathetic modulation of sBP 
Low frequency (ms2) LF Reflection of sympathetic modulation 
Ratio of low to high 
frequency 
LF/HF Sympathovagal balance index 
Increases reflect a shift to sympathetic 
dominance 
 LF/HF-dBP Sympathovagal balance index dBP 
 LF/HF-RRI Sympathovagal balance index of 
cardiovascular function 
 LF/HF-sBP Sympathovagal balance index sBP 
Low frequency 
normalised units (%) 
LFnu LF/(LF+HF) 
Index of sympathetic modulation 
 LFnu-dBP Sympathetic modulation of dBP 
 LFnu-RRI Sympathetic modulation of cardiovascular 
activity 
 LFnu-sBP Sympathetic modulation of sBP 
Normalised units Nu A measure of sympathetic and 
parasympathetic balance: proportion each 
domain contributes towards total PSD minus 
VLF contribution 
Power spectral density 
(ms2) 
PSD Measure of power distribution across 
frequencies 
Slope mean (ms/mmHg)  Baroreceptor sensitivity 
 
Table 14 Task Force® Monitor measures 
Sources (127, 290, 291) 
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2.14.7. Active standing 
A dynamic measure of sympathetic and parasympathetic function can be achieved on 
orthostatic challenge, where the drop in sBP or dBP on active stand is measured. An 
abnormal response is defined as a drop of ≥ 20 mmHg in sBP or ≥ 10 mmHg in dBP 
(292).   
 
One of the limitations of this definition is the fact that it does not recognise the 
significance of smaller, prolonged, symptomatic blood pressure drops and long 
recovery times. To address this, the area under the curve (AUC) can be calculated as a 
measure of the “whole picture”, using software developed by the medical physics 
department of Newcastle upon Tyne Hospitals NHS Trust. This is depicted in figure 7. 
 
 
Figure 7 AUC of sBP upon standing 
Taken from (288)  
 
Figure 7 shows the AUC of sBP on orthostatic challenge. Baseline sBP (at the end of the 
supine rest period) is shown as the dotted horizontal line.  Active stand is signified by 
the dotted vertical line. The solid line represents actual sBP - it drops on active stand 
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and its nadir is seen as the horizontal dashed line. Its return to baseline is seen as the 
vertical dashed line. The AUC is the shaded area. 
2.14.8. Baroreflex Sensitivity 
Changes in peripheral vascular tone and the force and rate of heart contraction in 
response to changes in baroreceptor activation are known as the baroreflex. 
Baroreflex sensitivity (BRS) has been found to be reduced in subjects with vasovagal 
syncope (293).  
 
BRS can be calculated by the Task Force® Monitor programme version 2.2 by 
identifying sBP changes occurring in association with either prolonged or shortened 
RRI over three or more beats.  Gradients of these associations are then calculated to 
give a mean value for the ten minute supine rest. This is the slope mean.   
 
The baroreflex effectiveness index (BEI) can also be calculated.  This provides a 
measure of baroreflex response to changes in blood pressure by calculating the ratio of 
spontaneous changes in sBP to corresponding changes in RRI (294). 
2.14.9. Valsalva manoeuvre 
The Valsalva manoeuvre is a measure of parasympathetic activity. It is calculated as RR 
min/RR rebound or HR Phase IV/HR Phase II. A normal response results in increased HR 
in phase II, as BP drops, and transient bradycardia secondary to baroreflex response in 
phase IV (295) (see table 4, section 1.10.3.3). A normal Valsalva ratio is >1.21 (normal 
range has also been stated as 1.29-1.46 depending on age and gender). A ratio of  
<1.21 indicates dysautonomia (296, 297).  
2.14.10. Standard operating procedure 
The SOP for autonomic assessment is included in Appendix B. Participants attended 
the CRF at the Royal Victoria Infirmary in Newcastle upon Tyne. They were tested 
between 9am and 10am. A light breakfast was permitted. Participants were asked to 
refrain for the following: 
 caffeine the morning prior to testing; 
 alcohol the morning prior to testing; 
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 nicotine for two hours prior to testing.  
2.14.11. Assessment during ten minute supine rest  
The initial part of the assessment involved a ten minute rest to measure parameters 
while supine. This was conducted as follows: 
 electrodes were attached as described in section 2.14.2; 
 the participant was asked to lie supine on a clinic bed and made as comfortable 
as possible; 
 the participant rested quietly, remaining awake; 
 recording was started when resting HR and BP were seen on the Task Force® 
Monitor screen; 
 the start point of the recording indicated the beginning of the ten minute rest. 
2.14.12. Assessment in response to an active stand  
At the end of the ten minute rest participants underwent a two minute active stand as 
follows: 
 two assistants were required; 
 participants were asked to bend at the waist to come to a sitting position with 
legs in front of them. This was achieved with the help of two assistants who 
used a back strap to lever the participant; 
 participants were asked to swing their legs off the bed; 
 participants were asked to stand immediately and remain standing for a 
duration of two minutes; 
 the beginning of the active stand was marked by “Active stand start” on the 
monitor and the end of the stand by “Active stand end”; 
 after completion of the active stand participants were asked to sit down on the 
bed; 
 participants were rested for two minutes to return to their cardiovascular 
baseline before performing the Valsalva manoeuvre. 
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2.14.13. Assessment in response to the Valsalva manoeuvre  
Prior to commencing the ten minute rest, each participant was given the opportunity 
to practice the technique used to perform the Valsalva manoeuvre in order to 
maximize good technique. This was limited to two or three seconds so participants did 
not tire. 
 
The Valsalva manoeuvre was performed as follows: 
 participants sat on the clinic bed; 
 a 10ml syringe was attached to a baumanometer; 
 participants were asked to take a deep breath in and blow into the 10ml 
syringe performing the Valsalva manoeuvre (exhaling against a closed glottis) 
to achieve a reading of 40mmHg on the baumanometer; 
 this was sustained for 15 seconds if possible; 
 the beginning and end of the manoeuvre was recorded by “Valsalva 1 start” 
and “Valsalva 1 end” respectively; 
 mmHg and time in seconds achieved were recorded if they differed from the 
target. 
2.14.14. Recovery 
Participants were asked to sit for two minutes to allow for recovery to baseline 
autonomic measures.  
 Cognitive function 2.15.
A battery of neuropsychological tests were administered by the CRA at the CRF to 
assess cognitive function. 
2.15.1. Rationale for choice of test 
The battery of tests used focus on memory and concentration, as current literature 
indicates that these domains are most affected in CFS patients (219). Reviews also 
indicate that in order to optimise cognitive testing in CFS patients verbal and non-
verbal, as well as recall, recognition and learning skills should be assessed. These tests 
should be challenging and carried out under time pressure (218). The tests used and 
their order of administration is shown in table 15. 
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The battery of neurocognitive tests was designed to assess a number of broad 
cognitive domains, as outlined below. The National Adult Reading Test (NART) was 
used before cognitive testing began, as a measure of pre-morbid Intelligence Quotient 
(IQ). 
 
Order of 
administration 
Test Domain 
1 National Adult Reading Test 
(NART) 
Screening for pre-morbid IQ 
2 Rey Auditory-verbal learning 
test (AVLT) 
Verbal learning and memory 
3 STROOP Colour Word Test Executive function and attention 
4 Digit Symbol Substitution 
Test (DSST) 
Psychomotor speed 
5 Digit Span Working memory and short-term 
memory 
6 Trail Making Executive function and attention 
7 Spatial Span Working memory and short-term 
dynamic visuospatial memory 
8 Visual Patterns Test (VPT) Short-term fixed visuospatial memory 
9 FAS Verbal Fluency Executive function and attention 
10 Attention Network Task 
(ANT) 
Executive function and attention 
 
Table 15 Tests performed depicted by order of administration 
2.15.2. Standard Operating Procedure 
The SOP for cognitive testing and the participant booklet are included in Appendices B 
and C. 
 
Cognitive testing was conducted immediately following autonomic assessment. It was 
commenced between 9.30am and 10.30am and lasted for approximately 90 minutes. 
Subjects refrained from caffeine and alcohol on the morning of the tests and from 
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nicotine for at least two hours before testing. Cardioactive medication was stopped for 
72 hours prior to testing as per the SOP for medication. The cognitive battery 
comprised a mixture of computerised, verbal and written tests, which were 
administered as per standardised instructions (see participant booklet Appendix C). 
2.15.3. Tests administered 
2.15.3.1. National Adult Reading Test 
The NART was used as a screening tool to measure pre-morbid IQ as an estimate of 
level of intellectual functioning before onset of illness. It is the most widely-used tool 
to estimate pre-morbid IQ and has been validated for this use (298). A list of 50 
phonetically irregular words is given to the subject who is asked to read them aloud. 
The number of errors is converted to give a verbal IQ score. 
2.15.3.2. Rey Adult Verbal Learning Test 
The Rey AVLT looks at immediate memory span, learning curve and short-term and 
long-term retention. It can also be used to assess retroactive and proactive 
interference tendencies, as well as tendencies to confusion and confabulation on 
memory tasks (207, 299). The Rey AVLT has been shown to be sensitive for verbal 
memory, outwith the associative context achieved with prose (294). 
 
To assess immediate recall the examiner reads 15 words (list A) at a rate of one per 
second. The subject is asked to repeat back as many as they can remember, in any 
order. This procedure is conducted a total of five times (trials I-V). 
 
The examiner immediately reads another list of 15 words (list B) once and the subject 
is asked to repeat back as many as possible. The subject is then asked to recall as many 
words as possible from list A without further hearing the list (trial VI). After 
approximately 30 minutes delay the subject is asked to recall as many words as 
possible from list A (trial VII). 
 
Finally, the subject is given a list of 50 words which contains all the items on lists A and 
B as well as semantically associated or phonetically similar words. They are asked to 
identify whether the words were on list A or B or not on either list. 
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This thesis examines total score, calculated by adding the first five recalls (trials I-V), to 
assess immediate verbal declarative memory, and percentage retained from trial VI on 
trial VII as a measure of delayed recall – the ability to recall information after 
interference. 
2.15.3.3. STROOP Colour Word Test 
The Golden version of the STROOP test was performed in three parts. Parts 1 and 2 
were used to look at cognitive processing and motor speed. Part 3 was also for 
focussed attention and ability to inhibit autonomic response tendencies. 
 
In part 1 the subject is given a list of 100 words (the colours red, green or blue) divided 
into five columns and printed in black ink. They are asked to read out as many as 
possible, as accurately as possible, in 45 seconds. If they reach the end of the 100 
words before the end of 45 seconds they start again at the beginning of the list (as is 
the case in parts 2 and 3). 
 
In part 2 the subject is given a list comprising 100 sets of four crosses printed in 
different coloured ink (red, green, blue). They are asked to read out as many as 
possible, as accurately as possible, in 45 seconds.  
 
In part 3 the subject is given a list of 100 words (red, green, blue) printed in a colour ink 
(red, green, blue) that does not match the word. They are asked to read out as many 
as possible, as accurately as possible, in 45 seconds. 
 
For each part, the number of words read out correctly and the number of errors made 
is recorded. This thesis examines “colour word” minus average of word reading plus 
colour naming. This provides a measure of interference. A negative score indicates a 
poorer ability to suppress word reading (300). 
2.15.3.4. Digit Symbol Substitution Test 
The DSST examines psychomotor speed, set shifting and selective sustained attention. 
It forms part of the Wechsler Adult Intelligence Scale Revised (WAIS-R) (301). 
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Three parts were used in this study. In part 1 the subject is presented with four rows of 
25 squares. Each square contains a symbol. The subject is asked to copy the symbol 
exactly into a square immediately underneath. Seven samples are used as an untimed 
practice. Subjects are asked to work as “quickly and accurately” as possible. They are 
timed for 90 seconds. The number correct or the time taken to complete all 93 
symbols is recorded.  
 
In part 2 the subject is presented with a key where the symbol is matched to a 
corresponding number. They are asked to put the number that corresponds to the 
symbol into the bottom box as “quickly and accurately as possible” in 90 seconds. The 
number correct or the time taken to complete all 93 symbols is recorded.  
 
In part 3 the subject is presented with a new key (symbols and numbers) and a sheet 
where the symbol has already been matched to a number. They are asked to identify 
errors, working from left to right, as “quickly and accurately as possible”. The number 
correct or the time taken to complete all 93 symbols is recorded. The results are 
largely unaffected by education (207). 
 
This thesis examines symbols per second from part 2, which provides a measure of 
psychomotor speed and attention. 
2.15.3.5. Digit Span 
Digit span looks at retention (forward version) and effort using working memory, short 
term memory and attention (backward version) (207).  
 
In the first part of the test the examiner reads out a series of numbers at a rate of one 
per second. The first sequence contains three numbers and after two sequences for 
each number of digits (i.e. two sequences of three digits) an additional digit is added 
up to a total of nine. When a sequence is repeated correctly the examiner moves on to 
the next number sequence. This continues until the participant fails to recall a pair of 
sequences with the same number of digits or until they reach the end of the task.  
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In the second part the examiner reads out a series of numbers and asks the participant 
to recall them in reverse order. The first sequence contains two digits and continues to 
eight digits. 
 
A total score summing the number of sequences recalled correctly (maximum 14) and 
a clinical measure (the highest number of digits recalled in one sequence) are 
recorded.  
 
This thesis examines the clinical measure. This provides a measure of verbal memory 
and mental manipulation. 
2.15.3.6. Trail Making Test 
The trail making test looks at divided attention and executive function. It also has a 
motor component (207, 302). There are two parts to the test. In part A the subject is 
asked to connect a series of numbered circles consecutively by drawing a line between 
numbers. In part B the subject is asked to connect numbered and lettered circles, 
alternating between the two and working consecutively. They are asked to work as 
quickly and accurately as possible. The time taken to complete in seconds and any 
errors made are recorded. 
 
This thesis examines shift (trial B minus trial A). This is a reliable measure of executive 
set shifting function -  the ability to alternate between tasks – and correlates to Stroop 
colour word score (303). 
2.15.3.7. Spatial Span 
Spatial Span is a computerised version of Corsi’s block tapping. It assesses visuospatial 
short-term memory (304). 
 
Subjects watch a sequence of blue squares turn yellow one at a time. They are then 
asked to repeat this sequence via a touch screen. After a correct response the length 
of sequence increases by one. After maximum recall has been achieved subjects are 
then asked to repeat sequences in reverse order. 
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Subjects are given four scores: a total forward score and a score for the longest 
forward sequence recalled; and a total backward score and a score for the longest 
backward sequence recalled. 
 
This thesis examines longest forward and backward scores. These provide a measure 
of immediate working memory. 
2.15.3.8. Visual Patterns Test 
The VPT is a computerised version of the matrices test. It assesses short-term visual 
memory (305) and is designed to assess visual recall. 
 
The subject is presented with a chessboard-like pattern where half the squares are 
black and half are white. The pattern begins with a 2x2 matrix and continues to a 5x6 
matrix (where 15 cells are filled) (305).They are asked to recreate the pattern on a 
blank matrix by identifying the squares that were black. A touch screen format is used. 
 
The subject is given a total score and a score for the maximum number of targets 
recalled. This thesis examines the maximum number of targets to provide a measure of 
short-term memory. 
2.15.3.9. FAS Verbal Fluency 
The FAS Verbal Fluency test is a controlled oral word association test. It examines 
verbal fluency, an executive function (207). 
 
There are three trials. Subjects are asked to list as many words as possible beginning 
with the letters F, A and S over a duration of 60 seconds per letter. Proper nouns or 
derivatives are not allowed. Accuracy is recorded as the overall number of correct 
words stated. 
2.15.3.10. Attention Network Task 
The ANT is used to assess attention. It is a computerised task. 
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Subjects are asked to press the left or right mouse button in response to visual stimuli 
in the form of five arrows. They are asked to focus on the middle arrow, which is 
flanked on either side by two either congruent or incongruent arrows. A cross appears 
in the centre of the screen and the arrows appear either above or below this cross. On 
some occasions before the arrows appear on the screen an asterix flashes above or 
below the cross as an alert that the arrows will appear in this position. 
 
The ANT assesses arousal (alerting), attention shifting (orienting/inhibition) and 
executive control (central and spatial difference). 
 Data analysis 2.16.
Data were analysed using GraphPad Prism version 6. 
 
The data were tested for normality by plotting a histogram and by performing a 
Kolmogorov-Smirnov Test for Normality. Normally-distributed data are summarised 
using the mean and standard deviation (SD). Skewed data are summarised using the 
median and interquartile range (IQR). Proportions are summarised using number and 
percentage. 
 
The relationship between categorical nominal and binary data was analysed using the 
Chi-squared test. The relationship between normally-distributed continuous data was 
analysed using the unpaired t-test, at a 5% significance level. The relationship between 
multiple means was analysed using ANOVA and a 5% significance level is given. 
 
Unpaired continuous skewed data were analysed using a non-parametric test, Mann 
Whitney U test. The Kruskal-Wallis test was performed to compare multiple non-
parametric datasets. A 5% significance level is given. 
 Methodological limitations 2.17.
Limitations of the study methodology are discussed below. 
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2.17.1. Recruitment 
It is difficult to rule out the possibility of selection bias. The participants recruited 
necessarily had to be sufficiently mobile to attend appointments and participate in 
investigations. More unwell sufferers of CFS who are not ambulatory would not be 
able to participate, which is likely to mean that a less severe CFS phenotype is 
investigated in this study as those with more severe illness, necessitating confinement 
in bed, could not participate. 
 
There is a chance that the study is subject to “healthy volunteer bias”. Participants 
were initially contacted through the CFS clinic at the Royal Victoria Infirmary and 
ongoing recruitment was through local support groups. There may be a systematic 
difference in those who volunteered to take part compared to those who did not, for 
example they may be more well and therefore more motivated. This also applies to 
control subjects, who were recruited via family members or from a university 
database. 
2.17.2. Implementation 
There is a strong possibility of recall bias with questionnaires asking about historically 
significant issues. It is often difficult to recall details of past events but this may be 
particularly the case in subjects with CFS who subjectively report problems with 
cognitive function. 
 
Similarly, there may be response bias when completing questionnaires. The possibility 
that participants answered the questionnaires in a particular way or exaggerated 
symptoms, in particular in view of the stigma that often surrounds this condition, 
cannot be ruled out as the questionnaires were self-reported. Some of the controls 
recruited were family members of subjects with CFS, which may bias them to respond 
to questions in a particular way to emphasise a difference. Conversely, it may also 
have encouraged more honest responses. 
 
Response bias was minimised through the use of validated questionnaires. The DSQ, 
used to define participants by diagnostic criteria met, was analysed in the US by an 
independent analyst blinded to the study cohorts. 
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There is a possibility of interviewer bias, as the CRA was not blinded to whether the 
participant was in the CFS or the control group. 
2.17.3. Confounders  
The possible confounding effect of medications was minimised by withholding 
medications prior to investigation as in section 2.10. Furthermore, participants 
meeting criteria for MDD were excluded. Controls were screened only if sedentary, to 
minimise the possibility of deconditioning accounting for any results. 
 
Baseline characteristics were recorded and comparison between two groups 
performed to ensure matched controls.  
2.17.4. Statistics 
The aim of the MRC study was to recruit a total of 81 participants (71 CFS; ten controls) 
to achieve the correct statistical power. The original application to the MRC set out to 
recruit three groups of CFS and a comparator control group. Budget limitations applied 
by the MRC reduced the available funding and therefore the number of groups 
reduced. As such, the study involves relatively small numbers of participants and it is 
possible that any observations could have been observed by chance and that the study 
is underpowered. 
 
ANOVA and non-parametric tests were used to compare outcome measures between 
DSQ groups. There are limitations to these methods. ANOVA allows multiple 
comparison, but it does not give information about which outcomes differ from one 
another. It is therefore difficult to draw conclusions about the nature and location of 
statistical differences. The use of non-parametric tests to compare skewed data is also 
limited in that they compare ranked data (the median not the mean).  
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Chapter 3. Results 
 Study cohort 3.1.
In total 170 information sheets were sent to CFS and control participants. One hundred 
subjects responded with interest in taking part. Figure 8 depicts the study consort 
diagram, recorded over the course of the study. 
 
Twenty four potential participants were excluded after the initial telephone screening. 
The reasons for their exclusion are shown in the consort diagram below. Three were 
taking antihypertensives; ten had a history of depression; two (CFS) had not been 
diagnosed at a specialist service, three (controls) were not sedentary and one could 
not be reached by telephone for the initial screening. 
 
    PIS sent                          170   
       
Medication         8 Declined to participate         2 
Depression       10      MR                                           1 
Diagnosis            2  Not eligible           24  Want to participate     100  Number of visits                    1 
Not sedentary    3       
Other                   1       
       
Medication         2       
Depression         5  Not eligible             7  Screened                         76   
       
       
    Included                          69   
      Declined to continue             6 
      Lost to follow-up                    1 
      Medication                              1 
    ANS and cognitive 
completed                      61 
  
 
Figure 8 Consort diagram of recruitment 
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Seventy six potential participants were invited for screening. Of these, two were 
excluded for taking antihypertensives and five were excluded for meeting criteria for a 
current or past major depressive episode. 
 
Sixty nine participants were eligible for entry into the study. Eight participants did not 
continue past the screening stage. Six withdrew from the study; one was lost to follow-
up and one commenced a new medication resulting in loss of eligibility. 
 
Sixty one participants underwent autonomic and cognitive testing. These were 
comprised of 51 CFS participants and ten controls. 
3.1.1. Baseline characteristics in CFS and controls 
Baseline characteristics of the CFS and control groups are depicted in table 16. All 
eligible CFS (n=59) and control (n=10) participants are included, as they were enrolled 
in the study at baseline. Co-morbidities were self-reported by affected system. 
 
The groups were well-matched at baseline in that there were no significant differences 
in age, gender, employment or education status, or pre-morbid IQ. The control group 
was slightly older than the CFS group (45 versus 49) but with a higher standard 
deviation is unlikely to be clinically significant. 
 
Two characteristics that merit further mention are the presence of co-morbidities, 
which is higher in the CFS group (92% versus 70%) and use of cardioactive medication 
(41% versus 0%). One of the initial aims of the study was to exclude participants on 
cardioactive medication or with co-morbidities associated with AD. In order to include 
sufficient numbers of CFS subjects it was necessary to allow participation of subjects 
on cardioactive medication. It was easier to identify healthy controls without co-
morbid disease and not taking medication. Cardioactive medication was stopped 
temporarily for a specified period before assessments (see section 2.10) to reduce the 
possibility of confounding. 
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 CFS 
(n=59) 
Controls 
(n=10) 
Age (years) mean (SD) 45 (12.4) 49 (15.3) 
Male n (%) 15 (25%) 3 (30%) 
Female n (%) 44 (75%) 7 (70%) 
Employed n (%)   
 No 39 (66%) 7 (70%) 
 Yes 20 (34%) 3 (30%) 
   Full time 7 (35%) 1 (33%) 
   Part time 13 (65%) 2 (67%) 
   Paid 19 (95%) 3 (100%) 
   Voluntary 1 (5%) 0 (0%) 
Student n (%)  2 (3%) 2 (20%) 
Years in Education n (%)   
 ≤11 11 (19%) 1 (10%) 
˃11 48 (81%) 9 (90%) 
Highest qualification n (%)   
 
 
None 3 (5%) 0 (0%) 
GCSE 14 (24%) 2 (20%) 
A level 14 (24%) 2 (20%) 
 Degree 28 (47%) 6 (60%) 
Premorbid IQ mean (SD) 117 (7.9) 122 (4.3) 
Co- morbidities   
 Yes 54 (92%) 7 (70%) 
 No 5 (8%) 3 (30%) 
Cardioactive medication   
 Yes 24 (41%) 0 (0%) 
 No 35 (59%) 10 (100%) 
 
Table 16 Baseline characteristics CFS and controls 
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3.1.2. Physical activity in CFS and controls 
All eligible participants included in the study were given the IPAQ Short Last 7 Days 
Self-administered version of the IPAQ questionnaire to complete in order to establish a 
baseline measure of activity and to try and ensure similar levels of activity between 
control and CFS groups. Mean scores and outcomes are reported in table 17. 
 
 CFS 
(n=50)* 
Controls 
(n=10) 
p value 
(Mann Whitney) 
IPAQ score 
median (IQR) 
198 (941) 1413 (1345) 0.0013 
Low n (%) 32 (64%) 2 (20%)  
Moderate n (%) 17 (34%) 6 (60%)  
High n (%) 1 (2%) 2 (20%)  
 
* one questionnaire not completed 
Table 17 IPAQ scoring and outcome measures CFS and controls 
 
Scores are lower than those seen in active, healthy volunteers in other studies, who 
typically show median scores of 4500-6000 (306, 307), and reflect the sedentary 
lifestyle of participants in this study. Nevertheless, controls had significantly higher 
IPAQ scores compared to CFS subjects. A greater proportion of controls met criteria for 
moderate activity compared to CFS subjects (60% versus 34%). More CFS subjects were 
classified as having low activity levels compared to controls (64% versus 20%). Two 
controls and one CFS subject had high activity levels. 
 
Despite participating in fewer than 30 minutes of exercise a week and living a 
sedentary lifestyle, controls still show higher levels of activity than CFS subjects. This 
may represent an aggregation of movement – which may not be vigorous – but which 
has an additive effect on IPAQ scoring to show higher activity levels. This finding may 
be an indicator of greater loss of functional ability in CFS subjects. 
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3.1.3. Participant questionnaires in CFS and controls 
Participants completed the FIS, COGFAIL and COMPASS questionnaires. The results 
comparing outcomes between CFS and controls are shown in table 18. 
 
 
CFS 
(n=49*) 
mean (SD) 
Controls 
(n=10) 
mean (SD) 
p value 
(unpaired t-test) 
FIS 91.7 (32.5) 0.2 (0.6) <0.0001** 
COGFAIL 53.9 (19.1) 30.4 (10.2) 0.0004** 
COMPASS 37.3 (15.1) 9.9 (4.8) <0.0001** 
COMPASS 31 26.4 (10.0) 8.1 (4.9) <0.0001** 
 
* two questionnaires not completed 
** significant at 5% level 
Table 18 Participant questionnaires CFS and controls 
 
CFS subjects have statistically significantly higher self-reported fatigue, as measured by 
the FIS (91.7 versus 0.2 (p=<0.0001)). There is greater variability in score in the CFS 
group compared to controls. 
 
CFS subjects have statistically significantly higher subjective cognitive impairment on 
COGFAIL (53.9 versus 30.4 (p=0.0004)). Both groups had some variability in scores, but 
the spread of scores was greater in the CFS group. 
 
CFS subjects have statistically significantly higher subjective autonomic symptoms. 
COMPASS scores were 37.3 versus 9.9 (p=<0.0001). There is greater variability in score 
in the CFS group compared to controls. CFS subjects also had significantly higher scores 
on COMPASS 31 (26.37 versus 8.1). This is statistically significant at the 5% level 
(p=<0.0001). There is greater variability in score in the CFS group compared to 
controls. 
 
Overall these results show that on subjective measurement CFS subjects reported 
greater impairment in terms of fatigue, cognitive function and autonomic symptoms 
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compared to controls. Furthermore, there was greater spread in scores in the CFS 
group, which suggests variability in symptoms and loss of function between CFS 
subjects, which may indicate different levels of disease severity. 
3.1.4. Baseline characteristics by DSQ 
All participants had been diagnosed with CFS and met the Fukuda criteria. Participants 
who were included in the study were given the DSQ to complete. The results from the 
CFS cohort are depicted in table 19 and show the number of CFS subjects that met 
each DSQ diagnostic subgroup. 
 
Fukuda alone Fukuda + 2003 
Research 
Fukuda + 2003 
Clinical 
Fukuda + 2003 + 
2011 
6 8 9 26 
  
Table 19 Number of participants by DSQ 
 
One participant completed the DSQ but did not go on to complete further questions or 
other investigations. For this reason they are not included in subsequent analyses.  
 
Baseline characteristics by DSQ diagnosis are shown in table 20. 
 
The groups are moderately well-matched. The mean age of participants meeting the 
Fukuda+2003 Clinical criteria and those meeting the Fukuda+2003+2011 criteria is 
slightly higher than the other two diagnostic groups, however this is not clinically 
significant. More men appear to meet the Fukuda+2003 Clinical criteria compared to 
the other three subgroups, however the actual numbers here are small and unlikely to 
represent a significant increase. 
 
Participants meeting the Fukuda+2003 Clinical and Fukuda+2003+2011 criteria are less 
likely to be in employment and also have a greater prevalence of co-morbidities. This 
may indicate greater functional disability in participants meeting these criteria. 
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  Fukuda 
alone 
(n=6) 
Fukuda + 
2003 
Research 
(n=8) 
Fukuda + 
2003 
Clinical 
(n=9) 
Fukuda + 
2003 + 
2011 
(n=26) 
Age (years) mean (SD) 43 (14.5) 41 (10.9) 49 (13.5) 47 (11.1) 
Male 
Female 
 1 (17%) 
5 (83%) 
1 (12.5%) 
7 (87.5%) 
4 (44%) 
5 (66%) 
6 (30%) 
20 (70%) 
Employed     
 No 3 (50%) 5 (38%) 5 (66%) 19 (73%) 
 Yes 3 (50%) 3 (62%) 4 (44%) 7 (27%) 
   Full time 0 (0%) 0 (0%) 4 (100%) 3 (43%) 
   Part time 3 (100%) 3 (100%) 0 (0%) 4 (57%) 
   Paid 3 (100%) 3 (100%) 4 (100%) 7 (100%) 
   Voluntary 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Student  0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Years in education     
 ≤11 1 (17%) 0 (0%) 1 (11%) 8 (31%) 
 ˃11 5 (83%) 8 (100%) 8 (89%) 18 (69%) 
Highest qualification      
 None 0 (0%) 1 (12.5%) 0 (0%) 2 (8%) 
 GCSE 1 (17%) 0 (0%) 1 (11%) 11 (42%) 
 A level 0 (0%) 3 (37.5%) 1 (11%) 6 (23%) 
 Degree 5 (83%) 4 (50%) 7 (78%) 7 (27%) 
Premorbid IQ mean (SD) 119 (6.6) 123 (3.1) 117 (6.6) 116 (9.2) 
Co- morbidities     
 Yes 5 (83%) 7 (87.5%) 8 (89%) 25 (96%) 
 No 1 (17%) 1 (12.5%) 1 (1%) 1 (4%) 
Cardioactive medication     
 Yes 1 (17%) 2 (25%) 5 (66%) 10 (38%) 
 No 5 (83%) 6 (75%) 4 (44%) 16 (62%) 
 
Table 20 Baseline characteristics by DSQ 
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3.1.5. Physical activity by DSQ 
The results of the IPAQ by DSQ are shown in table 21. 
 
 Fukuda 
alone 
 
(n=6) 
Fukuda + 
2003 
Research 
(n=8) 
Fukuda + 
2003 Clinical 
(n=8)* 
Fukuda + 
2003 + 2011 
(n=26) 
p value 
(Mann 
Whitney) 
IPAQ score 
median (IQR) 
819 (1418) 30 (938) 908 (983) 33 (480) 0.0414** 
Low 2 (33%) 5 (62.5) 4 (50%) 20 (77%)  
Moderate 4 (66%) 3 (37.5) 4 (50%) 5 (19%)  
High 0 (0%) 0 (0%) 0 (0%) 1 (4%)  
 
* Questionnaire not completed by one participant 
** significant at 5% level 
Table 21 IPAQ scoring and outcome measures by DSQ 
 
There is a statistically significant difference in IPAQ score between DSQ groups. CFS 
participants who meet the Fukuda alone criteria and those who meet the 
Fukuda+2003 Clinical criteria appear to have higher levels of activity compared to 
those meeting the Fukuda+2003 Research criteria and those who meet the 
Fukuda+2003+2011 criteria. Participants who meet Fukuda+2003+2011 have lower 
levels of activity compared to the other three groups, with 77% of participants 
reporting ‘low’ activity. This may represent greater functional impairment. This group 
also has the greatest spread of activity, with one participant achieving high levels.  
3.1.6. Participant questionnaires by DSQ 
The results of the participant questionnaires by DSQ diagnosis are shown in table 22. 
 
There are statistically significant differences in FIS and COMPASS scores. Participants 
meeting the Fukuda+2003+2011 criteria have higher subjective levels of fatigue, 
cognitive impairment and symptoms of dysautonomia. The lowest scores are seen in 
the group that meet Fukuda alone. 
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 Fukuda 
alone 
 
(n=6) 
mean (SD) 
Fukuda + 
2003 
Research 
(n=8) 
mean (SD) 
Fukuda + 
2003 
Clinical 
(n=9) 
mean (SD) 
Fukuda + 
2003 + 
2011 
(n=26) 
mean (SD) 
p value 
(ANOVA) 
 
FIS 58.2 (34.1) 93.1 (22.4) 81.7 (19.3) 102.5(33.3) 0.0131* 
COGFAIL  42.0 (17.4) 54.1 (20.9) 49.6 (15.8) 58.2 (19.3) 0.25 
COMPASS 27.5 (13.7) 37.3 (6.6) 28.3 (9.6) 42.6 (16.7) 0.0253** 
COMPASS 31 17.3 (9.6) 24.0 (5.4) 21.0 (8.7) 31.0 (9.4) 0.0017** 
 
** significant at 5% level 
Table 22 Participant questionnaires by DSQ 
 
These findings point towards an additive effect as more diagnostic criteria are met 
and, in combination with the findings on IPAQ, suggest greater functional impairment 
in the subgroup meeting Fukuda+2003+2011. 
3.1.7. Completion of study protocol 
The number of participants who completed all visits of the full MRC study within eight 
weeks is shown in table 23. Fifty nine CFS subjects were enrolled on the MRC study. 
Eight did not continue. In total 86% of the CFS group completed the study. Forty eight 
of 61 participants (79%) completed the full MRC project within eight weeks (56 days). 
All those who completed the study did so within 12 weeks. 
 
 Within 8 weeks Within 8-12 weeks 
All participants (%) 44 (72) 17 (28) 
CFS only (%) 37 (73) 14 (27) 
 
Table 23 Time to completion 
 
Difficulties in completing the study within eight weeks arose from participant-
determined and other factors. Delivery of the nuclear medicine equipment delayed 
some visits, as did limited MRI appointment availability. Participants had difficulty 
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attending appointments each week because of other commitments. CFS participants 
also preferred to space out appointments in order to pace themselves to enable 
completion of the study (in contrast to control subjects who preferred to compact 
investigations into a short timeframe). 
 
These results suggest that this cohort was comprised of highly-motivated subjects who 
were able and prepared to undergo considerable physical burden to complete all 
investigations. 
 Depression 3.2.
Initial telephone screening excluded ten potential participants because of psychiatrist-
diagnosed MDD. A total of 65 participants were screened. Sixty three participants have 
been included in the analysis. It was not possible to include two assessments for the 
following reasons. One CFS participant’s SCID-I assessment was performed by a third 
party and contained inaccuracies. This participant was noted to have depression but 
was included in the study. They subsequently withdrew from the study before it was 
possible to verify the results. One SCID-I assessment was misplaced. The misplaced 
SCID-I related to a CFS subject who was excluded because of past major depressive 
episodes, however more detailed information about this could not be recorded and is 
therefore not included in the analysis. 
 
The prevalence of depressive symptoms in the CFS cohort is reported in table 24. The 
UK prevalence of depression has been reported to be 4-10% for major depression and 
between 2.5-5% for low-grade chronic depressive symptoms (308, 309). In this study 
cohort 15% of the 100 people who expressed interest in participating and underwent 
at least a telephone screening had a diagnosis of previous or current MDD. 
 
Thirty two percent of CFS participants reported feeling depressed or down for at least 
two weeks. Sixteen percent reported loss of interest or pleasure and 13% reported 
both. The most prevalent of the “secondary” symptoms was a change in appetite, as 
well as change in sleep, loss of energy and concentration and feelings of 
worthlessness. Suicidal ideation and psychomotor change were the least prevalent. 
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Symptom  n (%) 
At least two weeks of:   
 Feeling depressed or down 20 (32) 
 Loss of interest or pleasure 
in things usually enjoyed 
10 (16) 
 Both of the above 8 (13) 
Of those with the above 
symptoms 
 
 
 Change in appetite 11 (47) 
 Change in sleep 6 (26) 
 Psychomotor change 4 (17) 
 Loss of energy 6 (26) 
 Feelings of worthlessness 9 (39) 
 Loss of concentration 5 (22) 
 Suicidal ideation 3 (13) 
 
Table 24 Depressive symptoms on SCID-I assessment tool at screening 
 
The number of depressive symptoms and percentage of participants in each category, 
as well as associated antidepressant use is reported in table 25. 
 
The majority (63.5%) of CFS participants in this study had no symptoms of depression. 
Eight percent had one or two symptoms and 22.2% had three or four symptoms. Four 
participants (6.3%) had five or more symptoms and were excluded from the study. 
 
Seventy five percent of participants who met a diagnosis of MDD were prescribed 
antidepressant medication. Of the participants with no recorded symptoms of 
depression 15% were being prescribed antidepressants. One participant with two 
symptoms of depression was prescribed antidepressant medication. 
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Number of symptoms n (%) Participants prescribed 
antidepressant 
medication n (% of those 
in symptom category) 
0 40 (63.5) 6 (15) 
1 2 (3.2) 0 (0) 
2 3 (4.8) 1 (33.3) 
3 12 (19.0) 0 (0) 
4 2 (3.2) 0 (0) 
5+ 4 (6.3) 3 (75) 
 
Table 25 Number of symptoms of depression and concomitant antidepressant use 
 
These findings highlight the challenges of diagnosing and managing two conditions 
(CFS and depression) that share symptoms. This is discussed in section 4.1.3. 
 Autonomic nervous system 3.3.
3.3.1. CFS and controls: At rest 
The results below compare autonomic testing between the CFS and control groups at 
rest. 
 
Table 26 shows a comparison of mean values for beat statistics between CFS and 
control groups. Overall there is no statistically significant difference between CFS and 
controls. Mean and standard deviations of all measures are broadly comparable. 
 
CFS and control groups both had a resting mean heart rate of 73-74 bpm, which lies in 
the normal range (86). Mean sBP is slightly lower in the control group compared to the 
CFS group, but CFS subjects show a wider standard deviation. Both groups have a 
mean sBP, dBP and mBP that lie towards the lower end of normal (310, 311). The 
reasons for this may include the fact that participants abstained from caffeinated 
drinks prior to testing, which may imply low fluid intake and hypovolaemia, and 
because blood pressure was measured supine (312). 
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Beat statistics CFS  
(n=51) 
mean (SD) 
Controls  
(n=10) 
mean (SD) 
p value 
(two sample t-
test) 
HR (bpm) 74.34 (10.26) 73.62 (7.11) 0.84 
sBP (mmHg) 108.8 (18.78) 104.9 (11.19) 0.52 
dBP (mmHg) 69.25 (11.04) 67.86 (6.55) 0.70 
mBP (mmHg) 79.54 (12.32) 78.23 (7.64) 0.75 
 
Table 26 Beat statistics CFS and controls 
 
Table 27 depicts a comparison of cardiac statistics. There are no statistically significant 
differences between CFS and control groups. 
 
Cardiac statistics CFS 
(n=51) 
mean (SD) 
Controls 
(n=10) 
mean (SD) 
p value 
(two sample t-test) 
SI (ml/m2) 41.03 (11.79) 42.74 (10.16) 0.67 
CI (l/min*m2) 3.00 (0.84) 3.2 (0.93) 0.61 
TPRI 2255 (810.9) 2052 (549.4) 0.45 
EDI 67.99 (19.51) 68.58 (16.19) 0.93 
IC 44.91 (18.15) 45.74 (15.51) 0.89 
ACI 64.81 (31.31) 56.99 (24.10) 0.46 
LVWI 3.145 (0.94) 3.285 (1.16) 0.68 
LVET 303.8 (17.80) 312.1 (11.08) 0.16 
TFC 27.50 (5.94) 28.41 (6.51) 0.67 
 
Table 27 Cardiac statistics CFS and controls 
 
Myocardial contractility has been measured using IC and ACI and LVWI. Values are on 
the lower side of the normal range. Afterload has been measured using TPRI. EDI has 
been used to measure preload. Both are within normal limits. Stroke index and cardiac 
index are within the normal range (280). 
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TFC is a measure of intra and extra-vascular fluid volume in the chest cavity. As fluid 
content increases, TFC decreases. TFC in CFS and control subjects was comparable to 
healthy volunteers in other studies and within normal limits (313). 
 
This shows that in this cohort CFS subjects and control subjects were within normal 
parameters when testing cardiac function using the above measures. 
 
Table 28 shows HRV statistics representing modulation of cardiovascular activity. 
There are no statistically significant differences between groups. Both cohorts appear 
to have a shift in balance towards increased sympathetic modulation of cardiovascular 
activity, as seen in the higher LFnu-RRI values and the LF/HF-RRI. 
 
Heart rate 
variability statistics 
CFS 
(n=51) 
mean (SD) 
Controls 
(n=10) 
mean (SD) 
p value 
(two sample t-test) 
LFnu-RRI 59.16 (16.87) 62.42 (12.89) 0.57 
HFnu-RRI 40.39 (16.94) 37.58 (12.89) 0.62 
LF/HF-RRI 3.06 (4.85) 2.25 (1.16) 0.72 
 
Table 28 Heart rate variability statistics CFS and controls 
 
Table 29 shows a comparison of dBP variability statistics between CFS and control 
groups. There are no statistically significant differences between groups. LFnu-dBP, a 
marker of sympathetic modulation of dBP, is higher than HFnu-dBP (a marker of 
parasympathetic modulation) and shows a balance towards greater sympathetic 
modulation in both groups. This is supported by the high LF/HF-dBP sympathovagal 
balance index. 
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Blood pressure 
variability statistics 
(dBP) 
CFS 
(n=51) 
mean (SD) 
Controls 
(n=10) 
mean (SD) 
p value 
(two sample t-test) 
LFnu-dBP 54.83 (13.78) 46.81 (19.01) 0.12 
HFnu-dBP 13.82 (10.64) 12.48 (10.75) 0.72 
LF/HF-dBP 7.05 (5.32) 6.14 (4.20) 0.61 
 
Table 29 Blood pressure variability statistics (dBP) CFS and controls 
 
There are no statistically significant differences in sBP BPV statistics between groups, 
as seen in table 30. Mean measures and variation are comparable in both CFS and 
control cohorts. Like dBP, higher LFnu-sBP indices in both groups suggest greater 
sympathetic activation than parasympathetic. This is also supported by the LF/HF-sBP, 
which is towards the higher side. 
 
Blood pressure 
variability statistics 
(sBP) 
CFS 
(n=51) 
mean (SD) 
Controls 
(n=10) 
mean (SD) 
p value 
(two sample t-test) 
LFnu-sBP 46.73 (14.33) 38.48 (13.86) 0.1 
HFnu-sBP 17.37 (11.75) 15.43 (10.68) 0.63 
LF/HF-sBP 4.70 (4.37) 3.80 (2.43) 0.53 
 
Table 30 Blood pressure variability statistics (sBP) CFS and controls 
 
Table 31 shows comparison of baroreflex sensitivity statistics at LAG1 (at rest). There 
are no statistically significant differences between CFS and control cohorts. Baroreflex 
sensitivity provides a measure of baroreflex control of the heart. The baroreflex 
effectiveness index provides a measure of the baroreflex response to changes in blood 
pressure. Both are within normal limits (314). A study comparing subjects with 
vasovagal syncope to controls did find comparable values to those seen in this study 
(281), and may reflect the fact that BP in these groups was at the lower end of normal. 
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Baroreflex sensitivity 
statistics LAG1 
CFS 
(n=51) 
mean (SD) 
Controls 
(n=10) 
mean (SD) 
p value 
(two sample t-
test) 
Baroreflex sensitivity 13.32 (8.14) 11.66 (9.58) 0.57 
Baroreflex 
effectiveness index 
59.98 (20.58) 58.08 (15.49) 0.78 
 
Table 31 Baroreflex sensitivity statistics LAG1 CFS and controls 
3.3.2. CFS and controls: Standing 
Table 32 shows a comparison of mean sBP on standing. Mean sBP and nadir on 
standing are not statistically significantly different between CFS and control groups. 
The overall drop of sBP on standing is statistically significantly different between 
groups, with less drop in the CFS cohort (11.43 versus 19.8 (p=0.0411)). 
 
 CFS 
(n=51) 
mean (SD) 
Controls 
(n=10) 
mean (SD) 
p value 
(two sample 
t-test) 
Mean sBP 110.2 (25.04) 109.5 (10.94) 0.93 
Nadir 98.75 (26.12) 89.7 (16.67) 0.3 
Drop 11.43 (11.98) 19.8 (9.18) 0.0411* 
 
* significant at 5% level 
Table 32 Systolic blood pressure on standing CFS and controls 
 
The nadir represents the lowest sBP value during the two minute active stand. OH is 
diagnosed with a fall in sBP of 20mmHg or greater (315). Both CFS and control groups 
lie within normal limits, although control subjects have a higher mean drop in sBP on 
standing. 
 
Table 33 shows comparison of mean dBP on standing. There is no statistically 
significant difference in mean dBP, nadir or drop between groups. Although not 
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statistically significant, the control group has a bigger mean drop on standing 
compared to the CFS cohort (8.85 versus 14.01). 
 
Both groups are within normal limits for mean dBP, although at the lower end of 
normal. A drop of 10mmHg in dBP on standing meets the definition of OH (315). The 
control group meets this definition. This may be explained by hypovolaemia. 
 
 CFS 
(n=51) 
mean (SD) 
Controls 
(n=10) 
mean (SD) 
p value 
(two sample 
t-test) 
Mean dBP 77.44 (17.73) 73.51 (6.49) 0.99 
Nadir 64.59 (16.33) 59.5 (7.68) 0.34 
Drop 8.85 (9.69) 14.01 (7.56) 0.12 
 
Table 33 Diastolic blood pressure on standing CFS and controls 
 
Table 34 depicts the 30:15 ratio during the active stand. This is a dynamic measure of 
parasympathetic activity. It represents the longest RRI at approximately the 30th beat 
to the shortest RRI at the 15th beat and is taken directly after standing. Small ratios are 
abnormal. 
 
 CFS 
(n=51) 
median (IQR) 
Controls 
(n=10) 
median (IQR) 
p value 
(Mann-
Whitney 
test) 
30:15 ratio 1.12 (1.07,1.17) 1.07 (1.04, 1.16) 0.24 
 
Table 34 30:15 ratio CFS and controls 
 
There is no significant difference in median 30:15 ratio between CFS and control 
groups. Ratios in both groups are lower than findings from control subjects in other 
studies (314), however both groups lie within the normal range of > 1.04 (316). 
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Table 35 shows comparison of AUC on standing. Median AUC at baseline is statistically 
significantly lower in the CFS group compared to the controls group, however this is 
not clinically significant. 
 
 
CFS 
(n=51) 
median (IQR) 
Controls 
(n=10) 
median (IQR) 
p value 
(Mann-
Whitney 
test) 
AUC (Baseline) 24.18 (0.0, 118.2) 129.2 (57.02,407.8) 0.0249* 
AUC – (20mmHg) 0.0 (0.0,0.0) 0.0 (0.0,0.0) >0.99 
 
* significant at 5% level 
Table 35 Area under the curve CFS and controls 
3.3.3. CFS and controls: Valsalva 
Table 36 shows comparison of Valsalva measurements between the CFS and control 
groups. The CFS group has a statistically significantly longer Valsalva ratio compared to 
the control group (0.70 versus 0.53 (p=0.0245)). There were no statistically significant 
differences in mean measures of Phase I, IIi or IV between groups. Ratios <1.21 imply 
dysautonomia. 
 
The Valsalva ratio for both groups is abnormal (<1.21 (296, 297)), which indicates 
dysautonomia in both CFS and control subjects. Age, gender and baseline blood 
pressure can affect the Valsalva ratio, with lower ratios seen in women, with increasing 
age (296). The low baseline blood pressure seen in both groups may also help to 
explain these results in these cohorts. 
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 CFS 
(n=49*) 
mean 
(SD) 
Controls 
(n=9*) 
mean 
(SD) 
p value 
(two sample t-
test) 
Valsalva ratio 0.70 (0.21) 0.53 (0.20) 0.0245** 
Phase I 12.08 (9.81) 17.64 (6.23) 0.11 
Phase IIi 8.61 (14.62) 4.53 (17.64) 0.46 
Phase IV 17.49 (15.70) 25.98 (27.47) 0.1955 
 
* unable to analyse due to missing BP readings 
** significant at 5% level 
Table 36 Valsalva ratio CFS and controls 
 
Overall there are no significant differences in objective autonomic measures between 
CFS and control groups on standing. This is discussed in section 4.1.1. 
3.3.4. DSQ: At rest 
The results reported below show comparison of objective measures of autonomic 
function in CFS subgroups as defined by the DSQ. 
 
One-way ANOVA has been used to compare means between groups. There are 
limitations to this method, which are discussed in section 2.17. 
 
Table 37 shows beat statistics between DSQ groups. There are no statistically 
significant differences between groups. All DSQ subgroups had HR in the normal range 
(86). Fukuda alone subjects had the lowest HR and Fukuda+2003+2011 the highest. 
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Beat 
statistics 
Fukuda 
n=6 
mean (SD) 
Fukuda + 
2003 
Research 
n=8 
mean (SD) 
Fukuda + 
2003 Clinical 
n=9 
mean (SD) 
Fukuda + 
2003 + 
2011 
n=26 
mean (SD) 
p value 
(ANOVA) 
HR (bpm) 69.57 
(6.25) 
75.69 
(6.81) 
73.07 
(9.24) 
76.59 
(11.50) 
0.43 
sBP (mmHg) 108.9 
(17.24) 
101.9 
(13.11) 
122.3 
(24.99) 
107.2 
(17.36) 
0.12 
dBP (mmHg) 71.61 
(17.37) 
64.91 
(6.08) 
71.90 
(14.75) 
69.62 
(9.47) 
0.59 
mBP (mmHg) 82.21 
(16.71) 
75.14 
(7.75) 
83.65 
(15.55) 
79.56 
(11.48) 
0.54 
 
Table 37 Beat statistics by DSQ 
 
Table 38 shows a comparison of cardiac statistics between DSQ groups. 
 
There are no statistically significant differences in any measures of cardiac function. 
Mean measures in the Fukuda+2003+2011 group are lower for all measures except 
TPRI. Measures in the Fukuda alone group are higher compared to the other 
subgroups, also with the exception of TPRI. Although not statistically significant, this is 
suggestive of different phenotypes between subgroups. 
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Cardiac 
statistics 
Fukuda 
n=6 
mean (SD) 
Fukuda + 
2003 
Research 
n=8 
mean (SD) 
Fukuda + 
2003 
Clinical 
n=9 
mean (SD) 
Fukuda + 
2003 + 2011 
n=26 
mean (SD) 
p value 
(ANOVA) 
SI (ml/m2) 47.30 
(12.59) 
45.04 
(12.52) 
41.10 
(12.32) 
37.46 
(10.33) 
0.16 
CI 
(l/min*m2) 
3.28 
(0.90) 
3.36 
(0.82) 
2.98 
(0.99) 
2.83 
(0.80) 
0.39 
TPRI 2026 
(506.9) 
1849 
(609.3) 
2464 
(1105) 
2394 
(802.0) 
0.3 
EDI 78.78 
(22.03) 
73.17 
(19.82) 
68.15 
(21.03) 
62.38 
(17.11) 
0.20 
IC 56.14 
(21.94) 
51.46 
(19.19) 
43.66 
(17.42) 
39.68 
(16.19) 
0.14 
ACI 81.76 
(38.24) 
74.57 
(32.03) 
64.97 
(34.75) 
56.08 
(27.31) 
0.21 
LVWI 3.68 
(1.574) 
3.28 
(0.8251) 
3.26 
(1.065) 
2.97 
(0.7564) 
0.38 
LVET 312.1 
(18.44) 
304.2 
(17.06) 
296.4 
(13.55) 
303.4 
(18.56) 
0.41 
TFC 28.59 
(3.894) 
28.09 
(6.559) 
28.75 
(6.877) 
26.68 
(6.218) 
0.78 
 
Table 38 Cardiac statistics by DSQ 
 
Myocardial contractility has been measured using IC and ACI and LVWI. These are 
within the normal range in all groups, however on the lower side of normal. The 
Fukuda+2003+2011 subgroup shows the lowest values across these parameters and 
may indicate decreased myocardial contractility compared to the other subgroups, in 
particular the Fukuda alone group, which has the highest value. 
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Afterload has been measured using TPRI and EDI has been used to measure preload. 
TPRI is within normal limits for all subgroups except Fukuda+2003 Research, where it is 
low. EDI is lowest in the Fukuda+2003+2011 group, and reflects a lower cardiac index 
in this group (317).  Stroke index and cardiac index are within the normal range (252) 
and are lowest in the Fukuda+2003+2011 subgroup. 
 
TFC is a measure of decreased intra and extra-vascular fluid volume in the chest cavity. 
It is comparable across all subgroups. 
 
Table 39 depicts HRV statistics by DSQ sub-group. One measure has statistically 
significant differences between groups. LF/HF-RRI differs across groups 
(2.26;7.72;3.14;1.84 (p=0.0262)). This reflects a shift in balance between sympathetic 
and parasympathetic activity between groups with Fukuda+2003 Research showing 
greater sympathetic activity and Fukuda+2003+2011 lower sympathetic modulation of 
cardiovascular activity. 
 
Heart rate 
variability 
statistics 
Fukuda 
n=6 
mean (SD) 
Fukuda + 
2003 
Research 
n=8 
mean (SD) 
Fukuda + 
2003 
Clinical 
n=9 
mean (SD) 
Fukuda + 
2003 + 2011 
n=26 
mean (SD) 
p value 
(ANOVA) 
LFnu-RRI 57.10 
(11.11) 
62.37 
(20.12) 
68.60 
(13.42) 
54.74 
(17.64) 
0.19 
HFnu-RRI 42.90 
(11.11) 
34.77 
(19.84) 
31.40 
(13.42) 
45.26 
(17.64) 
0.14 
LF/HF-RRI 2.26 
(1.92) 
7.72 
(11.01) 
3.14 
(1.87) 
1.84 
(1.62) 
0.0262* 
LF/HF 2.03 
(1.50) 
3.34 
(3.63) 
2.36 
(1.18) 
1.55 
(1.26) 
0.13 
 
* significant at 5% level 
Table 39 Heart rate variability statistics by DSQ 
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Table 40 shows dBP BPV statistics between DSQ subgroups. There are no statistically 
significant differences between groups, however the Fukuda+2003 Research group has 
the highest LF/HF-dBP ratio, which may indicate clinically significantly greater 
sympathetic modulation of dBP.  
 
The Fukuda+2003+2011 subgroup has the lowest LFnu-dBP, indicating lower 
sympathetic modulation of dBP. This is supported by a low LF/HF-dBP ratio. Overall, 
however, there is a mixed picture. 
 
Blood 
pressure 
variability 
statistics 
(dBP) 
Fukuda 
n=6 
mean (SD) 
Fukuda + 
2003 
Research 
n=8 
mean (SD) 
Fukuda + 
2003 
Clinical 
n=9 
mean (SD) 
Fukuda + 
2003 + 2011 
n=26 
mean (SD) 
p value 
(ANOVA) 
LFnu-dBP 57.39 
(12.11) 
63.52 
(11.29) 
55.66 
(10.97) 
50.17 
(14.50) 
0.09 
HFnu-dBP 11.52 
(4.90) 
9.66 
(7.49) 
14.59 
(8.75) 
15.65 
(13.01) 
0.54 
LF/HF-dBP 6.07 
(2.68) 
11.30 
(8.16) 
5.91 
(3.87) 
6.36 
(4.97) 
0.11 
 
Table 40 Blood pressure variability statistics (dBP) by DSQ 
 
Table 41 shows BPV of sBP between groups. LF/HF-sBP is statistically significantly 
different between groups. 
 
LF/HF-sBP is highest in the Fukuda+2003 Research group suggesting a balance towards 
greater sympathetic activity in this group. It is lowest in the Fukuda+2003+2011 group 
and suggests a balance to lower sympathetic activity in this subgroup. This is 
supported by the finding of a low LFnu-sBP in this subgroup, suggesting low 
sympathetic modulation of sBP, and of a higher HFnu-sBP, pointing towards greater 
parasympathetic modulation of sBP. 
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Blood 
pressure 
variability 
statistics 
(sBP) 
Fukuda 
n=6 
mean (SD) 
Fukuda + 
2003 
Research 
n=8 
mean (SD) 
Fukuda + 
2003 
Clinical 
n=9 
mean (SD) 
Fukuda + 
2003 + 2011 
n=26 
mean (SD) 
p value 
(ANOVA) 
LFnu-sBP 45.06 
(17.60) 
57.48 
(12.15) 
46.85 
(11.71) 
43.14 
(14.15) 
0.10 
HFnu-sBP 14.17 
(6.105) 
9.53 
(8.29) 
16.77 
(10.22) 
21.02 
(13.23) 
0.09 
LF/HF-sBP 3.51 
(1.29) 
10.49 
(7.29) 
4.14 
(2.80) 
3.30 
(2.48) 
0.0002* 
 
* significant at 5% level 
Table 41 Blood pressure variability statistics (sBP) by DSQ 
 
Table 42 shows BRS statistics at LAG1 compared between DSQ subgroups. 
 
Baroreflex 
sensitivity 
statistics 
LAG1 
Fukuda 
n=6 
mean (SD) 
Fukuda + 
2003 
Research 
n=8 
mean (SD) 
Fukuda + 
2003 
Clinical 
n=9 
mean (SD) 
Fukuda + 
2003 + 2011 
n=26 
mean (SD) 
p value 
(ANOVA) 
Baroreflex 
sensitivity 
12.26 
(4.74) 
19.10 
(7.50) 
13.17 
(9.35) 
10.47 
(4.50) 
0.0135* 
Baroreflex 
effectiveness 
index 
55.97 
(32.27) 
73.53 
(18.61) 
56.26 
(16.39) 
57.51 
(18.69) 
0.23 
 
* significant at 5% level 
Table 42 Baroreflex sensitivity statistics LAG1 by DSQ 
 
At LAG1 baroreflex sensitivity is statistically significantly different across groups and is 
lower in the Fukuda+2003+2011 group suggesting decreased baroreflex sensitivity to 
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controlling heart rate in this group, in particular compared to the Fukuda+2003 
Research group. 
 
The baroreflex effectiveness index is comparable across all groups, although slightly 
higher in the Fukuda+2003 Research group, which may indicate greater control. 
3.3.5. DSQ: Standing 
Tables 43 and 44 show mean drop, baseline and nadir in sBP and dBP between DSQ 
groups. There are no statistically or clinically significant differences between groups. 
 
Table 43 Systolic blood pressure on standing by DSQ 
 
Mean sBP is comparable across all groups and lowest in the Fukuda+2003 Research 
subgroup. This is reflected by a lower nadir. No group meets criteria for OH on sBP. 
 
This is also reflected in dBP on active stand, as shown in table 44. Mean dBP is 
comparable across groups and not statistically significantly different. 
 
 
 
 
 Fukuda 
n=6 
mean (SD) 
Fukuda + 
2003 
Research 
n=8 
mean (SD) 
Fukuda + 
2003 
Clinical 
n=9 
mean (SD) 
Fukuda + 
2003 + 2011 
n=26 
mean (SD) 
p value 
(ANOVA) 
Mean sBP 108.3 
(18.68) 
99.54 
(22.39) 
125.3 
(27.82) 
108.9 
(25.94) 
0.2 
Nadir 101.3 
(17.64) 
85.75 
(28.50) 
111.8 
(29.45) 
97.88 
(25.96) 
0.25 
Drop 7.00 
(6.51) 
13.79 
(8.00) 
13.57 
(17.13) 
11.01 
(12.54) 
0.72 
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 Fukuda 
n=6 
mean (SD) 
Fukuda + 
2003 
Research 
n=8 
mean (SD) 
Fukuda + 
2003 
Clinical 
n=9 
mean (SD) 
Fukuda + 
2003 + 2011 
n=26 
mean (SD) 
p value 
(ANOVA) 
Mean dBP 74.14 
(19.23) 
69.26 
(13.61) 
77.07 
(18.53) 
73.08 
(17.67) 
0.83 
Nadir 67.00 
(21.86) 
59.13 
(18.07) 
65.44 
(18.16) 
65.12 
(15.10) 
0.80 
Drop 7.14 
(5.10) 
10.14 
(5.63) 
11.63 
(11.90) 
7.96 
(11.12) 
0.76 
 
Table 44 Diastolic blood pressure on standing by DSQ 
 
Table 45 shows the 30:15 ratio on standing – a dynamic measure of parasympathetic 
activity. 
 
 Fukuda 
n=6 
median 
(IQR) 
Fukuda + 
2003 
Research 
n=8 
median 
(IQR) 
Fukuda + 
2003 
Clinical 
n=9 
median 
(IQR) 
Fukuda + 
2003 + 2011 
n=26 
median 
(IQR) 
p value 
(Kruskal-
Wallis) 
30:15 ratio 1.12 
(1.06,1.55) 
1.10 
(1.02,1.33) 
1.16 
(1.07,1.36) 
1.11 
(1.06,1.17) 
0.73 
 
Table 45 30:15 ratio by DSQ 
 
Median measures and IQR are comparable across groups and not statistically 
significantly different. Ratios across all subgroups are normal (>1.04). 
 
Table 46 shows median AUC between DSQ subgroups. There is no statistically or 
clinically significant difference between groups. 
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 Fukuda 
n=6 
median 
(IQR) 
Fukuda + 
2003 
Research 
n=8 
median 
(IQR) 
Fukuda + 
2003 
Clinical 
n=9 
median 
(IQR) 
Fukuda + 
2003 + 2011 
n=26 
median 
(IQR) 
p value 
(Kruskal-
Wallis test) 
AUC 
(Baseline) 
16.91 
(0.0,121.0) 
51.74 
(14.20,299.1) 
0.0 
(0.0,128.4) 
20.04 
(0.0,112.4) 
0.68 
AUC –
(20mmHg) 
0.0  
(0.0,0.0) 
0.0  
(0.0,0.0) 
0.0 
(0.0,69.48) 
0.0  
(0.0,0.0) 
0.50 
 
Table 46 Area under the curve by DSQ 
3.3.6. DSQ: Valsalva 
Table 47 shows median measures of Valsalva ratio. There are statistically significant 
between-group differences in Phases I and IIi. 
 
The Valsalva ratio is abnormal (<1.21) in all subgroups, which indicates dysautonomia. 
The statistically significant differences in Phases I and IIi may reflect parasympathetic 
activation by the baroreceptors (318). However, blood pressure in phases I and IIi has 
not been shown to decrease, which would be expected, and may therefore reflect 
poor Valsalva technique. 
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 Fukuda 
n=6 
median 
(IQR) 
Fukuda + 
2003 
Research 
n=8 
median 
(IQR) 
Fukuda + 
2003 Clinical 
n=9 
median 
(IQR) 
Fukuda + 
2003 + 2011 
n=24* 
median 
(IQR) 
p value 
(Kruskal-
Wallis 
test) 
Valsalva 
ratio 
0.56 
(0.40,0.82) 
0.68 
(0.47,0.96) 
0.81 
(0.68,0.97) 
0.74 
(0.52,0.87) 
0.22 
Phase I 13.30 
(8.14,20.55) 
14.44 
(7.25,26.69) 
3.54 
(-0.96,5.98) 
13.29 
(2.98,18.15) 
0.0282** 
Phase IIi 134.5 
(114.5,146.5) 
3.16 
(-1.12,17.82) 
10.03 
(-7.89,25.50) 
8.96 
(0.35,22.81) 
0.0013** 
Phase IV 21.16 
(7.01,37.89) 
17.77 
(7.43,37.59) 
15.77 
(4.11,22.93) 
16.36 
(1.89,30.95) 
0.70 
 
* unable to analyse two data sets due to missing BP readings 
** significant at 5% level 
Table 47 Valsalva ratio by DSQ 
 Cognitive function 3.4.
Results of the cognitive function assessments are shown below. Comparison to 
previous studies is made where no normal reference range is available. 
3.4.1. CFS and controls 
The number of participants is as per table 48 (Premorbid IQ CFS and controls) unless 
otherwise indicated. 
3.4.1.1. Premorbid IQ 
Table 48 shows premorbid IQ score as per NART. Premorbid IQ is neither statistically 
nor clinically different between the CFS and control groups. Although evidence for its 
effectiveness at predicting premorbid IQ is debated (298, 319), both groups have an IQ 
above the average score for the UK (a score of 108.5) (320). 
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CFS (n=51) 
mean (SD) 
Controls (n=10) 
mean (SD) 
p value 
(unpaired t-test) 
NART 117.9 (7.9) 122.3 (4.4) 0.09 
 
Table 48 Premorbid IQ CFS and controls 
3.4.1.2. Memory: Verbal 
Table 49 shows the results of measures of verbal memory. There are no statistically 
significant differences between CFS and controls. 
 
 
CFS (n=51) 
mean (SD) 
Controls 
(n=10) 
mean (SD) 
p value 
(unpaired t-
test) 
Rey AVLT    
 Total recall trials 1-5 46.9 (10.4) 50.5 (6.2) 0.30 
 Forgetting (% retained 
from A6 on trial A7) 
76.3 (21.1) 82.1 (18.4) 0.42 
Forward Digit Span    
 Clinical measure 6.6 (1.4) 6.9 (1.3) 0.52 
 
Table 49 Verbal memory CFS and Control 
 
Rey AVLT total recall is comparable to control subject in other studies and other 
normative data (207, 321, 322) and shows no statistically significant difference in 
immediate memory in CFS subjects. Delayed recall, as shown by percentage retained, 
is not statistically significantly different between groups and is comparable to that 
seen in healthy controls in other studies (322). Control participants recalled a higher 
total number of words over five trials of Rey AVLT and retained a higher percentage, 
although this was not clinically significant.  
 
Forward digit span is comparable to controls in other studies (321, 322). 
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3.4.1.3. Memory: Visuospatial  
Table 50 shows the results of measures of visuospatial memory. There are no 
statistically significant differences between CFS and control groups. 
 
Both groups recalled a comparable sequence number on spatial span and VPT, 
indicating no deficits in immediate visuospatial memory. All are comparable to control 
subjects in other studies (321, 322). 
 
 
CFS (n=50)* 
mean (SD) 
Controls (n=10) 
mean (SD) 
p value 
(unpaired t-test) 
Spatial span    
Forward longest 
sequence 
5.1 (1.3) 5.4 (1.4) 0.52 
Backward longest 
sequence 
4.9 (1.2) 4.4 (1.6) 0.25 
VPT    
Maximum number 
of targets 
9.9 (2.2) 9.9 (2.6) > 0.99 
 
* One participant was unable to complete the task 
Table 50 Visuospatial memory CFS and controls 
3.4.1.4. Executive: Verbal fluency 
Tables 51-54 show measures of executive function. 
 
Table 51 shows the results of measures of verbal fluency as per FAS. The number of 
correct words achieved on FAS is not statistically significantly different between 
groups, however controls achieved more correct words compared to CFS participants 
(46.0 versus 39.3). 
 
The mean score by CFS subjects is consistent with the results of a meta-analysis finding 
of a mean FAS score of 40.5 (SD 6.1) (323). Controls in this study performed slightly 
better, however this is likely to be explained by the wide standard deviation. 
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FAS CFS (n=50)* 
mean (SD) 
Controls (n=10) 
mean (SD) 
p value 
(unpaired t-test) 
Total correct 39.3 (10.6) 46.0 (14.2) 0.09 
 
* One participant was unable to complete the task 
Table 51 Verbal fluency CFS and controls 
3.4.1.5. Executive: Inhibition 
Table 52 shows the results of measures of inhibition whereby the subject’s ability to 
supress a usual response with a less habitual one is tested (324). There are no 
statistically significant differences between CFS and control subjects. 
 
STROOP CFS (n=50)* 
mean (SD) 
Controls (n=10) 
mean (SD) 
p value 
(unpaired t-
test) 
“Colour word” minus 
“average of word 
reading plus colour 
naming” 
 
-35.1 (14.3) 
 
-41.4 (9.2) 
 
0.18 
 
* One participant was unable to undertake the task due to colour blindness 
Table 52 Inhibition CFS and controls 
3.4.1.6. Executive: Mental manipulation 
Table 53 shows the results of measures of mental manipulation. Mean clinical 
measures (highest number of digits recalled) on reverse digit span are not statistically 
significantly different between CFS and controls. Controls had a higher mean clinical 
measure on reverse digit span compared to CFS participants, although this was not 
statistically significant (5.8 versus 5.0 (p=0.06)). 
 
Scores in both CFS and control groups are similar to normative measures (325). 
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Reverse digit span CFS 
mean (SD) 
Controls 
mean (SD) 
p value 
(unpaired t-
test) 
Clinical measure 5.0 (1.3) 5.8 (1.1) 0.06 
 
Table 53 Mental manipulation CFS and controls 
3.4.1.7. Executive: Set shifting 
Set shifting represents the ability to alternate attention between simultaneous tasks 
and requires the use of cognitive, perception and motor skills. There are no statistically 
significant differences in set shifting between CFS and controls, as seen in table 54. 
 
Trail making test CFS (n=50)* 
mean (SD) 
Controls 
(n-10) 
mean (SD) 
p value 
(unpaired t-
test) 
Shift (B-A) (seconds) 32.9 (23.1) 27.0 (11.2) 0.69 
 
* One participant was unable to complete the task 
Table 54 Set shifting CFS and controls 
3.4.1.8. Psychomotor speed 
Table 55 shows comparison of psychomotor speed between CFS and controls, as 
measured with the DSST. 
 
There is a statistically significant difference in mean number of symbols per second on 
DSST. Control participants completed more symbols per second compared to CFS (0.6 
versus 0.70 (p=0.0351)). This shows that this cohort of CFS subjects had statistically 
significantly reduced psychomotor speed (and attention) compared to control subjects. 
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DSST CFS 
mean (SD) 
Controls 
mean (SD) 
p value 
(unpaired t-
test) 
Symbols per second 0.6 (0.2) 0.7 (0.1) 0.0351* 
 
* significant at 5% level 
Table 55 Psychomotor speed CFS and controls 
3.4.1.9. Attention 
Table 56 shows comparison of attention between CFS and controls on ANT. There are 
no statistically significant differences between groups. 
 
ANT CFS (n=51) 
mean (SD) 
Controls (n=10) 
mean (SD) 
p value 
(unpaired t-test) 
Alerting 13.6 (29.8) 20.7 (24.7) 0.48 
Orienting 57.9 (46.2) 79.0 (42.8) 0.19 
Inhibition 119.2 (48.4) 104.4 (46.0) 0.38 
Central difference 135.1 (67.1) 126.9 (72.0) 0.73 
No stimulus 
difference 
104.5 (63.4) 99.1 (58.0) 0.81 
Spatial difference 114.8 (58.3) 87.1 (41.1) 0.16 
 
Table 56 Attention CFS and controls 
3.4.2. DSQ 
The following results show comparison of cognitive measures by DSQ subgroup. 
Participant numbers are as per premorbid IQ table 57, unless otherwise indicated. 
3.4.2.1. Premorbid IQ 
Premorbid IQ, as measured using NART, is comparable across all DSQ subgroups and 
not statistically significantly different, as seen in table 57. 
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All groups have a mean verbal IQ above average (320). Reading single words, as is done 
with NART, requires little sustained concentration. Significantly, however, NART has 
been shown to discriminate between healthy controls and cognitively impaired 
dementia subjects (326). The findings below, of a lower NART score in the 
Fukuda+2003+2011 subgroup, may reflect impaired cognitive ability in comparison to 
the Fukuda+2003 Research group or a loss of function (as reflected in findings of FIS 
and COMPASS scores), which may have contributed to an overall lower level of 
educational attainment. 
 
 
Fukuda 
(n=6) 
Fukuda + 2003 
Research 
(n=8) 
Fukuda + 
2003 Clinical 
(n=9) 
Fukuda + 
2003 + 2011 
(n=26) 
p value 
(ANOVA) 
NART 119.2 (6.6) 123.1 (3.1) 117.1 (6.6) 116.0 (9.2) 0.16 
 
Table 57 Premorbid IQ by DSQ 
3.4.2.2. Memory: Verbal 
Tables 58 and 59 show comparisons of measures of verbal memory. 
 
Table 58 compares verbal memory. There is a statistically significant inter-group 
difference in total recall over trials 1-5 on AVLT. Participants in the Fukuda+2003+2011 
group performed worse (42.2) than the other three groups and those meeting a 
Fukuda+2003 Research ‘diagnosis’ performed best (53.0). This suggests that 
Fukuda+2003+2011 subjects have a less efficient verbal declarative memory compared 
to the other groups. 
 
The Fukuda+2003+2011 group also had the lowest percentage retention on trial A7 
(70.5%) and the Fukuda+2003 Research group the highest (84.2%). Although this was 
not statistically significant, it does suggest that delayed recall may be less efficient in 
the Fukuda+2003+2011 group. 
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Forward digit span measures are not statistically or clinically different across groups 
and are comparable to scores observed in control subjects in other studies (321). 
 
 
Fukuda 
(n=6) 
mean (SD) 
Fukuda + 
2003 
Research 
(n=8) 
mean (SD) 
Fukuda + 
2003 
Clinical 
(n=9) 
mean (SD) 
Fukuda + 
2003 + 
2011 
(n=26) 
mean (SD) 
p value 
(ANOVA) 
Rey AVLT      
Total recall trials 1-5 51.3  
(6.3) 
53.0 
(4.47) 
49.4 
(11.7) 
42.15 
(10.1) 
0.014* 
Forgetting (% retained 
from A6 on trial A7) 
80.1 
(23.2) 
84.2 
(14.8) 
80.3 
(12.0) 
70.5  
(24.2) 
0.32 
Forward Digit Span      
Clinical measure 6.7 (1.2) 6.4 (1.2) 6.9 (1.5) 6.6 (1.5) 0.91 
 
* significant at 5% level 
Table 58 Verbal memory by DSQ 
3.4.2.3. Memory: Visuospatial 
Table 59 shows the results of comparisons of visuospatial memory across DSQ 
subgroups. There are statistically significant differences across all measures on spatial 
span and VPT. Participants in the Fukuda+2003+2011 group underperformed in all 
measures compared to the other subgroups. This suggests that the Fukuda+2003+2011 
group has a deficit in immediate working memory compared to the other groups. The 
scores in this group are lower than scores seen in control subjects in other studies 
(321, 322). 
 
There is a statistically significant difference in VPT scores between groups. The 
Fukuda+2003+2011 group underperforms compared to the other subgroups. 
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 Fukuda 
(n=6) 
mean (SD) 
Fukuda + 
2003 
Research 
(n=8) 
mean (SD) 
Fukuda + 
2003 
Clinical 
(n=9) 
mean (SD) 
Fukuda + 
2003 + 
2011 
(n=26) 
mean (SD) 
(n=25)** 
p value 
(ANOVA) 
Spatial span      
Forward longest 
sequence 
6.3  (0.8) 5.6 (0.9) 5.4 (1.5) 4.6 (1.2) 0.0054* 
Backward longest 
sequence 
5.0 (0.9) 5.9 (0.6) 4.8 (1.6) 4.6 (1.2) 0.0655* 
VPT      
Maximum number of 
targets 
10.5 (1.2) 11.4 (1.9) 11.0 (2.0) 8.8 (2.2) 0.0045* 
 
* significant at 5% level  
** One participant was unable to complete the task 
Table 59 Visuospatial memory by DSQ 
 
These findings suggest that visuospatial working memory, which allows temporary 
retention and manipulation of information (327) – as assessed by spatial span – and 
short-term visuospatial memory – as assessed by VPT (328), differ by diagnostic criteria 
and may be impaired in participants meeting Fukuda+2003+2011. 
3.4.2.4. Executive: Verbal fluency 
Tables 60-63 show comparisons of measures of executive function. 
 
There are no statistically significant differences in verbal fluency between subgroups, 
as seen in table 60. Nevertheless, participants in the Fukuda+2003+2011 group 
performed worse than other groups, with fewer correct words on FAS. The 
Fukuda+2003 Research group achieved the most number of words. 
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Although mean score in the Fukuda+2003+2011 group is lower than the other groups, 
it is in the lower range of normal when compared with mean normative scores on 
meta-analysis (323). These findings suggest that verbal fluency in this cohort of CFS 
subjects is within normal limits.  
 
FAS Fukuda 
(n=6) 
mean (SD) 
Fukuda + 
2003 
Research 
(n=8) 
mean (SD) 
Fukuda + 
2003 
Clinical 
(n=9) 
mean (SD) 
Fukuda + 
2003 + 
2011 
(n=25)* 
mean (SD) 
p value 
(ANOVA) 
Total correct 41.7  
(10.9) 
43.4  
(4.9) 
41.4  
(11.2) 
36.8  
(10.9) 
0.34 
 
* One participant was unable to complete the task 
Table 60 Verbal fluency by DSQ 
3.4.2.5. Executive: Inhibition 
Table 61 shows the results of measures of inhibition. 
 
STROOP Fukuda 
(n=6) 
mean (SD) 
Fukuda + 
2003 
Research 
(n=8) 
mean 
(SD) 
Fukuda 
+ 2003 
Clinical 
(n=9) 
mean 
(SD) 
Fukuda + 
2003 + 
2011 
(n=25)* 
mean (SD) 
 
p value 
(ANOVA) 
“Colour word” minus 
“average of word 
reading plus colour 
naming” 
-41.5  
(13.0) 
-34.7 
(15.7) 
-34.7 
(12.0) 
-33.9 
(15.7) 
 
0.73 
 
* One participant was unable to undertake the task due to colour blindness 
Table 61 Inhibition by DSQ 
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There are no statistically significant differences between groups, however the 
Fukuda+2003+2011 subjects were the worst performers. Nevertheless, inhibition 
appears to be comparable across diagnostic criteria. 
3.4.2.6. Executive: Mental manipulation 
Table 62 shows a comparison of mental manipulation between DSQ subgroups 
assessed by clinical measure of reverse digit span. There are no statistically significant 
differences between groups.  
 
Reverse digit span Fukuda 
(n=6) 
mean (SD) 
Fukuda + 
2003 
Research 
(n=8) 
mean (SD) 
Fukuda + 
2003 
Clinical 
(n=9) 
mean (SD) 
Fukuda + 
2003 + 
2011 
(n=26) 
mean (SD) 
p value 
(ANOVA) 
Clinical measure 4.8 (1.9) 5.4 (1.3) 5.2 (0.8) 4.9 (1.3) 0.75 
 
Table 62 Mental manipulation by DSQ 
3.4.2.7. Executive: Set shifting 
Table 63 shows a comparison of set shifting between DSQ subgroups as assessed with 
the trail making test. There are no statistically significant differences between groups, 
however the Fukuda+2003+2011 group took longer to complete the task on average – 
almost twice as long as the Fukuda alone group. 
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Trail making test Fukuda 
(n=6) 
mean (SD) 
Fukuda + 
2003 
Research 
(n=8) 
mean (SD) 
Fukuda + 
2003 
Clinical 
(n=9) 
mean (SD) 
Fukuda + 
2003 + 
2011 
(n=25)* 
mean (SD) 
p value 
(ANOVA) 
Shift (B-A) 22.0  
(9.5) 
33.5  
(20.9) 
26.0  
(10.1) 
39.4  
(27.8) 
0.26 
 
* One participant was unable to complete the task 
Table 63 Set shifting by DSQ 
3.4.2.8. Psychomotor speed 
Table 64 shows that there are statistically significant differences in psychomotor speed 
between groups, measured using the DSST. The Fukuda+2003+2011 group under-
performed compared to the other subgroups. This group also had a significantly 
reduced psychomotor speed and attention compared to other groups. 
 
DSST Fukuda 
(n=6) 
mean (SD) 
Fukuda + 
2003 
Research 
(n=8) 
mean 
(SD) 
Fukuda + 
2003 
Clinical 
(n=9) 
mean 
(SD) 
Fukuda 
+ 2003 + 
2011 
(n=26) 
mean 
(SD) 
p value 
(ANOVA) 
Symbols per second 0.7 (0.1) 0.7 (0.1) 0.6 (0.1) 0.5 (0.2) 0.0162* 
 
* significant at 5% level 
Table 64 Psychomotor speed by DSQ 
3.4.2.9. Attention 
Table 65 shows comparison of measures of attention using ANT. There are no 
statistically significant differences between groups. Nevertheless, the Fukuda+2003 
Research and Fukuda+2003+2011 groups performed worse on the alerting compared 
to the other two groups. 
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ANT Fukuda  
(n=6) 
mean (SD) 
Fukuda + 
2003 
Research 
(n=8) 
mean (SD) 
Fukuda + 
2003 
Clinical 
(n=9) 
mean (SD) 
Fukuda + 
2003 + 2011 
(n=24)* 
mean (SD) 
p value 
(ANOVA) 
Alerting 23.0 (21.9) 5.4 (23.1) 18.6 (33.6) 5.6 (39.7) 0.59 
Orienting 53.9 (52.5) 73.7 (37.8) 47.7 (18.1) 60.8 (53.8) 0.70 
Inhibition 110.3 (57.3) 105.0 (30.7) 125.6 (28.6) 124.1 (57.6) 0.74 
Central 
difference 
136.2 (86.1) 127.3 (29.8) 131.6 (28.0) 140.3 (83.4) 0.97 
No stimulus 
difference 
94.8 (74.1) 89.8 (50.7) 117.4 (52.1) 109.0 (72.4) 0.81 
Spatial 
difference 
99.5 (56.9) 98.13 (59.2) 127.7 (35.8) 123.0 (64.6) 0.59 
 
* Two participants were unable to complete the task 
Table 65 Attention by DSQ 
 
There were some statistically significant differences on cognitive assessment between 
DSQ subgroups. These results are discussed in section 4.1.2. 
 Summary 3.5.
A summary of the main findings and the principle differences between DSQ subgroups 
is shown below, for ease of reference (tables 66-69). 
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Criteria Differentiating symptom requirements (condensed) 
Fukuda criteria Baseline criterion: 
≥ six months of severe fatigue  
Plus ≥ four of the following: 
Post-exertional malaise 
Unrefreshing sleep 
Memory/concentration impairment 
Myalgia 
Arthralgia 
Headaches 
Lymphadenopathy 
Sore throat 
Canadian 
consensus/DSQ 
clinical 2003 
Addition of autonomic and neuroendocrine symptoms 
 
Perceptual and sensory disturbances 
Ataxia 
Muscle weakness 
Fasciculations 
Autonomic: orthostatic intolerance, PoTS, nausea, irritable 
bowel, urinary frequency, palpitations, exertional dyspnoea 
Neuroendocrine: loss of thermostatic stability, weight 
change 
 
Joint/muscle pain: can be widespread/migratory but 
specifically not involving abdomen or chest and no 
hyperalgesia 
Canadian 
consensus/DSQ 
research 2003 
All symptoms considered major 
 
Pain described as migratory and widespread: 
myofascial/joint/abdominal/head/chest 
Canadian 
(International) 
consensus 2011 
As Canadian consensus clinical 2003 but symptoms further 
categorised and greater number required to meet diagnosis 
 
Nature of pain can be migratory and widespread and can 
include chest and abdominal pain/generalised hyperalgesia 
 
Table 69 Summary of differentiating symptoms by DSQ criteria 
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Chapter 4. Discussion 
 Main findings and comparison with existing studies 4.1.
The main findings of this study will be discussed in the context of the original study 
aims and hypotheses and current literature. Differences between CFS and control 
groups are discussed first to provide context for the DSQ results. 
4.1.1. Autonomic dysfunction 
One of the aims of this study was to identify differences in AD by subgroup of CFS 
subjects, characterised by DSQ diagnostic criteria. It was hypothesised that AD does 
not differ by DSQ subgroup. A summary of the study findings is given below. 
 
Subjective measures of autonomic function were statistically significantly different 
between CFS and control groups, with CFS subjects reporting greater impairment on 
COMPASS, as well as greater fatigue.  
 
Objective testing did not reveal any statistically significant differences between CFS 
and control subjects. Resting HR and BP were at the lower end of the normal clinical 
reference range in both groups, as was cardiac function measured using SI, CI, EDI and 
LVWI. Examination of heart rate and blood pressure variability appeared to show a 
shift to increased sympathetic modulation in both groups. Baroreflex control was 
within normal limits in both CFS and control subjects. 
 
Neither mean BP nor nadir on standing was statistically or clinically significantly 
different and 30:15 ratio – an indicator of parasympathetic activity – was within 
normal parameters. Valsalva manoeuvre findings suggest a dysautonomia in both 
groups with a reduced Valsalva ratio. 
 
The findings summarised above show that there was no statistically significant 
objective difference in autonomic function in this cohort of CFS and control subjects. 
This differs from previous studies that have typically demonstrated a difference in 
autonomic function between CFS subjects and controls (124, 125) and may reflect a 
number of factors. 
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Firstly, sedentary controls were selected for participation. The intention in doing so 
was to match activity levels between CFS subjects and controls. The inclusion of non-
sedentary (that is, potentially active) control subjects in previous studies may have 
resulted in autonomic dysfunction being demonstrated in CFS subjects compared to 
controls, arising secondary to inactivity and consequent deconditioning. 
 
Both controls and CFS subjects appeared to exhibit some degree of dysautonomia and 
it is possible that this results from a sedentary lifestyle. Nevertheless, there is 
inconsistency in this study, in that controls – with higher IPAQ scores (and by 
implication therefore subjectively more activity) than CFS subjects – exhibit more 
features suggestive of dysautonomia compared to CFS subjects. Furthermore, this 
appears to be inconsistent with findings across DSQ subgroups, where the 
Fukuda+2003+2011 group has both lower activity levels on IPAQ and more features of 
clinical impairment on objective autonomic testing. This strongly suggests that there 
are other explanatory variables rather than deconditioning. This is further discussed in 
section 4.1.7. 
 
A second possible explanation for the findings may stem from that fact that this study 
excluded potential participants with a history of co-morbid depression. Autonomic 
dysfunction has been found in depression. Subjects in this study did not meet criteria 
for MDD according to the SCID-I assessment tool. It is possible that autonomic 
dysfunction seen in other studies results from co-morbid depression and is not a 
primary feature of CFS. Consistent exclusion criteria across studies and research 
centres would enable better delineation of these two conditions and their presenting 
symptoms. 
 
Finally, it is feasible that autonomic dysfunction, such as abnormalities in heart rate 
and blood pressure, experienced by CFS subjects is intermittent. Although assessment 
using the Task Force® Monitor provides a continuous measure, a limitation of the 
study methodology was that assessment was conducted during one time frame of 
approximately 20 minutes. If symptoms are experienced intermittently it is possible 
they are not being captured at the time of autonomic assessment, which may be 
exacerbated by testing under research – that is non-real life – conditions. This is a 
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possible explanation for the mismatch between subjective and objective autonomic 
features. 
 
Subjective autonomic symptoms between DSQ subgroups were statistically 
significantly different, with the lowest mean score in the Fukuda alone group and the 
highest in the Fukuda+2003+2011 group (and Fukuda+2003 Research group). This 
pattern was reflected in findings from the IPAQ and FIS questionnaires, which revealed 
statistically significantly greater subjective fatigue and lower activity in the 
Fukuda+2003+2011 and Fukuda+2003 Research groups compared to Fukuda alone. 
 
There were no statistically significant differences between groups on objective 
measures – with the exception of LF/HF-RRI. At rest, HR and BP were similar across 
DSQ subgroups groups. Cardiac statistics indicated decreased myocardial contractility 
in the Fukuda+2003+2011 group and decreased EDI and low CI and SI compared to the 
other subgroups. This group also showed decreased sympathetic modulation on HRV 
(LF/HF-RRI) and on BPV and decreased baroreflex sensitivity. 
 
Measures on standing were comparable between diagnostic subgroups. Valsalva ratio 
was abnormal in each group, consistent with findings comparing CFS and control 
subjects. This may reflect an underlying dysautonomia or the low baseline blood 
pressure. It may also reflect a poor Valsalva technique where the manoeuvre was not 
maintained for an adequate duration or the optimum pressure was not reached. 
 
Although not statistically significant, there were differences in objective autonomic 
parameters between DSQ subgroups. When considered at a clinical level these results 
show emerging between-group differences with a picture of greater objective 
‘impairment’ in the Fukuda+2003+2011 subgroup where mean measures are overall 
lower for all parameters except TPRI. Measures in the Fukuda alone group are higher 
compared to other subgroups, also with the exception of TPRI. 
 
It is significant that the Fukuda criteria do not require the presence of autonomic 
symptoms and this in itself may explain the findings. Equally, it is possible that there is 
an additive or cumulative effect across DSQ subgroups where more symptoms and the 
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potential for more migratory, widespread and potentially hyperalgesic pain with the 
Canadian 2011 criteria compared to Fukuda and Canadian 2003 Clinical results in 
greater symptom burden and disease severity. 
 
This picture may represent different disease phenotypes across different diagnostic 
groups, suggesting that the preliminary hypothesis – AD does not differ by diagnostic 
criteria met – may not be true when considered at a clinical level. Subjects meeting the 
Fukuda+2003+2011 criteria appear to exhibit potentially clinically significant greater 
impairment compared to the other subgroups, in particular those meeting the Fukuda 
alone criteria. Results suggesting lower cardiac muscle elasticity, lower stroke volume 
and reduced cardiac output in this subgroup add weight to this argument. 
 
The challenge is determining whether these additional symptoms are core to CFS and 
point towards a subgroup of patients with greater functional impairment and the 
possibility that CFS is a condition that lies across a disease spectrum, or whether they 
represent co-morbid disease or other non-specific, prevalent somatic symptoms and 
are confounding research into this condition. In either instance improved and 
consistent study criteria and delineation of CFS “diagnoses” through the use of a tool 
such as the DSQ in future research will provide a strong basis from which to answer 
these questions. 
4.1.2. Comparison with existing autonomic studies 
Study findings on self-reported symptoms of autonomic dysfunction – showing 
statistically significantly greater impairment among the CFS cohort compared to 
controls – are consistent with those of other studies (26, 122, 123). This strengthens 
existing evidence that subjective autonomic symptoms are common in CFS patients. 
 
This study found no statistically significant differences on objective autonomic testing 
between CFS and control subjects, which is consistent with some previous studies and 
conflicts with findings from others. This highlights the challenges of determining 
underlying pathophysiology where study findings are not always reproducible. 
Furthermore, it weakens the argument for a causal relationship (between 
dysautonomia and CFS) according to the Bradford-Hill criteria (329). 
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Meeus et al’s recent systematic review of six case control studies concluded that there 
is moderate evidence of decreased parasympathetic activity in CFS subjects with 
reduced heart rate and LF/HF and evidence of increased sympathetic activity on HUT 
(125). As discussed previously, concerns have been raised regarding the 
methodological quality of these studies and the validity of objective assessment. Tak et 
al argue that there is inadequate evidence to determine the role that AD has in CFS 
(153), with some studies showing no evidence of AD in CFS (135, 144). 
 
The findings reported in this thesis may result from a lack of statistical power, such 
that statistical significance at the 5% level was not detected. Furthermore, the 
inclusion and exclusion criteria may be significant. If these findings are considered in 
the context of the use of sedentary controls, this could indicate that deconditioning 
has a role in the presence of the dysautonomia in CFS found in other studies where 
comparison is made to physically active controls. Another important factor may be the 
exclusion of MDD. AD has been found in MDD and raises the question of whether 
autonomic symptoms seen in other studies result from co-morbid depression, or even 
whether MDD and CFS are conditions which lie on the same disease spectrum. 
 
COMPASS scores analysed by DSQ criteria revealed a consistently high score across all 
subgroups with statistically significant variation in score by subgroup. Fukuda alone 
scored the lowest and Fukuda+2003+2011 the highest.  
 
This may be explained by the fact that Fukuda criteria do not require the presence of 
autonomic symptoms. It also points towards the Fukuda+2003+2011 criteria 
representing a more severe disease phenotype with greater functional impairment. 
This is similar to findings in other studies, where comparison of Fukuda and Canadian 
clinical criteria has shown that those meeting the Canadian criteria have more physical 
symptoms and greater functional impairment (5, 330, 331). 
 
No other studies to date have examined differences in objective autonomic 
assessment between DSQ subgroups. 
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Although difficult to determine the role that deconditioning and MDD have in CFS and 
associated AD, the mixed findings indicate that there is a need to use matched controls 
in future studies, where MDD is excluded and activity levels are determined to enable 
recruitment of controls with sedentary lifestyles. 
4.1.3. Cognitive function 
Another aim of this thesis was to identify differences in cognitive impairment by 
subgroup of CFS subjects, determined by DSQ diagnostic criteria, to investigate the 
hypothesis that cognitive impairment does not differ by diagnostic criteria met. 
 
Subjective measurement of cognitive function with COGFAIL showed statistically 
significant differences between CFS and control subjects with CFS participants 
reporting impaired function.  
 
Objective measurement with a validated battery of tests showed statistically 
significant differences in psychomotor speed on DSST with CFS participants performing 
slower than controls. Other measures were comparable between groups and gave 
normative results. These included verbal and visuospatial memory, all assessed 
measures of executive function (verbal fluency, inhibition, mental manipulation and 
set shifting) and attention. 
 
Performance on DSST is dependant particularly on psychomotor speed and attention 
(207). The dissociation with impaired DSST performance and normal performance on 
tests of attention in CFS suggests that the DSST impairment in CFS may be caused by 
reduced psychomotor speed. 
 
Studies show that physical activity is associated with a protective effect on 
psychomotor processing speed (208). In this context, the finding that CFS subjects 
reported lower IPAQ scores compared to controls may offer an explanation. It is also 
possible that this represents an important feature of CFS where loss of psychomotor 
ability is a defining characteristic. Delineating the roles that processing and motor 
speed have in this is challenging, however, and has important implications in terms of 
the nature of the impairment, the domain affected and possible treatment. 
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Memory and executive function were not statistically different between controls and 
CFS groups but the different levels of functioning seen may have clinical significance. 
CFS participants recalled a lower total number of words over five trials of AVLT and 
retained a lower percentage, a measure of verbal memory. Similarly, controls 
appeared to demonstrate better executive function in verbal fluency and mental 
manipulation domains, achieving more correct words on FAS and recalling a greater 
number of digits on reverse digit span. 
 
This may indicate a loss of function in CFS that is subjectively significant and represents 
or exacerbates symptom burden and loss of functioning, in particular in terms of ability 
to continue in employment or studies. 
 
There were no statistically significant differences between DSQ subgroups on self-
reported cognitive impairment with COGFAIL. Nevertheless, Fukuda+2003+2011 
subjects reported higher scores compared to Fukuda alone, pointing towards greater 
self-perceived cognitive impairment in this group. This may be significant given the 
findings that this subgroup also appears to exhibit clinically greater impairment on 
autonomic assessment. 
 
Comparison of objective measures between DSQ diagnostic subgroups revealed 
statistically significant between-group differences.  
 
Verbal memory – as assessed using the AVLT total score – was more impaired in the 
Fukuda+2003+2011 subgroup than the Fukuda alone group. Digit span was 
comparable across groups. 
 
Assessment using AVLT is thought to provide a reflection of arousal, motivation, 
attention and concentration, as well as immediate verbal memory. Age has been 
shown to affect total recall score, with those above aged 60 scoring lower, as has 
gender, with women tending to score higher (207); however, this is unlikely to offer 
explanation for the study findings as age and gender spread were balanced between 
groups.  
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These differences in verbal memory may result from a stimulus overload, as seen when 
differences in AVLT and digit span favour AVLT (207). This arises from confusion where 
there is otherwise intact immediate memory and concentration. This overload may 
reflect greater fatigue or loss of function, which is consistent with the findings 
reported on subjective questionnaires. Stimulus overload is a common feature of CFS 
and patients can experience problems processing large amounts of information. This 
may be due to impaired inhibition, although this is not shown in the results here (with 
STROOP), or to abnormalities in the neurotransmitter functioning, such as serotonin. 
 
Statistically significant differences were observed between groups on visuospatial 
memory assessment. Working memory and short-term visuospatial memory appeared 
to be more impaired in the Fukuda+2003+2011 group. This group also had greater 
impairment compared to findings in controls in other studies (321, 325). The Fukuda 
alone group showed the least impairment. 
 
Assessment of executive function revealed no statistically significant differences 
between DSQ subgroups. Although executive verbal function on FAS was lower in the 
Fukuda+2003+2011 group, it was comparable to normative scores seen on meta-
analysis (323). Set shifting measured on TMT was worse in the Fukuda+2003+2011 
group compared to the other subgroups and may reflect impaired psychomotor 
function (332), particularly when considered in the context of findings on DSST. 
 
There were statistically significant between-group differences on DSST assessment. 
The Fukuda+2003+2011 group achieved fewer symbols per second compared to other 
groups. This suggests that there may be some psychomotor impairment in this group, 
which may reflect the increased symptom burden, the presence of more widespread, 
severe or hyperalgesic pain – as seen in the 2011 diagnostic criteria, or impaired 
processing speed. 
 
There were no statistically significant between-group differences in attention, as 
measured on ANT. Nevertheless, alerting (a measure of arousal) appeared to be 
clinically worse in the Fukuda+2003 Research and the Fukuda+2003+2011 groups. The 
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executive element was similar between subgroups, which is consistent with other 
findings. 
 
In summary, there were statistically significant differences in psychomotor speed, 
visuospatial memory and some measures of verbal memory across DSQ subgroups, 
with Fukuda+2003+2011 consistently underperforming compared to other cohorts. 
This mirrors subjectively higher scores on COGFAIL, indicating more cognitive 
impairment, greater fatigue on FIS and more AD symptoms on COMPASS. Fukuda 
alone and Fukuda+2003 Clinical appeared to perform better. 
 
It is not possible to draw conclusions regarding statistically significant between-group 
differences when using ANOVA, however there does appear to be a subset of CFS 
subjects in this study that is more severely cognitively impaired - that is those meeting 
the Fukuda+2003+2011 criteria (who also appear to have clinically greater autonomic 
dysfunction).  
 
This differs from the original hypothesis that cognitive impairment does not differ by 
diagnostic criteria met and points towards greater functional impairment in subjects 
meeting the Fukuda+2003+2011 criteria, suggesting that this may represent a more 
severe disease phenotype compared to Fukuda alone. 
 
The interplay between fatigue and cognitive function is important to consider, 
particularly in the context of possible stimulus overload and different apparent levels 
of impairment between DSQ subgroups. 
 
Cognitive impairment has been seen in a number of conditions associated with 
impaired sleep, including sleep apnoea. A study comparing cognitive performance 
between CFS and sleep apnoea subjects assessed verbal and visuospatial memory 
using AVLT and digit span and found impairment in both groups compared to 
normative data. They found no between-group differences on AVLT recall but more 
severe impairment in sleep apnoea subjects on digit span, as well as on measures of 
psychomotor performance, concluding that overall impairment was worse in sleep 
apnoea subjects compared to CFS subjects (254). 
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This suggests that cognitive impairment may arise secondary to symptoms of fatigue, 
rather than be a primary feature of CFS. This is supported by the fact that the most 
severe cognitive impairment in this study was found in the DSQ subgroup 
Fukuda+2003+2011, which also reported greater fatigue on FIS. 
 
The role that pain may have to play in this also deserves further investigation, in light 
of evidence that pain can impair cognitive function (333) and in view of the potentially 
different characteristics of the pain included in different criteria. 
 
The nature of the pain described in the Canadian 2011 criteria – which can be 
widespread, hyperalgesic in nature and include abdominal and chest pain  - may be 
more severe or widespread than in subjects in other subgroups and may exacerbate 
poorer cognitive function. 
 
Finally, the consistent clinical underperformance in the Fukuda+2003+2011 group 
across autonomic and cognitive assessment also points towards a possible relationship 
between these two processes. The analysis and research conducted here do not allow 
for more than supposition, however in light of the link between autonomic measures 
such as blood pressure and cognitive function (see section 1.14) it is possible that 
there is an association between the two. This merits further investigation. 
4.1.4. Comparison with existing cognitive studies 
The findings of greater subjective symptoms of cognitive impairment in this study 
cohort are consistent with findings in other studies (230, 231) and strengthen the 
evidence that CFS patients self-report cognitive problems. 
 
The challenges of objective assessment of cognitive impairment include the use of 
different tests and lack of knowledge of baseline ability. Current literature of cognitive 
impairment in CFS shows a mixed picture, with meta-analysis indicating possible 
overall deficits in attention, memory and reaction time (219). Few studies have 
reported impaired psychomotor skills in CFS. 
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This contrasts to findings in this study, which showed no statistically significant 
differences in memory or attention between CFS and control subjects and statistically 
significant differences in psychomotor speed on DSST. This may reflect a loss of 
physical rather than cognitive function or impaired processing speed resulting from 
stimulus overload.  
 
The lack of consistency with other studies does contribute to an overall picture of the 
challenges associated with the use of different test batteries and gives weight to the 
argument that adopting a uniform set of tests (and inclusion/exclusion criteria) across 
all studies may aid comparison of results. 
 
No other studies to date have assessed objective cognitive parameters by DSQ 
subgroup. A small number of studies examining phenotypes by different diagnostic 
criteria on self-reported symptoms show that there is greater subjective functional 
impairment and fatigue in patients meeting the Canadian Clinical criteria (2003) 
compared to the Fukuda alone criteria (5, 51). This is consistent with the findings 
presented here, which further build on this and show that subjects meeting 
Fukuda+2003+2011 have the greatest functional impairment compared to other DSQ 
subgroups. 
4.1.5. Depressive symptoms 
This thesis aimed to explore the prevalence and nature of depressive symptoms in this 
well-defined cohort of CFS subjects, with the hypothesis that depressive symptoms are 
common in CFS. 
 
The nature of conducting this research study meant that there was time at each 
screening visit to explore depressive-type symptoms in depth to understand their 
nature and origins and help differentiate whether they were better accounted for by 
depression or CFS. It is possible that patients seen in a primary care setting may have 
been found to meet criteria for depression, where time restraints necessitate a more 
“tick box” approach to diagnosis. Equally, while mental health professionals also 
explore the nature of these symptoms in greater depth, is it possible that CFS is not a 
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diagnosis at the forefront of their minds and is therefore missed, in favour of a 
diagnosis of depression. 
 
The prevalence of MDD in the study cohort compared to the UK as a whole was higher. 
This may be due to the considerable disease burden associated with CFS, which 
predisposes to co-morbid depression: the prevalence of depression in chronic disease 
is estimated to be 20% (334). It may also be explained by the fact that there are 
overlapping symptoms, the natures of which are difficult to distinguish and 
characterise and this may result in misdiagnosis. Equally, these overlapping symptoms 
may be the manifestation of a common underlying aetiopathogenesis encompassing 
two conditions that lie across a disease spectrum. 
 
Nearly 40% of this CFS cohort reported symptoms of depression, which included 
secondary symptoms such as change in appetite, sleep disturbance and loss of energy 
and concentration. Some of these occur in many diseases and are therefore not 
defining features of depression. They are significant as they may be presenting 
symptoms of patients later diagnosed with CFS but may initially be thought to be 
associated with depression, a more prevalent diagnosis.  
 
Subsequent exploration of these depressive-type symptoms may go on to reveal low 
mood or cessation of activities, contributing to a diagnosis of depression, but which 
arise as a consequence of CFS and resultant functional impairment, frustration and 
guilt about the burden on family members. 
 
Differentiating between the “depressed mood” of depression and the “frustration and 
low mood” in CFS is key to correct diagnosis. One study participant with co-morbid CFS 
and MDD stated that feeling down in MDD improved with exercise and did not with 
CFS, thereby enabling them to differentiate between the two. CFS participants also 
highlighted a difference between a lack of motivation and loss of pleasure to perform 
activities (with depression) compared to a lack of ability but with a strong motivation 
(with CFS). These differentiations are significant but may be under-explored by 
clinicians. 
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In total, 63% of the CFS subjects in this study reported no symptoms of depression on 
SCID-I assessment. A significant limitation of screening for depression using DSM 
criteria was that if patients reported no “primary” symptoms – feeling depressed or 
down, or loss of interest – no enquiry was made regarding other “secondary” 
symptoms. It is therefore likely that secondary symptoms that overlap with CFS 
symptoms, such as sleep disturbance, psychomotor change and loss of concentration, 
were under-reported and not included in the analysis. 
 
Anecdotally, CFS patients report trials of antidepressant medication. In this study, 15% 
of CFS participants with no recorded depressive symptoms were prescribed 
antidepressants. It is important to note that actual numbers of participants are small; 
however, the finding may have important implications. 
 
Estimation of antidepressant use in a non-depressed population without CFS is 
difficult. A Canadian study examined data from the Canadian Community Health 
Survey from 2002 and showed that 5.8% of Canadians were prescribed 
antidepressants, compared to a 4.8% prevalence of a major depressive episode. Of 
those taking antidepressants 33.1% had a past-year episode of major depression. Of 
those without a past-year episode of depression, over 60% had had migraine, 
fibromyalgia, anxiety disorder, or past depression (335).  
 
This suggests that antidepressant medication is used for reasons other than 
depression, perhaps as a form of pain management or as a trial for hard-to-treat 
symptoms. The lack of improvement in CFS symptoms seen in studies exploring their 
efficacy (174) suggests that their use may be unsuitable and that in the absence of co-
morbid depression their prescription may be inappropriate and perhaps erroneously 
intensify the perception of CFS as a psychiatric disorder. 
 
These findings illustrate the challenges of understanding which symptoms are better 
attributed to CFS and which to depression. They also suggest that the original 
hypothesis that depressive symptoms are common in CFS may be correct but that 
there are significant challenges in determining whether these symptoms are better 
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accounted for by depression or by CFS and that their proper exploration is central to 
correct diagnosis. 
4.1.6. Completion of a complex and physically-demanding study 
The final aim of this thesis was to determine whether CFS patients can participate in a 
study that involves considerable personal burden. 
 
Of the CFS subjects enrolled, 86% (51/58) completed the full study and were able to 
undergo combinations of six half-day or three full-day visits, plus a screening visit, 
within a three-month period. Furthermore, 100 CFS patients (59% of the total sent 
information sheets) expressed interest in participating, requesting that they be 
contacted for initial screening by the study team.  
 
Not only does this indicate that this cohort of CFS subjects was highly motivated to 
complete the study, it also implies that there is a widespread motivation from patients 
to investigate the aetiology of CFS. This motivation may stem from a wish to determine 
the physiological basis for symptoms and enable treatment. It may also be to counter 
the stigma associated with the condition and “prove” to disbelievers that CFS has been 
and continues to be wrongly attributed to malingering. 
 
This determination and resilience – particularly in the face of stigma – also strongly 
suggests that this cohort of CFS subjects was highly motivated and optimistic about the 
outcome of research, which may signal an important differentiating feature from 
depressive symptoms, where feelings of hopelessness tend to dominate. 
 
These findings indicate that the opening hypothesis is correct: CFS patients are able to 
participate in and complete a complex and physically-demanding study. Nevertheless, 
the longer-term impact of the physical, mental and emotional exertion of participation 
was not measured in this study and the consequences may be considerable. 
 
Of particular note, and in relation to this, is the fact that participants necessarily had to 
be ambulatory in order to meet the inclusion criteria and actively participate in 
investigations. As a result, while there was a spectrum of disease severity amongst the 
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CFS subjects included in this study, it is likely that at the time of investigation those 
enrolled largely represented a “milder” phenotype and more severely affected 
patients were not included. This has implications for the study findings, as including 
participants with more severe disease may have shown a larger effect size – with more 
autonomic and cognitive impairment – in comparison to controls or between DSQ 
groups. 
4.1.7. The role of deconditioning 
All participants were considered sedentary at the start of the study, undergoing fewer 
than 30 minutes of exercise three times a week. Despite this, the CFS group reported 
significantly lower levels of activity on IPAQ compared to controls. Even with the 
possibility of bias when using subjective methods to assess activity levels, this indicates 
that there is considerable variation in levels of activity within populations that are 
classified as sedentary. In the context of this study, it suggests that the CFS cohort has 
a significantly less active lifestyle than sedentary controls, which may result from the 
impact of greater functional impairment. 
 
Furthermore, there is a significant difference in IPAQ score between DSQ groups, with 
Fukuda alone and Fukuda+2003 Clinical scoring higher than Fukuda+2003 Research 
and Fukuda+2003+2011. 
 
An important question concerns direction of causality: whether lower activity results 
from symptom burden, for example fatigue or autonomic symptoms, or whether these 
symptoms arise from a less active lifestyle and deconditioning. 
 
It is not possible to draw conclusions regarding this. Nevertheless, there is 
inconsistency between IPAQ results and objective markers of dysautonomia – reduced 
IPAQ score does not correspond to reduced cardiac output or increased heart rate (see 
tables 64 and 66). Although this should be interpreted cautiously, given the limitations 
of the IPAQ questionnaire and the absence of statistical analysis to corroborate the 
observation, this implies that the dysautonomia seen in the Fukuda+2003+2011 group 
may be part of the disease symptomatology that in itself contributes to increased 
fatigue and loss of function rather than due to deconditioning. 
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Furthermore, there is a statistically different level of subjective functional impairment 
between DSQ subgroups on FIS and COMPASS, with Fukuda+2003+2011 showing 
greater impairment across all measures including COGFAIL. This group of subjects was 
also less likely to have continued education longer than 11 years and had fewer further 
education qualifications (27% had obtained degree level education compared to 83% 
of Fukuda alone subjects). Therefore, it may be that greater impairment impedes 
conventional achievement and exacerbates a loss of social functioning, including 
activity levels. 
 
Overall, these findings suggest that the Fukuda+2003+2011 subgroup has a higher 
degree of functional impairment, which is reflected in a lower IPAQ score. This may 
result from the greater number of symptoms required and the addition of potentially 
more widespread, migratory pain where hyperalgesia is a feature (stemming from the 
2011 criteria). 
 Conclusion 4.2.
The findings of this study show significant differences in subjective cognitive and 
autonomic measures between DSQ subgroups. They also show clinical between-group 
differences in objective assessment of autonomic and cognitive function. This suggests 
that CFS – as classified using current diagnostic criteria – may constitute a disease 
spectrum, with different phenotypes and severities. 
 
The differences observed between DSQ subgroups may be a reflection of the additive 
effect of the diagnostic criteria. The absence of autonomic symptoms in the Fukuda 
criteria implies a different, less severe, disease phenotype with fewer features of AD. 
In contrast, symptoms of AD are present in the 2003 criteria and include ataxia, muscle 
weakness and OI. Further still, the 2011 criteria have a requirement for a greater 
symptom burden, which can include widespread migratory pain and hyperalgesia. 
 
The Fukuda+2003+2011 subjects appear to have greater autonomic and cognitive 
impairment. The presence of autonomic symptoms, such as muscle weakness, and the 
possibility of more widespread, severe pain may explain poorer psychomotor 
performance in the Fukuda+2003+2011 subgroup. However, given that the 
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Fukuda+2003 (Research and Clinical) criteria subjects appeared to perform better, this 
suggests that, rather than the presence of autonomic symptoms, it may be increased 
symptom burden or type of pain that reflects a more severe disease phenotype. 
 
The possibility that current criteria include symptoms that are not primary features of 
CFS, that represent distinct, undiagnosed co-morbid disease and that may be 
confounding clinical presentation and research, must also be considered. The number 
of symptoms included in the Canadian 2011 criteria and the number of physiological 
systems that can be implicated may mean that, rather than diagnosing a more severe 
CFS phenotype, these criteria in fact capture CFS and other co-morbidities with non-
specific symptoms. This is important not only because it is likely to affect management 
and subsequent prognosis, but also as it may give rise to an inaccurate and confused 
picture of which condition (or conditions) is being researched. 
  
Furthermore, it is possible that the inclusion of more widespread pain with or without 
hyperalgesia in the 2011 criteria may be a confounding symptom – particularly in view 
of the association between pain and both autonomic dysfunction and cognitive 
impairment (attention, psychomotor speed, verbal and working memory) (333, 336, 
337). 
 
There were significant differences in subjective measures between CFS and control 
subjects, with CFS subjects reporting greater impairment. Objective autonomic and 
cognitive assessment provided a mixed picture and may reflect the small number of 
control subjects and signify that the study was underpowered. Another potential 
explanation comes from the fact that this study both excluded depression and 
recruited sedentary controls. 
 
The role that co-morbid psychiatric disease and deconditioning may play in results 
from other studies must be considered. While some of those excluding co-morbid 
depression have found autonomic features in CFS subjects and not in controls, others 
have not (134, 142, 144). It is therefore important to consider whether AD arises from 
co-morbid depression or whether both depression and CFS – with their overlapping 
symptomatology – represent a spectrum of disease where AD is a feature in some but 
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not all patients. Future research should explore this possibility and adopt a consistent 
approach to establish the presence of depression in CFS subjects. 
 
Similarly, the impact of deconditioning in CFS, its potentially confounding role and the 
implications for findings of AD is significant and one which should be recognised in the 
design of future studies. 
 
Finally, this study shows that CFS patients are highly motivated to participate in 
research to explore the pathology underlying this condition. This presents a strong 
argument for larger-scale studies which include more severely affected patients that 
will enable broader and more in-depth research into what may be a spectrum of 
disease. 
 Strengths and limitations 4.3.
4.3.1. Strengths 
The MRC study recruited a highly-motivated cohort of CFS subjects who were able to 
undergo a comprehensive series of investigations to give a dataset which is almost 
100% complete. The number of questionnaires and objective tests conducted means 
that for the first time it has been possible to look in-depth at potential phenotypic 
differences between DSQ subgroups. 
 
The data have also illustrated that CFS patients are able – and prepared – to undergo 
and complete such a comprehensive study, which may allow for future comprehensive 
research. 
 
Screening participants for depression has made it possible to begin to understand the 
overlap between MDD and CFS, as well as helping to define some of the differentiating 
features. Furthermore, it sets a president for future research that controls for co-
morbid depression that will allow greater understanding of whether they are distinct 
pathologies or whether they lie on the same disease spectrum. 
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4.3.2. Limitations 
There are limitations to these data. The study may lack statistical power. The original 
intention was to recruit 71 CFS participants and ten controls, which was not possible 
within the specified time period. The sample sizes in the DSQ groups are small, which 
means it is difficult to conclude that the differences seen are significant, however 
these differences are consistent across all questionnaires, which points towards 
variation in phenotypes. Finding healthy volunteers who were prepared to act as 
controls and participate in all investigations of the original MRC study was difficult and 
this is in part reflected by the small number of controls, which does limit comparison 
between groups. 
 
The smaller cohort may have resulted in a small effect size and subsequent statistical 
significance remaining undetected. Findings in this study of no statistically significant 
differences may therefore have resulted from a type II error – wrongly concluding 
there was no difference between cohorts. The need for a realistic and pragmatic 
approach to recruitment meant that further recruitment was not possible within the 
study timeframe and therefore analysis was conducted using existing data but this is 
noted as a significant limitation. 
 
The challenge of recruiting control subjects who were both sedentary and prepared to 
commit to the number of investigations required for the wider MRC study meant it 
was necessary to permit inclusion of family members of CFS participants. This aided 
the recruitment of a minimum number of controls and concerns a very small number 
of subjects. Nevertheless, research suggests that there is an underlying genetic 
component to the pathophysiology of CFS and this implies that family members may 
exhibit similar phenotypic features to CFS subjects and therefore not allow for 
adequate differentiation on objective assessment. 
 
The Task Force® Monitor was calibrated prior to the start of the study. This calibration 
was not repeated at the study close. It is therefore difficult to determine that after 18 
months of autonomic assessment the measures were still being accurately recorded. 
This is a limitation that is acknowledged here and that should be addressed in 
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subsequent studies. This lack of calibration may also have affected the equipment used 
to conduct the Valsalva, giving erroneous readings. 
 
For the purposes of the study the CFS and control groups were matched in terms of 
living a sedentary lifestyle. The IPAQ was used to give a more in-depth understanding 
of activity levels between groups. There are a number of limitations with using the 
IPAQ, which may have affected results. Firstly, caution has been advised when using 
the IPAQ score as an outcome measure in studies (338) and its validity as an objective 
measure of activity and its test-retest reliability have been questioned (339, 340). 
Secondly, a number of participants reported problems completing the questionnaire, 
as they found it difficult to quantify how much time they spend doing particular 
activities. 
 
All the participant questionnaires examined self-reported measures and were 
completed independently by each participant. There is a possibility of both reporting 
and recall bias with this approach. CFS participants may be more likely to report severe 
symptoms in order to raise awareness of their condition, or may be more acutely 
aware of such symptoms than a healthy participant who may never have considered 
their presence previously. Recall bias is also likely to be a problem, in particular in 
consideration of CFS participants who consider themselves to have reduced cognitive 
function and poor memory. 
 
Participants in this CFS cohort necessarily had to be well enough to attend hospital for 
appointments and therefore more severely affected CFS patients are significantly 
under-represented in this study. Subjectively reported fatigue severity has been found 
to positively associate with higher COMPASS score (122). It is possible that more 
severe disease may be associated with greater AD and would therefore differ from 
controls.  
 
There is a high degree of inter-rater and test-retest variation when implementing the 
SCID-I (341). All except one assessment – which was subsequently excluded – were 
conducted by one assessor, however, there is a possibility that outcomes would vary 
depending on variables such as day of assessment and does imply that participants 
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with co-morbid or past depression may have been wrongly included. Participants may 
also have under-reported symptoms to enter into the study or be subject to recall bias. 
 
In order to better clarify the potential for misdiagnosis between the two conditions 
future screening using the SCID-I would be improved by asking all participants about all 
symptoms, not limiting questions about “secondary” symptoms dependent on the 
presence of depressed mood or loss of pleasure. 
 
Finally, this was an observational study. As a consequence, it is not possible to 
determine causality. Such a design is, however, more practical given the relatively low 
incidence of CFS, which would mean that a cohort study – although providing stronger 
evidence – would be extremely costly and would need to be conducted over a 
considerable time period. 
 Implications 4.4.
This is the first study investigating objective differences in autonomic and cognitive 
features across DSQ subgroups. Its findings begin to paint a picture that CFS represents 
a disease spectrum, with different disease severity, or even different diseases with 
distinct underpinning aetiologies. 
 
Subjects meeting the Fukuda+2003+2011 criteria appear to perform less well on 
objective cognitive and autonomic assessment and report greater functional 
impairment on subjective questionnaires compared to subjects meeting Fukuda alone. 
Significant differences between criteria include the addition of autonomic symptoms, 
greater number of symptoms and the nature and extent of pain. 
 
On the basis of the study findings, the current use of different diagnostic criteria to 
define CFS in different studies appears at best to be assessing different severity 
phenotypes and may even be assessing different diseases. This has potentially very 
significant repercussions for furthering understanding of the underlying 
aetiopathogenesis of this debilitating condition and is likely to be contributing to the 
sometimes conflicting and mixed results seen across studies. 
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This is exacerbated by the overlap between CFS symptoms and symptoms of 
depression. Lack of consistent exclusion for this co-morbidity and lack of in-depth 
knowledge of the complex interplay between the two conditions imply that existing 
research is exploring subsets of patients with CFS, depression or both conditions. 
Better understanding these symptoms is key to distinguishing between the two and 
examining whether they lie across one disease spectrum or represent distinct 
pathologies. Furthermore, it will aid identification of appropriate treatment and 
management options with the aim of improving quality of life for patients. 
 
There is evidence from the findings of this study of clinical differences in objective 
autonomic parameters across groups of CFS subjects. Damage to the autonomic 
nervous system appears to take the form of an initial sympathetic over-modulation 
followed, in more severe disease, by sympathetic underactivity and increased 
parasympathetic modulation, as seen with subjects meeting the Fukuda+2003 
Research and Fukuda+2003+2011 criteria respectively. This supports the theory that 
abnormalities in the autonomic nervous system are a potentially important feature of 
CFS and hold promise for better understanding the underlying pathophysiology of this 
condition. 
 
When considered in the context of wider research findings and current theories there 
is a strong argument for a trigger in the form of an infectious agent, such as EBV or 
human herpes virus 6, with subsequent damage to the autonomic nervous system 
resulting from vagal nerve damage. This may be particularly so in individuals who have 
an underlying genetic susceptibility. 
 
Adopting a consistent approach to the inclusion of controls with matched activity 
levels and exclusion or in-depth classification and understanding of co-morbid 
depression will allow for better differentiation between what may be a CFS spectrum 
or different diseases. 
 
Furthermore, a greater understanding of the implications of adopting different 
diagnostic criteria needs to be prioritised, and is central to better elucidating the core 
characteristics of CFS. 
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These approaches will aid researchers in their understanding of whether AD is a 
central feature of the disease and whether it represents a neurological underpinning 
aetiopathogenesis or a confounder that arises secondary to underlying pathology. 
 Future research 4.5.
This research did not assess the longer-term impact on CFS subjects of completing a 
study of this magnitude. Capturing this information, in the form of repeat 
questionnaires or qualitative interview, would enable understanding of the way in 
which such a physically, mentally and emotionally demanding study affects CFS 
participants. 
 
Anecdotally, CFS patients report fatigability with exertion over time. Conducting 
repeated cognitive assessment over consecutive days may aid understanding of 
whether this self-reported fatigability is also seen on objective testing, and this may 
represent an important disease marker which has not hitherto been investigated. 
 
Better defining the phenotype of DSQ subgroups is central to improving understanding 
of the pathophysiology that underpins CFS and what may be a spectrum of disease. 
Current research – and the use of different diagnostic criteria – may be investigating 
different disease phenotypes or even different diseases and co-morbidities.  
 
Furthermore, the shared symptomatology between MDD and CFS raises the possibility 
that some or all of these shared symptoms are complicating research by incorrectly 
selecting individuals with either one or both conditions, or that these diseases may be 
part of a similar disease spectrum. 
 
Investigating patients with more severe disease is key to understanding whether it is a 
disease spectrum or distinct conditions that are seen in what is currently termed CFS. 
This might be achieved through the use of portable equipment that can be taken to 
patients’ bedsides at home. 
 
Finally, a more consistent approach to conducting future research would enable better 
comparison between studies and reduce the role that confounders have to play in 
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findings. The use of uniform assessment methods and tools, as well as consistent 
exclusion for co-morbid depression and well-matched sedentary controls, should allow 
for improved within and between study comparisons.  
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B Questionnaires 
Autonomic Symptom Profile 
 
Answer every question by darkening the appropriate oval. If you are unsure about how to 
answer a question, please give the best answer you can.  Please darken the corresponding oval 
completely.  Fill in the number in the box if provided.  This is an American questionnaire – so 
some of the spellings are strange and the numbers erratic, please just ignore this and answer 
the questions as they appear.  Many thanks.  
 
18. In the past year, have you ever felt faint, dizzy or ‘goofy’ or had difficulty thinking soon 
after standing up from a sitting or lying position ? 
O 1    Yes  If you marked Yes go to question 19. 
O 2  No   If you marked No go to question 37. 
 
19. When standing up, how frequently do you get these feelings or symptoms ? 
O 1  Rarely 
O 2 Occasionally 
O 3 Frequently 
O 4  Almost always 
 
20. How would you rate the severity of these feelings or symptoms ? 
O 1  Mild 
O 2  Moderate 
O 3 Severe 
 
21. For how long have you been experiencing these feelings or symptoms ? 
O 1  Less than 3 months 
O 2    3-6 months 
O 3 7 to 12 months 
O 4 13 months to 5 years 
O 5 more than 5 years 
O 6 as long as I can remember. 
 
22. In the past year, how often have you ended up fainting soon after standing up from a 
sitting or lying position ? 
O 0  Never 
O 1 Once 
O 2 Twice 
O 3     Three times 
O 4 Four times 
O 5  Five or more times 
199 
 
 
23. How cautious are you about standing up from a sitting or lying down position ? 
O 1  Not cautious at all 
O 2   Somewhat cautious 
O 3   Extremely cautious 
 
24. What part of the day are these feelings worst ? (check one only) 
O 1  Early morning  
O 2 Rest of the morning 
O 3 Afternoon 
O 4 Evening  
O 5  At night, when I get up after I’ve been sleeping 
O 6  No particular time is worst 
O 7  Other time, please specify ………………………………………… 
 
25. In the past year, have these feelings or symptoms that you have experienced: 
O 1  Got much worse 
O 2 Got somewhat worse 
O 3 Stayed about the same. 
O 4 Got somewhat better 
O 5 Got much better 
O 6  Completely gone. 
 
Please rate the average severity you have experienced in the past year for each of the following 
symptoms.                        
        never had         Mild         Moderate 
 Severe 
 
26. Rapid or increased heart rate   O 1     O 2            O 3      
 O 4 
(palpitations) 
 
27.  Sickness to your stomach (nausea)      O 1               O 2            O 3                       
O 4 
or vomiting ? 
 
28. A spinning or swimming sensation ?     O 1               O 2            O 3                 
 O 4 
 
29. Dizziness ?                                           O 1               O 2            O 3                 
 O 4 
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30. Blurred vision ?                                    O 1               O 2            O 3                       
O 4 
 
31. Feeling of weakness ?                         O 1               O 2            O 3                       
O 4 
 
32. Feeling shaky or shaking sensation?   O 1               O 2            O 3                       
O 4 
 
33. Feeling anxious or nervous ?               O 1               O 2            O 3                       
O 4 
 
34. Turning pale ?                                        O 1               O 2            O 3                       
O 4 
 
35. Clammy feeling to your skin ?              O 1               O 2            O 3                       
O 4 
 
36. Do you have any biological (blood, natural) relatives among your patients, grand parents, 
brothers, sisters, or children who have frequent dizziness after standing from a sitting or lying 
position ? 
 
O 1 Yes    O 2 No                          If Yes, please list their names and relationships to 
you. 
 
Name     Relationship 
…………………….             ………………………………. 
…………………….             ………………………………. 
…………………….             ………………………………. 
 
In the past year, have you ever felt faint, dizzy, or ‘goofy’ or had difficulty thinking: 
 
37. soon after a meal ?        O 1 Yes 
 O 2 No  
 
38. after standing for a long time ?      O 1 Yes  
 O 2 No 
 
39. during or soon after physical activity or exercise ?   O 1 Yes  
 O 2 No  
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40. during or soon after being in a hot bath, shower, tub or sauna ? O 1 Yes  
 O 2 No 
 
41. Have you ever felt dizzy or faint or actually fainted  
when you saw blood or had blood samples taken ?   O 1 Yes  
 O 2 No 
 
In the past year, have you fainted: 
 
42. while passing urine ?      O 1 Yes  
 O 2 No  
 
43. while coughing ?       O 1 Yes 
 O 2 No 
 
44. while pressing on your neck ?      O 1 Yes 
 O 2 No 
 
45. before a public speech ?        O 1 Yes  
 O 2 No 
 
46. any other time ?        O 1 Yes  
 O 2 No 
 
If you checked Yes to any of these questions on fainting please describe circumstances. 
…………………………………………………………………………. 
…………………………………………………………………………. 
 
47. In the past year, have you ever completely lost consciousness after a spell of dizziness ? 
 
O 1 Yes  O 2 No 
 
48. In the past year, have you had any seizures or convulsions ?  O 1 Yes  
 O 2 No           
please describe circumstances …………………………….. 
 
  
In the past 5 years how would you rate the amount of trouble, if any you have had: 
  
      None            Some           A lot 
 Constant 
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49. with paralysis in parts of your face ?  O 1             O 2         O 3                 O 4 
 
50. with feelings of complete weakness 
all over your body ?    O 1             O 2         O 3                 O 4 
 
51. with attacks of uncontrollable 
movements of your arms and legs ?  O 1             O 2         O 3                 O 4 
 
52. with attacks in which you couldn’t 
control your speech ?    O 1             O 2         O 3                 O 4 
 
53.  Have you ever in your adult life had a spell of dizziness ?     O 1  Yes  O 2  No  
 
54. In the past year, have you ever noticed colour changes in your skin, such as red, white or 
purple ? 
 
O 1  Yes If yes, continue with question 55.            O 2  No  If no, go to question 
65. 
 
What colour skin changes have occurred (check all that apply) 
 
55. O My skin turns red. 
 
56. O My skin turns white. 
 
57. O My skin turns purple. 
 
58. O Other, please specify ………………………………………………… 
 
What parts of your body are affected by these colour changes ? (check all that apply) 
 
59. O  My hands. 
 
60. O  My feet. 
 
61. O  Other parts, please specify …………………………………………… 
 
62. O  Entire body. 
 
63. For how long have you been experiencing these changes in skin colour ? 
O 1 Less than 2 months 
O 2 3-6 months 
203 
 
O 3 7-12 months 
O 4    13 months to 5 years 
O 5 More than 5 years 
O 6  As long as I can remember 
 
 
64. Are these changes in skin colour: 
   O 1 Getting much worse 
   O 2 Getting somewhat worse 
   O 3 Staying about the same 
   O 4 Getting somewhat better 
   O 5 Getting much better 
   O 6 Completely gone 
 
65. In the past year, after a long hot bath or shower, have you ever noticed the pads on the 
ends of your fingers wrinkle up ? 
O 1 Yes   O 2  No  
 
66. In the past 5 years, what changes, if any, have occurred in your general body sweating? 
O 1  I sweat much more than I used to. 
O 2  I sweat somewhat more than I used to. 
O 3  I haven’t noticed any changes in my sweating. 
O 4  I sweat somewhat less than I used to. 
O 5  I sweat much less than I used to. 
 
67. In the past 5 years, what changes, if any, have occurred in the amount your feet sweat 
? 
O 1  They sweat much more than they used to. 
O 2  They sweat somewhat more than they used to. 
O 3  I haven’t noticed any changes. 
O 4  They sweat somewhat less than they used to. 
O 5  They sweat much less than they used to. 
 
68. In the past 5 years, what changes, if any, have occurred in facial sweating after eating 
spicy foods ? 
O 1  I sweat much more than I used to. 
O 2  I sweat somewhat more than I used to. 
O 3  I haven’t noticed any changes in my sweating. 
O 4  I sweat somewhat less than I used to. 
O 5  I sweat much less than I used to. 
O 6  I avoid eating spicy foods because I sweat so much. 
O 7  I avoid eating spicy foods for other reasons. 
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In the past 5 years, what changes, if any, have occurred in your ability to tolerate heat 
during a hot day, strenuous work or exercise, hot bath or shower, hot tub or sauna ? (check 
all that apply). 
 
69.  O I now get more overheated. 
 
70.  O I now get dizzy.  
 
71.  O I now get short of breath. 
 
72.  O Other changes, please specify ………………………………………….. 
 
73.  O No change. 
 
74.   Do your eyes feel excessively dry ?   O  1  Yes  O  2  
No 
 
75.   Does your mouth feel excessively dry ?            O  1  Yes  O  2  
No 
 
76.   Do you have excessive amounts of saliva formation ? O  1  Yes  O 2   No 
 
77. What is the longest period of time that you have had any one of these symptoms: dry 
eyes, dry mouth, or increased saliva production ? 
O 0  I have not had any of these symptoms. 
O 1  Less than 3 months. 
O 2  3 to 6 months. 
O 3  7 to 12 months. 
O 4  13 months to 5 years. 
O 5  More than 5 years. 
O 6  As long as I can remember. 
 
78. For the symptom of dry eyes, dry mouth, or increased saliva production that you have 
had for the longest period of time, is this symptom: 
O 0  I have not had any of these symptoms. 
O 1  Getting worse. 
O 2  Getting somewhat worse. 
O 3  Staying about the same. 
O 4  Getting somewhat better. 
O 5  Getting much better. 
O 6  Completely gone. 
 
79. What weight changes, if any, have you had over the past year ? 
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O 1  I have lost about ………………… pounds. 
O 2  My weight has not changed. 
O 3  I have gained about ……………..pounds. 
 
80. In the past year, have you noticed any changes in how quickly you get full when eating 
a meal ? 
O 1  I get full a lot more quickly now than I used to. 
O 2  I get full more quickly now than I used to. 
O 3  I haven’t noticed any change. 
O 4  I get full less quickly now than I used to. 
O 5  I get full a lot less quickly now than I used to. 
 
81. In the past year, have you felt excessively full or persistently full (bloated feeling) after 
a meal ? 
O 1  Never  O 2 Sometimes        O 3 A lot of the time 
 
82. In the past year, have you felt like you had a persistent upset stomach (nausea) ? 
O 1  Never  O 2 Sometimes        O 3 A lot of the time 
 
83. In the past year, have you vomited after a meal ? 
O 1  Never  O 2 Sometimes        O 3 A lot of the time 
 
84. In the past year, have you had a cramping or colicky abdominal pain ? 
O 1  Never  O 2 Sometimes        O 3 A lot of the time 
 
85. Are these pains usually after a meal ?      O 1  Yes  O 2 No 
 
86. How long have you had these cramping or colicky abdominal pains ? 
O 1  Less than 3 months 
O 2  3 to 6 months 
O 3  7 to 12 months 
O 4  13 months to 5 years 
O 5  More than 5 years 
O 6  As long as I can remember 
 
87. In the past year, have you had any bouts of diarrhea ? 
O 1  Yes  If yes continue with question 88     O 2  No  If no go to question 94 
 
88. How frequently does this occur ? 
O 1  Rarely      O 2 Occasionally 
O 3  Frequently ………..times per month O 4 Constantly  
 
89. How severe are these bouts of diarrhoea ? 
O 1  Mild   O 2 Moderate  O 3 Severe  
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90. What part of the day do they seem to be worse ? 
O 1  First thing in the morning 
O 2  Rest of the morning 
O 3  Afternoon 
O 4  Evening 
O 5  During the night 
O 6  No particular time 
 
91. Do these bouts of diarrhoea usually occur after meals  O 1    Yes   O 2    
No  
 
92. Are these bouts of diarrhoea accompanied with lots of rectal gas (flatus) 
O  1     Never O 2 Occasionally               O 3 Frequently   O 4  Always 
 
93. Are your bouts of diarrhea getting: 
O 1  Much worse 
O 2  Somewhat worse 
O 3  Staying the same 
O 4  Somewhat better 
O 5  Much better 
O 6  Completely gone 
 
94. In the past year, have you been constipated ?   
 O 1  Yes  If Yes continue below with question 95 O 2   No  If No go to question 98. 
 
95. How frequently are you constipated ? 
O 1  Rarely      O 2 Occasionally 
O 3  Frequently ………..times per month O 4 Constantly  
 
96. How severe are these bouts of constipation ? 
O 1  Mild   O 2 Moderate  O 3 Severe  
 
97.  Is your constipation getting:          
O 1  Much worse 
O 2  Somewhat worse 
O 3  Staying the same 
O 4  Somewhat better 
O 5  Much better 
O 6  Completely gone 
 
98. Overall, are your abdominal symptoms of vomiting, diarrhoea, constipation, or weight 
loss getting: 
O 0  I have not had these symptoms. 
O 1  Much worse 
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O 2  Somewhat worse 
O 3  Staying the same 
O 4  Somewhat better 
O 5  Much better 
O 6  Completely gone 
 
99. Which one of the following symptoms have been most troublesome for you (check only 
one). 
O 0  None 
O 1  Vomiting  
O 2  Diarrhoea 
O 3  Constipation 
O 4  Weight loss 
 
100.How long have you had this most troublesome symptom. 
O 0  I do not have any of these symptoms 
O 1  less than 3 months 
O 2  3 to 6 months 
O 3  7 to 12 months 
O 4  13 months to 5 years 
O 5  more than 5 years 
O 6  As long as I can remember 
 
101 Is this most troublesome symptom getting: 
O 0  I do not have any of these symptoms 
O 1  Much worse 
O 2  Somewhat worse 
O 3  Staying the same 
O 4  Somewhat better 
O 5  Much better 
O 6  Completely gone 
 
102 In the past 5 years, how would you rate the amount of trouble, if any, you have had with 
difficulty swallowing. 
O 1  No trouble 
O 2  Some trouble 
O 3  A lot of trouble 
O 4  Constant trouble 
 
103. In the past 5 years, how would you rate the amount of trouble, if any, you have had 
with everything you eat tasting the same. 
O 1  No trouble 
O 2  Some trouble 
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O 3  A lot of trouble 
O 4  Constant trouble 
 
Have you ever in your life: 
104  Been nauseated or vomited    O 1  Yes   O 2    No 
 
105  had a bout of diarrhea    O 1  Yes   O 2    No 
 
106. lost your appetite for at least part of the day O 1  Yes   O 2    No 
 
107. Felt discomfort or pain in the pit of the stomach O 1  Yes   O 2    No 
 
108. In the past year, have you ever leaked urine or lost control of your bladder function ? 
O 1  Never      O 2 Occasionally 
O 3  Frequently ………..times per month O 4 Constantly  
 
109. In the past, have you had difficulty passing urine ? 
O 1  Never      O 2 Occasionally 
O 3  Frequently ………..times per month O 4 Constantly  
 
110. In the past year, have you had trouble completely emptying your bladder ? 
O 1  Never      O 2 Occasionally 
O 3  Frequently ………..times per month O 4 Constantly  
 
111. How would you describe your current sexual desire ? 
O 1  Completely absent   O 2 Greatly reduced 
O 3  Somewhat reduced   O 4 About the same or more than 
in the past 
 
IF MALE COMPLETE QUESTIONS 112 -123 . FEMALES GO TO QUESTION 124  
 
112. Are you able to have a full erection ? 
O 1  Never, under any circumstances 
O 2  Much less frequently than in the past 
O 3  Somewhat less frequently than in the past 
O 4  The same, or more frequently, than in the past 
 
Which of the following statements apply to your situation ? (Fill in all that apply) 
 
113. O  1 My ability to have intercourse has not changed. 
 
114. O  1 I have erections but am unable to have intercourse. 
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115. O  1 I can have intercourse only some of the time. 
 
116. O  1 My erections are definitely impaired. 
 
117. O  1 I am able to have intercourse, but am unable to ejaculate 
 
118.  O  1 I have ‘dry’ orgasms and afterward my urine looks milky. 
 
119.  O  1  I have been unable to have erections or they have been impaired since I started 
taking a medication called …………………………………………………………. 
 
120.  O  1 Other situation, please describe ………………………………………….. 
 
121.  O  1 None of the above apply. 
 
122. How long have you had difficulty with erectile function ? 
O 0  I do not have this difficulty 
O 1  Less than 3 months 
O 2  3 to 6 months 
O 3  7 to 12 months 
O 4  13 months to 5 years 
O 5  More than 5 years 
O 6  As long as I can remember 
 
123. Is this difficulty getting: 
O 0  I do not have difficulty 
O 1  Much worse 
O 2  Somewhat worse 
O 3  Staying the same 
O 4  Somewhat better 
O 5  Much better 
O 6  Completely gone 
 
124. In the past year, without sunglasses or tinted glasses, has bright light bothered your 
eyes ? 
O 1  Never      O 2 Occasionally 
O 3  Frequently    O 4 Constantly  
 
125. How severe is the sensitivity to light ? 
O 1    Mild    O 2  Moderate    O  3   Severe 
 
126. In the past year, have you had trouble focussing your eyes ? 
O 1  Never      O 2 Occasionally 
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O 3  Frequently    O 4 Constantly  
 
127. How severe is this focusing problem ? 
O 1    Mild    O 2  Moderate    O  3   Severe 
 
128. In the past year have you had blurred vision ? 
O 1  Never      O 2 Occasionally 
O 3  Frequently    O 4 Constantly  
 
129. How severe is the focusing problem 
O 1    Mild    O 2  Moderate    O  3   Severe 
 
130 In the past year, have you had difficulty seeing at night ? 
O 1  Never      O 2 Occasionally 
O 3  Frequently    O 4 Constantly  
 
131. How severe is the focusing problem 
O 1    Mild    O 2  Moderate    O  3   Severe 
 
132 In the past year, has the same degree of light seemed: 
O 1  Excessively dimmer  O 2 Much dimmer 
O 3  About the same   O 4 Much brighter 
O 5  Excessively brighter 
 
133. Which one of the following eye symptoms is the most troublesome for you ? 
O 0  None  O  1 Trouble focusing O 2 Blurred vision 
 O 3  Difficulty seeing at night. 
 
134. How long have you had this troublesome eye symptom ? 
O 0  I don’t have any of these symptoms 
O 1  Less than 3 months 
O 2  3 to 6 months 
O 3  7 to 12 months 
O 4  13 months to 5 years 
O 5  More than 5 years 
O 6  As long as I can remember 
 
135. Is this most troublesome symptom with your eyes getting: 
O 0  I don’t have any of these symptoms 
O 1  Much worse 
O 2  Somewhat worse 
O 3  Staying the same 
O 4  Somewhat better 
O 5  Much better 
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O 6  Completely gone 
 
136. In the past year, have you ever noticed or been told that while sleeping you stop 
breathing for several seconds ? 
O 1   Yes   O 2  No  
 
137. In the past year, have you ever noticed or been told that while sleeping you snore 
loudly ? 
O 1   Yes   O 2  No  
 
Have you ever been told you have or been diagnosed as having : 
 
138.   Narcolepsy    O 1  Yes   O 2  No  O 3 
Don’t know  
  
139.   Obstructive sleep apnoea    O 1  Yes   O 2  No  O 3 
Don’t know 
 
140. Abnormal or disordered sleep 
Patterns     O 1  Yes   O 2  No  O 3 
Don’t know 
 
141. Currently, how refreshing and restorative is your sleep  
O 1  Not at all restorative – derive no benefit 
O 2  Some slight restorative value 
O 3  Restorative, but not adequate 
O 4  Relatively satisfactory 
O 5  Very satisfactory – feel completely refreshed 
 
142. Compared with a year ago, how would you rate your own sleep over the last month ? 
O 1  Last month was much worse than a year ago 
O 2  Last month was slightly worse than a year ago 
O 3  Last month was about the same as a year ago 
O 4  Last month was slightly better than a year ago 
O 5  Last month was much better than a year ago 
 
143. Have you ever in your adult life had difficulty getting to sleep or staying asleep once 
you were asleep? 
O 1  Yes   O 2 No 
 
144. In the past year, have you ever noticed or been told that during the day you 
sometimes breathe very loudly (e.g. croup) ? 
 O 1 Yes   O 2 No 
 
How would you describe your alcohol use of the past year (check all that apply) 
145.  O 1  I have not drunk any alcohol over the last year 
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146. O 1 I drink socially only. 
 
147. O 1 I have used alcohol excessively in the past year. 
 
148. O 1 I have been intoxicated one or more times in the past year. 
 
149. O 1 I have passed out from drinking too much alcohol one or more times in the past 
year. 
 
How would you describe your drug use over the past year ? (check all that apply) 
 
150.  O 1 I have not used any drugs in the last year 
 
151.  O 1 I have used drugs excessively in the last year 
 
152.  O 1 I have been intoxicated from drugs one or more times in the last year. 
 
153.  O 1 I have passed out from taking drugs one or more times in the last year. 
 
154. Have you ever felt that you have used alcohol or drugs excessively ?   O 1  Yes  
 O 1  No 
 
155. Have you ever been told or have you been diagnosed as having alcohol of drug 
dependency ? 
O 1  Yes   O 2 No 
 
156. Have you received treatment for alcohol or other drug dependency 
O 1  Yes   O 2 No   Please list the drugs involved including alcohol 
     
 …………………………………………………………………….. 
Which of the following describe your cigarette smoking ? (check all that apply) 
157. O 1  I have never smoked cigarettes 
 
158. O 1 I have smoked cigarettes in the past but stopped: Date stopped : 
 
163.  O 1 I am currently smoking about ……………………… cigarettes per day. 
 
166. In the past 5 years, how would you rate the amount of trouble, if any you have had with 
over sensitive hearing ? 
O 1  None  O 2 Some   O 3 A lot   O 4 Constant 
 
167. Have you ever in your adult life had difficulty keeping your mind on your job or task ? 
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O 1  Yes   O 2 No 
 
What medications have you taken in the past month ? 
 
Name of medication  How often do you take it  How much do you 
take each time 
……………………..              ……………………………………               
………………………………………. 
……………………..              ……………………………………                
……………………………………… 
…………………….               ……………………………………               
………………………………………. 
……………………                ……………………………………               
………………………………………. 
…………………….               ……………………………………               
………………………………………. 
……………………..              ……………………………………               
………………………………………. 
……………………..              ……………………………………               
………………………….................. 
 
We welcome below (or on a separate sheet) any comments you might have about what 
might have caused or been associated with your current illness or anything that might be 
helpful to us in understanding your current condition. 
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The Cognitive Failures Questionnaire (Broadbent, Cooper, FitzGerald & Parkes, 1982) 
 
The following questions are about minor mistakes which everyone makes from time to time, but 
some of which happen more often than others. We want to know how often these things have 
happened to your in the past 6 months.  Please circle the appropriate number. 
 
  Very 
often 
Quite 
often 
Occasion-   
ally 
Very  
rarely 
Never 
1. Do you read something and find 
you haven’t been thinking about 
it and must read it again? 
    4     3     2     1     0 
2. Do you find you forget why you 
went from one part of the house 
to the other? 
    4     3     2     1     0 
3. Do you fail to notice signposts on 
the road? 
    4     3     2     1     0 
4. Do you find you confuse right 
and left when giving directions? 
    4     3     2     1     0 
5.   Do you bump into people?     4     3     2     1     0 
6. Do you find you forget whether 
you’ve turned off a light or a fire 
or locked the door? 
    4     3     2     1     0 
7. Do you fail to listen to people’s 
names when you are meeting 
them? 
    4     3     2     1     0 
8. Do you say something and 
realize afterwards that it might be 
taken as insulting? 
    4     3     2     1     0 
9. Do you fail to hear people 
speaking to you when you are 
doing something else? 
    4     3     2     1     0 
10. Do you lose your temper and 
regret it? 
    4     3     2     1     0 
11. Do you leave important letters 
unanswered for days? 
    4     3     2     1     0 
12. Do you find you forget which way 
to turn on a road you know well 
but rarely use? 
    4     3     2     1     0 
13. Do you fail to see what you want 
in a supermarket (although it’s 
there)? 
    4     3     2     1     0 
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  Very 
often 
Quite 
often 
Occasion-   
ally 
Very  
rarely 
Never 
14. Do you find yourself suddenly 
wondering whether you’ve used 
a word correctly? 
    4     3     2     1     0 
15. Do you have trouble making up 
your mind? 
    4     3     2     1     0 
16. Do you find you forget 
appointments? 
    4     3     2     1     0 
17. Do you forget where you put 
something like a newspaper or a 
book? 
    4     3     2     1     0 
18. Do you find you accidentally 
throw away the thing you want 
and keep what you meant to 
throw away – as in the example 
of throwing away the matchbox 
and putting the used match in 
your pocket? 
    4     3     2     1     0 
19. Do you daydream when you 
ought to be listening to 
something? 
    4     3     2     1     0 
20. Do you find you forget people’s 
names? 
    4     3     2     1     0 
21. Do you start doing one thing at 
home and get distracted into 
doing something else 
(unintentionally)? 
    4     3     2     1     0 
22. Do you find you can’t quite 
remember something although 
it’s “on the tip of your tongue”? 
    4     3     2     1     0 
23. Do you find you forget what you 
came to the shops to buy? 
    4     3     2     1     0 
24. Do you drop things?     4     3     2     1     0 
25. Do you find you can’t think of 
anything to say? 
    4     3     2     1     0 
 
Reproduced by permission from the British Journal of Clinical Psychology. 
Broadbent, D.E., Cooper, P.F., FitzGerald, P., & Parkes, K.R. (1982). The Cognitive 
Failures Questionnaire (CFQ) and its correlates. British Journal of Clinical Psychology, 21, 
1-1 
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 DePaul Symptom Questionnaire 
Please answer the following questions. 
1. What is your height?      
2. What is your weight?     
3. What is your date of birth?      
4. What is your gender?       
 5.  To which of the following race(s) do you belong? 
Black, African-American 
White 
American Indian or Alaska Native 
Asian or Pacific Islander 
Other race (Please specify)       
  
6.  Are you of Latino or Hispanic origin?  
Yes No 
7.  What is your current marital status?  
  partner             
  
  
  
  
8. Do you have any children? 
  Skip to Question 9) 
8a. How many children do you have?  
8b. How many of your children are under 18 years old?     
9. How many people live in your home?       
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10. What grade or degree have you completed in school? 
 
  
  
  
 e degree  
  
11. What is your current work status? (Check all that apply)   
 
   
  
   
 
-time   
-time  
11a. If you are on disability, for what condition do you receive disability compensation? 
 Please Specify        
12. What is your current occupation?  
Current        
12a. If you are currently not working, what was your most recent occupation? 
 Most Recent                 
For the following questions (13-66), we would like to know how often you have had each 
symptom and how much each symptom has bothered you over the last 6 months. For 
each symptom please circle one number for frequency and one number for severity. Please 
fill the chart out from left to right.   
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Symptoms 
Frequency: 
Throughout the past 6 
months, how often have you 
had this symptom? 
 
For each symptom listed 
below, circle a number from: 
0 = none of the time 
1 = a little of the time 
2 = about half the time 
3 = most of the time 
4 = all of the time 
Severity: 
Throughout the past 6 
months, how much has this 
symptom bothered you? 
For each symptom listed 
below, circle a number from: 
0 = symptom not present 
1 = mild 
2 = moderate 
3 = severe 
4 = very severe 
13) Fatigue/extreme 
tiredness 
0          1           2          3         
4 
0          1           2          3         
4 
14) Dead, heavy feeling 
after starting to exercise 
0          1           2          3         
4 
0          1           2          3         
4 
15) Next day soreness or 
fatigue after  non-
strenuous, everyday 
activities  
0          1           2          3         
4 
0          1           2          3         
4 
16) Mentally tired after the 
slightest effort 
0          1           2          3         
4 
0          1           2          3         
4 
17) Minimum exercise 
makes you physically tired    
0          1           2          3         
4 
0          1           2          3         
4 
18) Physically drained or 
sick after mild activity    
0          1           2          3         
4 
0          1           2          3         
4 
19) Feeling unrefreshed 
after you wake up in the 
morning 
0          1           2          3         
4 
0          1           2          3         
4 
20) Need to nap daily  
0          1           2          3         
4 
0          1           2          3         
4 
21) Problems falling asleep 
0          1           2          3         
4 
0          1           2          3         
4 
22) Problems staying asleep 
0          1           2          3         
4 
0          1           2          3         
4 
23) Waking up early in the 
morning (e.g. 3am) 
0          1           2          3         
4 
0          1           2          3         
4 
24) Sleep all day and stay 
awake all night 
0          1           2          3         
4 
0          1           2          3         
4 
25) Pain or aching in your 
muscles 
0          1           2          3         
4 
0          1           2          3         
4 
26) 
Pain/stiffness/tenderness in 
more than one joint without 
swelling or redness 
0          1           2          3         
4 
0          1           2          3         
4 
27) Eye pain  
0          1           2          3         
4 
0         1           2          3         
4 
 Frequency: Severity: 
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Symptoms 
Throughout the past 6 
months, how often have you 
had this symptom? 
 
For each symptom listed 
below, circle a number from: 
0 = none of the time 
1 = a little of the time 
2 = about half the time 
3 = most of the time 
4 = all of the time 
Throughout the past 6 
months, how much has this 
symptom bothered you? 
For each symptom listed 
below, circle a number from: 
0 = symptom not present 
1 = mild 
2 = moderate 
3= severe 
4 = very severe 
28) Chest pain  
0          1           2          3         
4 
0          1           2          3         
4 
29) Bloating 
0          1           2          3         
4 
0          1           2          3         
4 
30) Abdomen/stomach pain 
0          1           2          3         
4 
0          1           2          3         
4 
31) Headaches 
0          1           2          3         
4 
0          1           2          3         
4 
32) Muscle twitches 
0          1           2          3         
4 
0          1           2          3         
4 
33) Muscle weakness 
0          1           2          3         
4 
0          1           2          3         
4 
34) Sensitivity to noise 
0          1           2          3         
4 
0          1           2          3         
4 
35) Sensitivity to bright 
lights 
0          1           2          3         
4 
0          1           2          3         
4 
36) Problems remembering 
things 
0          1           2          3         
4 
0          1           2          3         
4 
37) Difficulty paying 
attention for a long period 
of time 
0          1           2          3         
4 
0          1           2          3         
4 
38) Difficulty finding the 
right word to say or 
expressing thoughts 
0          1           2          3         
4 
0          1           2          3         
4 
39) Difficulty understanding 
things  
0          1           2          3         
4 
0          1           2          3         
4 
40) Only able to focus on 
one thing at a time 
0          1           2          3         
4 
0          1           2          3         
4 
41) Unable to focus vision 
and/or attention  
0          1           2          3         
4 
0          1           2          3         
4 
42) Loss of depth 
perception  
0          1           2          3         
4 
0          1           2          3         
4 
43) Slowness of thought 
0          1           2          3         
4 
0          1           2          3         
4 
44) Absent-mindedness or 
forgetfulness 
0          1           2          3         
4 
0          1           2          3         
4 
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45) Bladder problems 
0          1           2          3         
4 
0          1           2          3         
4 
46) Irritable bowel problems 
0          1           2          3         
4 
0          1           2          3         
4 
 
 
 
 
Symptoms 
Frequency: 
Throughout the past 6 
months, how often have you 
had this symptom? 
 
For each symptom listed 
below, circle a number from: 
0 = none of the time 
1 = a little of the time 
2 = about half the time 
3 = most of the time 
4 = all of the time 
Severity: 
Throughout the past 6 
months, how much has this 
symptom bothered you? 
For each symptom listed 
below, circle a number from: 
0 = symptom not present 
1 = mild 
2 = moderate 
3= severe 
4 = very severe 
47) Nausea 
0          1           2          3         
4 
0          1           2          3         
4 
48) Feeling unsteady on 
your feet, like you might fall 
0          1           2          3         
4 
0          1           2          3         
4 
49) Shortness of breath or 
trouble catching your 
breath 
0          1           2          3         
4 
0          1           2          3         
4 
50) Dizziness or fainting 
0          1           2          3         
4 
0          1           2          3         
4 
51) Irregular heart beats 
0          1           2          3         
4 
0          1           2          3         
4 
52) Losing or gaining 
weight without trying 
0          1           2          3         
4 
0          1           2          3         
4 
53) No appetite  
0          1           2          3         
4 
0          1           2          3         
4 
54) Sweating hands  
0          1           2          3         
4 
0          1           2          3         
4 
55) Night sweats  
0          1           2          3         
4 
0          1           2          3         
4 
56) Cold limbs (e.g. arms, 
legs, hands) 
0          1           2          3         
4 
0          1           2          3         
4 
57) Feeling chills or shivers  
0          1           2          3         
4 
0          1           2          3         
4 
58) Feeling hot or cold for 
no reason 
0          1           2          3         
4 
0          1           2          3         
4 
59) Feeling like you have a 
high temperature  
0          1           2          3         
4 
0          1           2          3         
4 
60) Feeling like you have a 0          1           2          3         0          1           2          3         
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low temperature  4 4 
61) Alcohol intolerance 
0          1           2          3         
4 
0          1           2          3         
4 
62) Sore throat 
0          1           2          3         
4 
0          1           2          3         
4 
63) Tender/sore lymph 
nodes 
0          1           2          3         
4 
0          1           2          3         
4 
64) Fever  
0          1           2          3         
4 
0          1           2          3         
4 
65) Flu-like symptoms 
0          1           2          3         
4 
0          1           2          3         
4 
66) Some smells, foods, 
medications, or chemicals 
make you feel sick  
0          1           2          3         
4 
0          1           2          3         
4 
67. Have you always had persistent or recurring fatigue/energy problems, even back to your 
 earliest memories as a child? (By persistent or recurring, we mean that the fatigue/energy 
 problems are usually ongoing and constant, but sometimes there are good periods and bad 
 periods.) 
    
68. Since your fatigue/energy related illness began, do your headaches either happen more 
 often, feel worse or more severe, or are they in a different place or spot?  
Yes    ving a problem with fatigue/energy 
  
69. How long ago did your problem with fatigue/energy begin? 
 
-12 months 
-2 years 
 
 
with fatigue/energy 
70. Have you been diagnosed with Chronic Fatigue Syndrome or Myalgic Encephalomyelitis?    
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70a. If yes, what year were you diagnosed?    
70b. Do you currently have a diagnosis of Chronic Fatigue Syndrome or Myalgic 
 Encephalomyelitis?  
    
70c. Who diagnosed you with Chronic Fatigue Syndrome or Myalgic Encephalomyelitis? 
 -Diagnosed    
70d. Have any of your family members been diagnosed with Chronic Fatigue Syndrome or 
    Myalgic Encephalomyelitis? 
    
  If yes, please list their relation to you and current age    
           
    
 
71.  Did you experience any of the following symptoms regularly and repeatedly in the months 
and years before your fatigue/energy problems began? 
 
 
 
 
 
 
 
 
m with fatigue/energy 
72. If you rest, does your problem with fatigue/energy go away? (Check one)      
   
   
  (Skip to Question 73)  
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  atigue/energy (Skip to Question 73) 
72a. How long do you have to rest for your problem with fatigue/energy to entirely or 
 partially go away?  
-  
73. If you were to become exhausted after actively participating in extracurricular activities, 
 sports, or outings with friends, would you recover within an hour or two after the activity 
 ended?   
 
74. Do you reduce your activity level to avoid experiencing problems with fatigue/energy?     
    
75. Do you experience a worsening of your fatigue/energy related illness after engaging in 
 minimal physical effort?     
  lem with fatigue/energy 
75a. Do you experience a worsening of your fatigue/energy related illness after engaging 
in  mental effort?      
 
75b. If you feel worse after activities, how long does this last? (Check one)   
           - - -13 Hrs       
  -  
76. Are you currently engaging in any form of exercise?  
         (Skip to Question 77)            
76a. If you do not exercise, why aren’t you exercising?  (Check all boxes that you agree 
 with)    
  
  
  
  
77. Over what period of time did your fatigue/energy related illness, develop? (Check one)    
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           -6 months           
            Over 7-12 months            
           -2 years                 
            
     
 
78. How would you describe the course of your fatigue/energy related illness? (Check one)  
          
          
          
          
      periods)       
         , but never disappear 
      completely)  
  
79. Which statement best describes your fatigue/energy related illness during the last 6 
 months? (Check one) 
         
alk around the house, but I cannot do light housework. 
-time. 
-time at work or on some family responsibilities. 
 
 can work full time and finish some family responsibilities but I have no energy left 
    for anything else.    
 
80. Did your fatigue/energy related illness start after you experienced any of the following? 
 (Check one or more and please specify) 
         
An accident          
A trip or vacation         
An immunization (shot at doctor’s office)      
Surgery          
Severe stress (bad or unhappy event(s))      
Other           
I am not ill 
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81. Have you ever consulted a medical doctor or health professional about your fatigue/energy 
 problem? 
   (Skip to Question 83)     
82. Do you currently have a medical doctor overseeing your fatigue/energy problem? 
    
83. Do you have any medical illness (es) that might be causing your symptoms? 
Yes (Skip to Question 84)   
83a. What medical illnesses do you have? 
Illness name(s) and year it began:       
83b. For which of these conditions are you currently receiving treatment?    
84.  Are you currently taking any medications (over the counter or prescription)?   
(Skip to Question 86) 
84a. What medications are you taking?         
85. Do you think any medication(s) is (are) causing your problem with fatigue/energy? 
          (Skip to Question 86)  
 (Skip to Question 86) 
85a. Please specify which medications:       
86. Have you ever been diagnosed and/or treated for any of the following: (Check all that 
 apply and write year (s) experienced, years treated, and medication (if applicable) 
 in the blank) 
           
      
  (Manic-depression)       
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  Please specify)        
   
87. What do you think is the cause of your problem with fatigue/energy? (Check one)  
 
 
 
 
 
atigue/energy 
88. Do you think anything specific in your personal life or environment accounts for your 
 problem with fatigue/energy?   
          (Skip to Question 89)         
 Skip to Question 89)  
88a. Please specify:         
89. In the past 4 weeks, approximately how many hours per week have you spent doing:  
Household related activities?   hours per week              
Social/Recreational related activities? hours per week         
Family related activities?   hours per week  
Work related activities?  hours per week 
90. In the past 4 weeks, have you had to reduce the number of hours you previously spent 
(prior  to your illness) on occupational, social or family activities because of your health or 
 problems with fatigue/energy?     
   (Skip to Question 91)  
90a. Before your fatigue/energy related illness, approximately how many hours did you 
 used to spend on: 
Household related activities?     hours per week       
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Social/Recreational related activities?   hours per week           
Family related activities?           hours per week     
Work related activities?  hours per week   
91. Please rate the amount of energy you had available yesterday, using a scale from 1 to 100 
where 1= no energy and 100 = your pre-illness energy level.  (If you don't have a 
fatigue/energy related illness, a score of 100 = having abundant energy such that you 
could work full time and complete your family responsibilities)     
92. Please rate the amount of energy you expended (used) yesterday, using a scale from 1 to 
100 where 1 = no energy and 100 = your pre-illness energy expended    
93. Please rate the amount of fatigue you had yesterday, using a scale from 1 to 100 where 1 
= no fatigue and 100 = severe fatigue      
94. For the past week, please rate the amount of energy you had available using a scale from 
1 to 100 where 1 = no energy and 100 = your pre-illness energy level    
95. For the past week, please rate the amount of energy you have expended (used) using a 
scale from 1 to 100 where 1 = no energy and 100 = your pre-illness energy expended  
96. For the past week, please rate the amount of fatigue you have had using a scale from 1 to 
100 where 1 = no fatigue and 100 = severe fatigue    
97. Since the onset of your problems with fatigue/energy, have your symptoms caused a 50% 
or greater reduction in your activity level? 
     
98. Do you experience frequent viral infections with prolonged recovery periods? 
      
99. Are you intolerant of extremes of temperatures (when it is extremely hot or cold)? 
      
MOS SURVEY 
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This survey asks for your views about your health.  This information will help keep track of how 
you feel and 
how well you are able to do your usual activities. Answer every question by marking the answer 
as 
indicated.  If you are unsure about how to answer a question, please give the best answer you 
can. 
1.In general, would you say your health is:  (Please circle one) 
  .................................................................................. Excellent 1 
  .................................................................................. Very good 2 
  .................................................................................. Good 3 
  .................................................................................. Fair 4 
  .................................................................................. Poor 5 
2. Compared to one year ago, how would you rate your health in general now? 
(Please circle one) 
  .................................................................................. Much better than one year 
ago 1 
  .................................................................................. Somewhat better now than 
one year ago 2 
  .................................................................................. About the same as one 
year ago 3 
  .................................................................................. Somewhat worse now than 
one year ago 4 
  .................................................................................. Much worse now than one 
year ago 5 
 
 
3. The following items are about activities you might do during a typical day.  Does 
your health now 
 limit you in these activities? If so, how much? 
Activities Yes, 
Limited 
A Lot 
Yes,  
Limited 
A Little 
No, Not 
Limited 
At All 
Vigorous activities: running, lifting heavy objects, participating 
in strenuous sports 
1 2 3 
Moderate activities: moving a table, pushing a vacuum cleaner, 
bowling, playing golf 
1 2 3 
Lifting or carrying groceries 1 2 3 
Climbing several flights of stairs 1 2 3 
Climbing one flight of stairs 1 2 3 
Bending, kneeling, or stooping 1 2 3 
Walking more than a mile 1 2 3 
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Walking several blocks 1 2 3 
Walking one block 1 2 3 
Bathing or dressing yourself 1 2 3 
 
4. During the past 4 weeks, have you had any of the following problems with your work or other 
  regular daily activities as a result of your physical health? 
Problems Yes No 
Cut down on the  amount of time you spent on work or other 
activities  
1 2 
Accomplished less than you would like 1 2 
Were limited in the kind of work or other activities 1 2 
Had difficulty performing the work or other activities (For example, 
it took extra effort) 
1 2 
 
 5. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of any emotional problems (such as feeling depressed or 
anxious)? 
Problems Yes No 
Cut down the amount of time you spent on work or other activities 1 2 
Accomplished less than you would like 1 2 
Didn’t do work or other activities as carefully as usual 1 2 
 
6. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with  your normal social activities with family, neighbors, or groups? (Please circle 
one) 
  Not at all ................................................................... 1 
  Slightly ...................................................................... 2 
  Moderately ................................................................ 3 
  Quite a bit ................................................................. 4 
  Extremely ................................................................. 5 
 7. How much bodily pain have you had during the past 4 weeks? 
  None ......................................................................... 1 
  Very mild .................................................................. 2 
  Mild ........................................................................... 3 
  Moderate .................................................................. 4 
  Severe ...................................................................... 5 
  Very Severe .............................................................. 6 
 
 8. During the past 4 weeks, how much did pain interfere with your normal work (including both 
work  outside the home and housework)? 
  Not at all ................................................................... 1 
  Slightly ...................................................................... 2 
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  Moderately ................................................................ 3 
  Quite a bit ................................................................. 4 
  Extremely .................................................................. 5 
9. These questions are about how you feel and how things have been with you during the past 
4 weeks. For each question, please give the one answer that comes closest to the way you 
have been feeling. How much of the time during the past 4 weeks- 
Questions All 
of 
the 
Time 
Most 
of 
the 
Time 
A 
Good 
Bit of 
the 
Time 
Some 
of the 
Time 
A 
Little 
of 
the 
Time 
None 
of 
the 
Time 
Did you feel full of pep? 1 2 3 4 5 6 
Have you been a nervous person? 1 2 3 4 5 6 
Have you felt so down in the dumps that 
nothing could cheer you up? 
1 2 3 4 5 6 
Have you felt calm and peaceful? 1 2 3 4 5 6 
Did you have a lot of energy? 1 2 3 4 5 6 
Have you felt down-hearted and blue? 1 2 3 4 5 6 
Did you feel worn out? 1 2 3 4 5 6 
Have you been a happy person? 1 2 3 4 5 6 
Did you feel tired? 1 2 3 4 5 6 
 
10. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting with friends, relatives, etc.)? 
  All of the time ............................................................ 1 
  Most of the time ........................................................ 2 
  Some of the time ....................................................... 3 
  A little of the time ...................................................... 4 
  None of the time ....................................................... 5 
 11. How TRUE or FALSE is each of following statements for you? 
Statements Definitely 
True 
Mostly 
True 
Don’t 
Know 
Mostly 
False 
Definitely 
False 
I seem to get sick a little easier than other 
people 
1 2 3 4 5 
I am as healthy as anybody I know 1 2 3 4 5 
I expect my health to get worse 1 2 3 4 5 
My health is excellent 1 2 3 4 5 
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Fatigue Impact Scale (FIS) 
 
Please put a tick or cross in the box that best addresses your fatigue 
[If the question is not relevant to you, please tick “not applicable”] 
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1.  I feel less alert 
 
      
2.  I feel that I am more isolated from social contact  
 
      
3.  I have to reduce my workload or  
responsibilities 
      
4.  I am more moody. 
 
      
5.  I have difficulty paying attention for a long period       
6.  I feel I cannot think clearly. 
 
      
7.  I work less effectively (this applies to work inside or outside 
the home) 
      
8.  I have to rely more on others to help me or do things for me.       
9.  I have difficulty planning activities ahead of time 
 
      
10.  I am more clumsy and uncoordinated 
 
      
11.  I find that I am more forgetful 
 
      
12.  I am more irritable and more easily angered 
 
      
13.  I have to be careful about pacing my physical activities       
14.  I am less motivated to do anything that requires physical 
effort 
      
15.  I am less motivated to engage in social activities 
 
      
16.  My ability to travel outside my home is limited 
 
      
17.  I have trouble maintaining physical effort for long periods       
18.  I find it difficult to make decisions 
 
      
19.  I have few social contacts outside my own home 
 
      
20.  Normal day to day events are stressful for me 
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21.  I am less motivated to do anything which requires thinking       
22.  I avoid situations that are stressful for me  
 
      
23.  My muscles feel much weaker than they should do       
24.  My physical discomfort is increased 
 
      
25.  I have difficulty dealing with anything new 
 
      
26.  I am less able to finish tasks that require thinking 
 
      
27.  I feel unable to meet the demands that people place on me       
28.  I am less able to provide financial support for myself and my 
family 
      
29.  I engage in less sexual activity 
 
      
30.  I find it difficult to organise my thoughts when I am doing 
things at home or at work 
      
31.  I am less able to complete tasks that require physical effort       
32.  I worry about how I look to other people 
 
      
33.  I am less able to deal with emotional issues 
 
      
34.  I feel slowed down in my thinking 
 
      
35.  I feel it hard to concentrate 
 
      
36.  I have difficulty participating  fully in family activities       
37.  I have to limit my physical activities 
 
      
38.  I require more frequent or longer periods of  
rest 
      
39.  I am not able to provide as much emotional support to my 
family as I should. 
      
40.  Minor difficulties seem like major difficulties       
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IPAQ 
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C Standard Operating Procedures 
SOP for Pre-screening telephone call 
SOP Number: 1  
Version Number & Date:  V1.0. dated 9/11/12 Effective Date:  
Superseded Version Number & Date (if applicable):  Review Date: 
Author signature 
Approval signature 
Background  
This SOP is to provide clear instructions on the pre-screening telephone call. 
Scope 
The SOP covers what to discuss in the pre-screening telephone call. 
Roles and Responsibilities 
All personnel involved in the task must be fully trained and deemed competent by their 
supervisor. 
Procedure 
1. Clarify what the participant understands about the project. 
2. Answer any questions or offer further explanation as appropriate. 
3. Explain that there are some criteria that mean people cannot participate and that you 
would like to check a few things now before calling people out to the hospital. 
4. Clarify that it is ok to ask these questions. 
5. Run through exclusion criteria:  
a. Have you previously participated in this study before? 
b. Are you involved in any other trials? 
Are you able to attend Newcastle Hospitals? 
c. What medications do you take? (any affecting autonomic nervous system should be 
excluded) 
d. Do you have other medical problems? (clarify which. If diabetes should be excluded) 
e. Have you ever been diagnosed with any problems with your mood? (if yes cannot 
participate) 
f. Could you be pregnant? (if yes advise taking pregnancy test before participation) 
g. Do you have a pacemaker? (if yes cannot participate) 
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h. Have you ever had an operation where metal has been inserted into your body? (if yes 
seek clarification from MR centre about contra-indications) 
6. If there are any questions about patient responses speak to another member of the 
team and arrange to phone the patient back. 
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SOP for Taking consent 
 
SOP Number: 1  
Version Number & Date:  V1.0. dated 9/11/12 Effective Date:  
Superseded Version Number & Date (if applicable):  Review Date: 
Author signature 
Approval signature 
Background  
This SOP is to provide clear instructions on taking consent. 
Scope 
The SOP covers what to discuss when taking consent and what to record in the notes. 
Roles and Responsibilities 
All personnel involved in the task must be fully trained and deemed competent by their 
supervisor. 
Things to discuss 
Ask the patient what they understand about the project. 
Are there any questions they would like to ask? 
Explain that need to mention some things. Discuss: 
1. The aim of the study in to see how blood pressure regulation and brain function 
interrelate. To explore how this may help us to develop treatments and improve 
quality of life. Participant may not get any direct benefit from the research. 
2. Number of visits. Talk about plan to complete all visits within four weeks if possible. 
Understand that the number and nature of visits is quite demanding so can be spread 
out. 
3. Nature of the visits: 
a. Screening. This includes a DSMIV assessment.  
b. Assess for mood disorders 
c. If found will not be able to participate 
d. Will inform GP of diagnosis for management 
e. Autonomic assessment and cognitive assessments. 
f. Blood tests. 
i. Looking at cortisol, cytokines. 
ii. Further sample will be stored for future tests. 
g. MRI scans. 
i. Cannot participate if any contraindications as per safety questionnaire. 
h. Medical physics. 
i. Involves blood tests as per SOP. 
4. Draw attention to possible side effects including: 
a. bruising form blood taking, vein blockage, small nerve injury causing 
numbness and pain. Usually resolve with time. 
b. MR scan noisy/claustrophobic 
c. Small dose of radiation in medical physics tests. Equivalent to 13 months of 
background radiation in Newcastle area or CT head. 
d. Consider the number of visits. 
5. All data is recorded anonymously. Data collected by Nuclear Medicine will be stored 
under patient’s details on NHS system and transferred anonymously. 
6. Participation is voluntary. Free to withdraw at any time without giving a reason and 
this will have no effect on future care. 
7. The sponsor of the research study in Newcastle upon Tyne Hospitals NHS Foundation 
Trust. 
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8. The funding has come from Medical Research Council. 
9. Explain that participant’s medical notes and data collected in the study may be looked 
at by people working for Newcastle upon Tyne Hospitals NHS Foundation Trust and 
regulatory authorities where necessary. Data will be entered in these notes by 
researchers working on the project. 
10. GP will be informed of participation in the study.  
11. When having the tests, ie MRI scans, there is a possibility that an abnormality will be 
observed. The scans will be looked at by radiographers and by members of the 
research team. Tests not being done for diagnostic purposes so there is no guarantee 
that abnormalities would be detected. If anything abnormal was seen the scan would 
be sent to a radiologist for an expert opinion about whether further investigation or 
treatment were necessary. In this instance your GP would be contacted and informed 
of the results. 
12. Draw attention to PALS in the instance of wanting advice. 
13. Contact for the study: 
a. Laura Maclachlan, Tel: 0191 208 1357 
b. Professor Julia Newton, Tel: 0191 222 6000, email: julia.newton@ncl.ac.uk 
 
What to include in the notes 
1. Patient has read version 5 1 5 12 of the patient information sheet. Understand what 
the research involves. 
2. They have had at least 24 hours to consider the information. Have had the opportunity 
to ask questions. 
3. They understand their participation is voluntary and they are free to withdraw at any 
time. 
4. Patient understands that parts of their medical notes and data collected during the 
study may be looked at by individuals from the Newcastle upon Tyne Hospitals NHS 
Foundation Trust, their representatives/agents or regulatory authorities where it is 
relevant to my taking part in this research. 
5. Agree to the use of blood samples 
6. Agree to GP being informed of participation and any important findings 
7. Side effects discussed including radiation, MR scans and risks of blood taking. 
8. Discussed potential benefits of taking part. 
9. Given information about contact person. 
 
Original consent form into site file. 
Copy of consent form and PIS into patient notes 
Copy of consent form to the CRF 
 
NB use the latest version of consent form and PIS (currently v5 1 5 12) 
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SOP for SCID assessment 
 
SOP Number: 1  
Version Number & Date:  V3.0. dated 08/03/13 Effective Date:  
Superseded Version Number & Date (if applicable):  Review Date: 
Author signature 
Approval signature 
Background  
This SOP is to provide clear instructions on the SCID assessment. 
Scope 
The SOP covers what to discuss in the SCID assessment. 
Roles and Responsibilities 
All personnel involved in the task must be fully trained and deemed competent by their 
supervisor. 
Procedure 
Explain that these questions are to ensure there are no confounding factors in the study. 
Ask patient about how they are feeling. 
Explore mood over the course of the illness and diagnosis. 
Use wording as per SCID. 
Do not include A38 dysthymic disorder. 
Do not include module G1-5 Somatoform Disorders. 
Exclusion 
Any current or past diagnosis according to SCID with the following exceptions: 
Simple bereavement 
Module G6 Pain Disorder but do not use this as an exclusion criteria. 
Module F Anxiety Disorders but do not use this as an exclusion criteria. 
Module E Substance Abuse if not in the last six months and for substance dependence if not in 
the last year. 
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SOP for Medications  
 
SOP Number: 1  
Version Number & Date:  V3.0. dated 28/11/13 Effective Date:  
Superseded Version Number & Date (if applicable):  Review Date: 
Author signature 
Approval signature 
Background  
This SOP is to provide clear instructions on what medications are exclusion criteria and what to 
do with other medication.  
Scope 
The SOP covers information about what medications are exclusion criteria and what to do with 
other medication.  
Exclusion 
Antihypertensive mediation, including but not limited to: 
 ACE-inhibitors; 
Diuretics *; 
Calcium channel blockers; 
Beta-blockers. 
Naltrexone. 
Inclusion 
Simple analgesia taken prn, including 
 Paracetamol; 
 Ibuprofen. 
Other medications 
The following medications should be stopped for 72 hours prior to autonomic testing and 
blood tests. Can be continued for MR scans and nuclear medicine. This is a participant 
decision, if they wish to take part in the research: 
 SSRIs 
 Amitriptyline 
 Antihistamines 
LDN (low dose naltrexone) 
Vesicare 
Opioid analgesics 
PPIs 
Fludrocortisone 
Nortriptyline 
Duloxetine 
* Bendroflumethiazide for idiopathic oedema 
 
The following medication should be stopped for 24 hours prior to autonomic testing and blood 
tests. Can be continued for MR scans and nuclear medicine. This is a participant decision, if 
they wish to take part in the research: 
 Midodrine 
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SOP for Autonomic testing 
 
SOP Number: 1  
Version Number & Date:  V1.1. dated 24/04/13 Effective Date:  
Superseded Version Number & Date (if applicable):  Review Date: 
Author signature 
Approval signature 
Background  
This SOP is to provide clear instructions on using the Taskforce monitor for autonomic 
testing. 
Scope 
The SOP covers how to use the Taskforce Monitor. 
Roles and Responsibilities 
All personnel involved in the task must be fully trained and deemed competent by 
their supervisor. 
Procedure 
The autonomic testing should be carried out between 9am and 10am. 
Participant refrains from caffeine and alcohol the morning prior to testing and for 
nicotine for two hours before testing. A light breakfast can be eaten. Refer to SOP for 
medications version 2 for instructions about medications. 
Explain mechanism and procedure for Valsalva technique before attaching electrodes. 
10 minute Rest 
Equipment needed 
 Task Force Monitor 
 Electrodes, including impedance electrodes 
1. Ask patient to gel their hands 
2. Rest patient on bed 
3. Attach patient to Task Force Monitor Equipment as per below: 
 
Impendence electrodes: 
In addition: Small electrode and clip attaches to left ankle. 
Image taken from 
http://www.sciencedirect.com/science/article/pii/S0010482505000685 Accessed 
13/11/12. 
Place remaining electrodes on anterior thorax in approximately the 2nd intercostal 
space mid-axillary on the left and right side and below the impedance electrodes on 
the left and right side. Start from right 2nd intercostal space and place in the following 
order: red, yellow, green, blue. 
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4. Set intervention time: 10 min Rest: Start 
5. Patient rests quietly for 10 minutes while heart rate and blood pressure are 
monitored 
6. Set intervention time: 10 min Rest: End 
Active Stand 
 
Equipment needed 
 Task Force Monitor 
2 people are needed to do this procedure 
After patient has rested for 10 minutes 
1. Assist patient to stand  
2. Insert intervention: Active Stand: Start as patient comes to the standing 
position 
3. Stand patient for 2 minutes 
4. Ask and observe patient for any symptoms 
5. Insert intervention: Active Stand: End 
6. Sit patient down 
Valsalva 
Equipment needed 
 Task Force Monitor 
 10 ml Syringe  
 baumanometer 
1. Set intervention: Valsalva1: Start 
2. Allow patient to recover to baseline for two minutes. 
3. Patient takes a deep breath in 
4. Place syringe in mouth 
5. Blow until baumanometer reads 40mmHg for 15 seconds 
6. Set intervention: Valsalva1: End while patient is blowing 
7. Patient stops blowing, sits quietly, breathing normally, and not talking until 
recordings have returned to normal 
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D Cognitive testing booklet 
 
NATIONAL ADULT READING TEST (NART) 
 
Participant Code……………………………     Date …………….   Time ……………  
 
Instruction: Give NART sheet to participant and ask them to read out each word. 
 
CHORD 
ACHE 
DEPOT 
AISLE 
BOUQUET 
PSALM 
CAPON 
DENY 
NAUSEA 
DEBT 
COURTEOUS 
RAREFY 
EQUIVOCAL 
NAIVE 
CATACOMB 
GAOLED 
THYME 
HEIR 
RADIX 
ASSIGNATE 
HIATUS 
SUBTLE 
PROCREATE 
GIST 
GOUGE 
SUPERFLUOUS 
SIMILE 
BANAL 
QUADRUPED 
CELLIST 
FACADE 
ZEALOT 
DRACHM 
AEON 
PLACEBO 
ABSTEMIOUS 
DETENTE 
IDYLL 
PUERPERAL 
AVER 
GAUCHE 
TOPIARY 
LEVIATHAN 
BEATIFY 
PRELATE 
SIDEREAL 
DEMESNE 
SYNCOPE 
LABILE 
CAMPANILE
 
Number of errors:  ……… 
 
Verbal IQ:  ………
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STROOP COLOUR WORD TEST 
 
Participant Code……………………………     Date …………….   Time ……………  
 
Part 1: Read out words (Word page)   
Participant reads out the words printed in black as quickly as possible. Record the number of 
correct words read in 45 seconds, and any errors.  
 
“This is a test of how fast you can read words on this page. After I say begin, you are to read 
down the columns starting with the first one until you complete it and then continue without 
stopping down the remaining columns in order. If you finish all the columns before I say “Stop”, 
then return to the first column and begin again. Remember do not stop reading until I tell you 
to “Stop” and read out load as quickly as you can. If you make a mistake, I will say “No” to you. 
Correct your error and continue without stopping.” 
 
Start timing when participant says first word. 
 
RED BLUE GREEN RED BLUE 
GREEN GREEN RED BLUE GREEN 
BLUE RED BLUE GREEN RED 
GREEN BLUE RED RED BLUE 
RED RED GREEN BLUE GREEN 
BLUE GREEN BLUE GREEN RED 
RED BLUE GREEN BLUE GREEN 
BLUE GREEN RED GREEN RED 
GREEN RED BLUE RED BLUE 
BLUE GREEN GREEN BLUE GREEN 
GREEN RED BLUE RED RED 
RED BLUE RED GREEN BLUE 
GREEN RED BLUE RED GREEN 
BLUE BLUE RED GREEN RED 
RED GREEN GREEN BLUE BLUE 
BLUE BLUE RED GREEN RED 
RED GREEN BLUE RED GREEN 
GREEN RED GREEN BLUE BLUE 
RED BLUE RED GREEN RED 
GREEN RED GREEN BLUE GREEN 
 
Number of items: ……… 
 
Number of errors: ……… 
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Part 2: Name colours (Colour page) 
Participant names the colours of XXXX as quickly as possible. Record the number of 
correct colours named in 45 seconds and any errors.  
 
“This is a test of how fast you can name the colours (red, green or blue) on this page. 
You will complete this page just as you did the previous page, starting with the first 
column. Remember to name the colours out loud as quickly as you can.” 
 
BLUE RED BLUE GREEN RED 
RED BLUE GREEN RED BLUE 
GREEN GREEN RED BLUE GREEN 
BLUE RED BLUE GREEN RED 
GREEN GREEN RED RED BLUE 
RED BLUE GREEN BLUE GREEN 
GREEN GREEN RED GREEN RED 
RED RED BLUE RED BLUE 
BLUE BLUE GREEN BLUE GREEN 
RED RED RED GREEN BLUE 
BLUE BLUE GREEN BLUE GREEN 
GREEN GREEN BLUE RED RED 
RED BLUE RED BLUE BLUE 
GREEN GREEN GREEN RED GREEN 
BLUE RED BLUE GREEN RED 
GREEN GREEN GREEN BLUE BLUE 
BLUE RED RED GREEN RED 
RED BLUE BLUE RED GREEN 
GREEN RED GREEN BLUE BLUE 
BLUE GREEN BLUE RED RED 
 
Number correct: …………   
Number errors: ………… 
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Part 3: Name colours of words (Colour-Word page) 
Participant names the colours of word as quickly as possible. Record the number of correct 
colours named in 45 seconds and any errors.  
 
“This Word page is like the page you just finished. I want you to name the colour of the ink the 
words are printed in, ignoring the word that is printed for each item. For example [point to the 
first item], this is the first item: what would you say? [If correct ask for second item; if incorrect 
reiterate naming of colour of ink and repeat first item.] Good. You will do this page just like the 
others, starting with the first column and then going on to as many columns as you can. 
Remember, if you make a mistake, just correct it and go on.” 
 
BLUE RED BLUE GREEN RED 
RED BLUE GREEN RED BLUE 
GREEN GREEN RED BLUE GREEN 
BLUE RED BLUE GREEN RED 
GREEN GREEN RED RED BLUE 
RED BLUE GREEN BLUE GREEN 
GREEN GREEN RED GREEN RED 
RED RED BLUE RED BLUE 
BLUE BLUE GREEN BLUE GREEN 
RED RED RED GREEN BLUE 
BLUE BLUE GREEN BLUE GREEN 
GREEN GREEN BLUE RED RED 
RED BLUE RED BLUE BLUE 
GREEN GREEN GREEN RED GREEN 
BLUE RED BLUE GREEN RED 
GREEN GREEN GREEN BLUE BLUE 
BLUE RED RED GREEN RED 
RED BLUE BLUE RED GREEN 
GREEN RED GREEN BLUE BLUE 
BLUE GREEN BLUE RED RED 
 
Number correct: …………   
Number errors: ………… 
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DIGIT SPAN – FORM 1 
 
Participant Code……………………………     Date …………….   Time ……………  
 
Digits Forward Pass/Fail Score 2, 1 or 0 
9-8-3   
1-3-7  
7-2-4-6   
8-7-3-4  
9-6-2-8-5   
5-4-3-9-7  
2-8-6-4-1-9   
5-8-3-6-1-9  
2-4-8-7-5-9-1   
2-8-4-1-7-9-3  
6-5-8-1-9-2-4-7   
3-8-2-9-1-5-4-7  
5-6-2-8-7-4-1-3-9   
 4-2-5-6-8-9-1-3-7  
 
Total Forward 
Max = 14 
 
Digits Backward Pass/Fail Score 2, 1 or 0 
1-9   
6-3  
2-4-5   
8-6-1  
5-3-2-7   
9-4-1-5  
2-8-6-1-4   
5-3-9-4-1  
3-1-4-9-8-7   
2-4-5-6-8-1  
2-9-3-6-5-4-7   
3-9-1-2-8-4-6  
2-8-5-7-1-9-6-3   
 5-6-9-1-8-2-7-3  
 
Total Backward 
Max = 14 
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Trail-Making Test 
 
Participant Code……………………………     Date …………….   Time ……………  
 
Administration: 
Part A 
Participant instructed to draw a line between the numbers in order as quickly as 
possible. 
This should be timed. Errors should be corrected. 
 
Time to complete (secs)…………. 
 
Number of errors…………. 
 
Part B 
Participant instructed to draw a line switching between number and leeter in order. 
Start with the number 1. 
This should be timed. Errors should be corrected. 
 
Time to complete (secs) …………. 
 
Number of errors………….
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Spatial Span 
 
Participant Code……………………………     Date …………….   Time ……………  
 
Administration: 
Start Presentation and load “SpatialSpan.exp” experiment (if not already loaded). Run 
scenario and enter participant code. Follow the instructions on screen and observe 
participant during the first trials. Scores will be displayed at the end of the run (until 
you press “continue”). 
 
 
Forward Score: ……… 
 
Backward Score ………
254 
 
Participant Code……………………………     Date …………….   Time ……………  
 
Rey AVLT word recall & recognition (Long term memory) 
 
After approx. 30 mins, recall of words from the first list only (the one that was read 5 
times), before going on to the Recognition trial. 
 
Again, write down all words that are given. 
 
A7 
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AVLT WORD RECOGNITION CHECKLIST (A/B) – FORM 1 
 
Instructions: For each word, please indicate whether you think the word came from 
list A (the list we repeated multiple times), from list B (the list you only heard once), or 
was on neither of these two lists. 
 
BELL HOME TOWEL BOAT GLASSES 
     
WINDOW FISH CURTAIN HOT STOCKING 
     
HAT MOON FLOWER PARENT SHOE 
     
BARN TREE COLOUR WATER TEACHER 
     
RANGER BALLOON DESK FARMER STOVE 
     
NOSE BIRD GUN ROSE NEST 
     
WEATHER MOUNTAIN CRAYON CLOUD CHILDREN 
     
SCHOOL COFFEE CHURCH HOUSE DRUM 
     
HAND MOUSE TURKEY STRANGER TOFFEE 
     
PENCIL RIVER FOUNTAIN GARDEN LAMB 
 
 
 
TOTAL CORRECT HITS FROM LIST A   …… 
 
TOTAL CORRECT HITS FROM LIST B   …… 
 
FALSE POSITIVES:    LIST A   ……      LIST B   …… 
 
MISSES:    LIST A   ……      LIST B   …… 
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THE REY AUDITORY-VERBAL LEARNING TEST 
(AVLT A/B) – FORM 1 
Scoring sheet 
Participant Code……………………………      
 
 
List A A1 A2 A3 A4 A5 List B B A6 A7 
DRUM      DESK    
CURTAIN      RANGER    
BELL      BIRD    
COFFEE      SHOE    
SCHOOL      STOVE    
PARENT      MOUNTAIN    
MOON      GLASSES    
GARDEN      TOWEL    
HAT      CLOUD    
FARMER      BOAT    
NOSE      LAMB    
TURKEY      GUN    
COLOUR      PENCIL    
HOUSE      CHURCH    
RIVER      FISH    
score      score    
 
TOTAL A1 – A5  ……   A6  ……  A6-A5 (R.I.) …… 
 
B ……   A7  ……  B-A1 (P.I.) …… 
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Visual Patterns Task 
 
Participant Code……………………………     Date …………….   Time ……………  
 
Total score: ………..    Max. Number of Targets: …………  
 
Instructions for use: 
 Start Presentation and open VPT experiment (if not open already) 
 Start scenario and enter participant code (if a response file for the participant 
had been created earlier, the new responses will be appended to this file) 
 Follow the instructions on the screen; help participants for questions 
 Record total score and max number of targets from status window 
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 Verbal Fluency 
 
Participant Code……………………………     Date …………….   Time ……………  
 
Write down all words that are given. Mark every 15s quarter of the test. Time for 60 
seconds in total. 
 
F     A     S 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total: ………..    Total: ………..    Total: ………..
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Attention Network Task 
 
Participant Code……………………………     Date …………….   Time ……………  
 
Participant number: …………… 
 
Instructions for use: 
 Double-click on “Attention.ebs” shortcut 
 Press F7 to start 
 Enter a participant number (can be date, but must be between 1 and 32768), 
and record above 
 Enter session number (usually 1; 2 or more for repeat starts) 
 Follow the instructions on the screen; help participants for questions 
 
 
  
260 
 
 
E MRC study ethics approval 
 
 
 
261 
 
 
 
 
 
 
262 
 
 
 
 
